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CHAPTER 1
The FMR1 gene and fragile X-associated tremor/ataxia syndrome 
12 CHAPTER 1
 The FMR1 gene and the unstable CGG-repeat  |  1.1 
Fragile X syndrome has been recognised as the most common inherited form of mental retardation 1. 
Its name refers to a fragile site, which was discovered on the long arm of the X chromosome of four 
mentally retarded patients 2. This fragile site was later found to be inducible when culturing cells in folic 
acid-deficient medium. This facilitated the establishment of a link between expression of the fragile 
site (at Xq27) and the clinical phenotype 3,4. Cloning of the gene responsible for fragile X syndrome, 
FMR1 (fragile X mental retardation 1), revealed the presence of an expanded ((CGG)n) in the 5’UTR. In 
fragile X syndrome this repeat exceeds 200 trinucleotides (full mutation: FM)  5-7. FMR1 consists of 17 
exons, spanning a 38 kb region 8. The (CGG)n in the FMR1 gene is considered a ‘dynamic mutation’; 
the phenomenon that a trinucleotide repeat becomes dramatically unstable once it exceeds a certain 
threshold length 9. Depending on the length of the (CGG)n, different clinical outcomes can develop 
(figure 1.1). Observations and hypotheses on when instability takes place are discussed in chapter 2. 
Analysis of repeat length variation in the normal population showed a range of allele sizes 
between 6 to 54 CGGs 10, with an average of 29 to 30 repeats 11. Alleles of between 45 and 54 CGGs form 
a distinct category. They were named grey zone alleles, when it was appreciated that these alleles are 
more likely to be unstable upon transmission, than are (CGG)n shorter than 45 trinucleotides 
10,12. Grey 
zone alleles frequently contain a long and uninterrupted (CGG)n 
12. The longest tract of uninterrupted 
(CGG)n appears to determine instability and susceptibility to disease, whereby the presence of a pure 
CGG-tract of more than 33 triplets appeared to greatly enhance the chance of unstable transmission. 
Thus, AGG interruptions might stabilise a (CGG)n 
13. This could be through prevention of formation of 
stable secondary RNA structures such as hairpins, as has been shown to occur in in vitro studies 14. 
Hairpins might decrease the efficiency of FMRP translation initiation 15. AGG interruptions, through 
influencing RNA structure, predominantly determine the extent of instability of long normal and short 
premutation alleles 14. 
The remaining repeat range of 55 to 200 CGGs has been defined as the premutation (PM) 16. 
Initially, it was thought that the only risk associated with the PM was for the (CGG)n to expand to an 
FM allele, as alleles in this size range are quite unstable upon maternal transmission 17. The risk of 
expansion from a female PM carrier to an FM in her progeny increases with repeat length 18. In few 
cases, a contraction of maternal origin is seen. Inheritance of a (CGG)n of paternal origin shows a less 
consistent pattern, as expansions, contractions and stable transmissions occur. Expansion of a PM to an 
FM is restricted to maternal transmission. Also, daughters of a male FM carrier, affected with fragile X, 
never show clinical or cytogenetical signs of fragile X syndrome. This was explained by the finding that 
FM males only carry PM alleles in their sperm 19. Thus, both allele size and the parent’s sex determine the 
risk of expansion from parent to offspring 20. 
One in 813 males and one in 259 females of the general population in North America were 
described to carry the PM 11,21. A recent study in 40 000 women in Israel revealed a prevalence of 1 in 
154. No difference in carrier frequency was seen between women with and without family history of 
mental retardation and developmental abnormalities 22. However, it is now known that different ethnic 
groups show a different prevalence, for example it is less common in Asian populations 23, while it is 
more prevalent in Mediterranean groups 24,25.
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Early in situ hybridisation studies in mice revealed that Fmr1 mRNA is abundant and widespread in 
early embryogenesis. Later in embryonic development a specific expression pattern develops, with 
high expression mainly in brain, testes and ovaries. Adult mice also showed high expression in brain 
and testes. No Fmr1 expression was seen in mature ovaries, despite the high levels in the foetal ovaries, 
when proliferation of oogonia takes place. Thus, the FMR1 gene might have a function during germ 
cell proliferation in both sexes 26-28. FMR1 mRNA expression in human foetuses was high in the nervous 
system, but also in some non-neuronal tissues such as cartilage, hepatocytes, the spinal cord and the 
retina 29,30. 
In fragile X patients, the (CGG)n of over 200 trinucleotides (FM) and the upstream promoter 
region of the FMR1 gene are usually hypermethylated  5,6,31. As a result, gene transcription is silenced, 
thus the gene product fragile X mental retardation protein, FMRP, is not produced. The complete lack 
of FMRP in neurons is the cause of the mental retardation seen in fragile X patients 32. The functions of 
FMRP and the consequences of the absence of FMRP in fragile X syndrome are discussed in more detail 
below. 
Transcriptional silencing of the FMR1 gene  |  1.2
Many studies have addressed the question of how methylation of CpGs in the FMR1 gene leads to gene 
silencing. Local chromatin changes as a result of methylation mediate indirect mechanisms, while a 
direct effect is the inhibition of binding of transcription factors to the promoter 33,34. Methyl binding 
proteins (such as MeCP2) recognise methylated CpG residues, upon which a multiprotein complex is 
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Figure 1.1  |  (CGG)n length and FMR1 expression and clinical outcome. This figure shows the consequences of the different repeat length categories 
on transcription, translation and clinical phenotype. (Adapted from 76 with permission of the authors.) See page 163 onwards for colour version of this figure. 
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recruited. This protein complex includes histone deacetylases (HDACs) 35,36. HDACs remove acetyl groups 
from lysines of histone H3 and H4 amino terminal tails, which results in increased condensation of the 
chromatin (heterochromatin), which is associated with inactive gene regions 37. The FMR1 gene normally 
shows acetylated histones H3 and H4, while cells of patients with fragile X show reduced acetylation 38. 
Experiments in cells of fragile X patients showed that methylation and deacetylation indeed cooperate 
in silencing chromatin domains, when histone hyperacetylating drugs could synergistically potentiate 
reactivation of the FMR1 gene induced by a demethylating agent 33,39. Further analysis of epigenetic 
modification in three different regions of the FMR1 gene revealed that epigenetic codes relevant to the 
transcription of the gene are concentrated in the 5’UTR region 40. 
Histones can also be modified in ways other than acetylation, for example by the addition 
or removal of phosphate or methyl groups 41. Methylation of lysines 4 and 9 of histone 3 (H3K4 and 
H3K9, respectively) has been looked at intensively and it became clear that methylation of H3K4 is 
associated with a transcriptionally active state, while methylation of H3K9 correlates with transcriptional 
inactivation 42,43. Methylated H3K9 has been suggested to recruit histone methyl transferases, associated 
with HDACs, which then results in histone deacetylation 44. However, studies in cell lines suggest that 
methylation of H3K9 and partial deacetylation, normally associated with heterochromatin, can coexist 
with H3K4 methylation, which is correlated with active FMR1 transcription 40. 
Two brothers with expanded (CGG)n in the full mutation range have been described, who 
were spared from the fragile X phenotype. Although cytogenetical analysis revealed a fragile site, the 
FMR1 promoter was unmethylated and they did produce FMR1 mRNA and FMRP. This indicates that 
inactivation of FMR1, due to methylation and not the expansion itself, is the cause of the symptoms 
seen in fragile X syndrome 45. Characterisation of a human embryonic stem cell line derived from a 
pre-implantation embryo with FM range repeat showed that the FMR1 gene was unmethylated and 
expressed, despite the presence of an FM allele. More specifically, it displayed the features of active 
chromatin 46. Thus, these results confirm that the (CGG)n by itself is not sufficient to cause transcriptional 
silencing of FMR1 31. Upon differentiation (by inducing formation of teratomas in immunodeficient 
mice) this ES cell line underwent partial transcriptional silencing. Differentiation lead to reduced H3 tail 
acetylation, and H3K9 became methylated, while FMR1 mRNA levels decreased. However, the 5’UTR of 
FMR1 was still hypomethylated. Thus, the authors concluded that de novo methylation of the upstream 
regulatory region of FMR1 follows transcriptional silencing, whereby the chromatin changes take place 
relatively early during differentiation. DNA methylation appears to contribute to the maintenance, rather 
than to the induction of transcriptional inactivation in somatic cells in patients with fragile X 46. This role 
for DNA methylation has previously been described with regard to X-inactivation in females 47. 
However, many questions remain to be addressed about the precise molecular mechanism 
by which FMR1 transcription is regulated, of which the answers might prove valuable for developing 
therapeutical strategies involving reactivation of the FMR1 gene in fragile X syndrome. 
The gene product FMRP  |  1.3
FMRP is an RNA-binding protein (RNA-BP), as it bears two KH-domains and an RGG-box; both are 
sequences with RNA-binding capacities 48-50. Among many other mRNAs, FMRP can bind its own 
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message with high affinity in vitro 48. Furthermore, a nuclear localisation signal and a nucleur export 
signal have been identified, suggesting that FMRP shuttles between the nucleus and the cytoplasm 51-54. 
85% of cellular FMRP is present on actively translating polyribosomes, underscoring the role of FMRP as 
an RNA-BP 55. FMRP has been identified in ribonucleoprotein (RNP) particles. RNA was shown to bind in 
stoichiometric ratios, suggesting that each FMRP molecule bears two RNA-binding sites 48. A minority of 
FMRP is found in the nucleus, either at the nucleopore, or associated with the nucleolus 55-57. 
Immunocytochemical studies in mice revealed that Fmrp is ubiquitously expressed up until 
day 14 of embryonic development. In later embryonic development a more specific pattern arises 
with tissues of ectodermal origin (brain, ganglia, hair follicles, sensory cells, adrenal medulla) and the 
gonads (mesodermal origin) showing the highest expression levels 58. FMRP expression in human 
embryos (3-7 weeks) was consistent with the murine expression pattern, showing highest expression 
in brain and testes 29,30,59,60. In adult human brain, FMRP is present in high quantities in neurons, while 
little or no FMRP is detected in glia and oligodendrocytes 28,30,59,61,62. High levels of FMRP expression in 
human tissue coincide with clinical involvement in fragile X Syndrome 59,60,63,64. The absence of evident 
neuropathological abnormalities of fragile X foetuses suggests that the FMR1 gene product FMRP is not 
crucial in early stages of development of the nervous system 29.
After identification of the FMR1 gene research has focused on the cellular function of FMRP. 
The RNA-binding capacities, association with ribosomes and the cytoplasmic localisation in dendrites 
pointed towards a function for FMRP in mRNA transport or translation. mRNA transport and translation 
in dendrites is important for neuronal function, including modulation of synaptic plasticity. This is 
essential in memory consolidation and learning 65,66. Altered spine morphology (long and thin dendritic 
spines) has been observed in post mortem brains of fragile X patients 67-69 and in FMR1 KO mice 70-72 
Target mRNAs of FMRP that are involved in synaptic function or dendritic growth have been identified, 
which is very interesting in light of the aberrant spine maturation 49. FMRP was found to strongly 
inhibit translation of several mRNAs in vitro, through inhibition of the assembly of the 80S ribosomal 
complexes on target mRNA. The second KH-domain appears crucial in this process, as the I304N mutant 
FMRP, with a mutation in this RNA-binding domain, failed to inhibit translation 73. Thus, a model has 
been proposed that FMRP binds specific mRNAs and mediates the targeting of these transcripts into 
the dendrite. During transport they remain translationally inactive until appropriate synaptic input 
allows translation. Thus, FMRP might have a role in transport and/or translational efficiency of specific 
mRNAs at the synapse. The absence of FMRP would then lead to translational dysregulation of a subset 
of mRNAs at the synapse. Translational dysregulation of mRNAs normally associated with FMRP is 
proposed to be the underlying cause of mental retardation in fragile X 49,74,75.  
Clinical symptoms associated with the premutation  |  1.4
As mentioned above, it was long thought that carriership of the PM was not associated with clinical 
problems, other than the risk of expansion to an FM upon transmitting the PM allele to the next 
generation. However, a small subgroup of PM carriers was reported to have mild learning disabilities and 
social phobias or anxiety disorder 76. Furthermore, it became apparent that 20% of female PM carriers 
manifest premature ovarian failure (POF: cessation of menstruation at or before 40 years of age)77. 
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Women with the PM, even if they are still cycling, have higher levels of follicle stimulation hormone (FSH) 
than do healthy women 78. It has recently been suggested that Anti-Müllerian Hormone (AMH) may be 
a better marker of ovarian decline. AMH is expressed only in growing follicles, thus serves as a marker 
for the size of the primordial follicle pool in women. Indeed, female PM carriers, with (CGG)n lengths 
beyond 70, had lower AMH levels than did female PM carriers with (CGG)n shorter than 70 nucleotides. 
Thus, lower AMH levels are suggestive of early ovarian decline in women with (CGG)>70 
79. Penetrance 
and age at onset of POF, as well as the increase of FSH levels, correlate with (CGG)n length 
80. However, 
a non-linear relationship has been described for age at menopause and premutation size, in which 
premutations in the mid-size range are at greatest risk for POF, while larger repeat tracts are associated 
with a lower risk 81. It has been proposed that premature ovarian insufficiency (POI) is a more accurate 
term for the disorder, to describe the broad range of clinical manifestations associated with what used 
to be classified as POF 82.
Over the past few years, it has become apparent that PM carriers are also at risk of developing 
a progressive neurodegenerative disorder, which is clinically and neuropathologically entirely distinct 
from fragile X syndrome 83-85. In 2001, five male PM carriers were described who suffered from progressive 
action tremor, causing executive function deficits, cerebellar dysfunction, cognitive decline and 
Parkinsonism associated with generalised brain atrophy. Also autonomic dysfunction and peripheral 
neuropathy were reported 83. Since it had already been established that PM carriers have elevated FMR1 
mRNA levels in their lymphocytes, but only somewhat reduced FMRP levels 86, it was then hypothesised 
that the progressive nervous system degeneration as seen in those five male PM carriers might be the 
result of the elevated FMR1 mRNA levels 83. The new syndrome was called fragile X-associated tremor/
ataxia syndrome (FXTAS) 84. However, not all PM carriers develop FXTAS; of male PM carriers ascertained 
through family members with fragile X syndrome, more than a third of men older than 50 years showed 
both tremor and ataxia 87. Penetrance increases with age, to at least 50% in men aged 70-90 years. It 
has now been suggested that penetrance increases with CGG repeat length. For instance; most people 
with FXTAS had (CGG)n with over 70 CGGs, while in the general population only 22% of PM alleles are of 
this size or larger 88. Based on the findings of Jacquemont et al. 88, Allen and co-workers defined alleles 
with over 70 CGGs as ‘at risk’ alleles, while a repeat shorter than 70 trinucleotides was considered a ‘low 
risk’ allele. Preliminary analyses of neuromotor tests did not reveal a difference between low-risk allele 
carriers and non-carriers 89.
It is as yet unknown whether specific prodromal signs exist for FXTAS. Although elevated 
FMR1 mRNA levels in blood from PM carriers (devoid of FXTAS symptomatology) have been found to be 
associated with more psychological symptoms 90, naturally at the time it was unknown whether these 
PM carriers will later develop FXTAS. As awareness about FXTAS grows, monitoring of PM carriers (in 
known fragile X families) is likely to give insight into whether PM carriers are also at risk of developing 
problems before FXTAS develops and whether possible prodromal symptoms have predictive value 
for FXTAS development. This will of course also have importance for genetic counselling of fragile X 
families.
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Clinical aspects of FXTAS  |  1.5
FXTAS patients generally present with cerebellar gait ataxia and intention tremor 84, but may 
develop other neurological symptoms such as Parkinsonism, autonomic dysfunction and peripheral 
neuropathy and may suffer from cognitive decline ranging from mild frontal executive and memory 
deficits to global dementia 91. The dementia resembles cognitive performance in the frontal variant of 
frontotemporal dementia, but not dementia in Alzheimer’s disease 92,93. There is substantial variation in 
clinical presentation, as illustrated by the broad range of diagnoses given to patients who were later 
diagnosed with FXTAS, once the syndrome had been identified and described 94. 
Evidence is accumulating that the severity of some aspects of the disorder is correlated with 
the length of the (CGG)n. For instance, age at death negatively correlated with the number of (CGG)n 
95. 
(CGG)n length was also reported to negatively correlate with age at onset of the major clinical motor 
symptoms, action tremor and gait ataxia 96. Two earlier studies had not found any association between 
(CGG)n length and age at onset of clinical symptoms 
84,91. This difference was explained by cohort size 
and the width of the repeat range tested. Age at onset of symptoms was not correlated to FMR1 mRNA 
levels, nor to FMRP levels 96. This was explained by the finding that FMR1 mRNA levels were measured 
in peripheral lymphocytes. The increase of FMR1 mRNA levels in brain tissue from one FXTAS patient 
relative to a control subject is smaller than when FMR1 mRNA levels in blood are compared. This is due 
to the higher abundance of FMR1 mRNA in brain versus in blood (measured relative to GUS mRNA), also 
in controls. Differences in transcript levels in brain vary considerably over different regions, although 
they are driven by the same (CGG)n length, which is generally consistent throughout the brain 
97. It is 
possible that region-specific transcriptional regulation by transcription factors determines the variable 
FMR1 expression levels throughout the brain. A lack of correlation between FMR1 transcription and 
onset of motor problems is not surprising, as FMRP levels are not deviant from normal controls 96. 
(CGG)n length was also described to correlate with increased cognitive and functional impairment in 
PM carriers 91. Total brain volume reductions and increased white matter disease correlated with the 
number of CGGs 98,99. Similar, though smaller volumetric changes were seen in PM carriers without 
symptoms of FXTAS, suggesting that neuropathological changes take place before clinical symptoms 
become apparent 98.
It has been described that the abnormal elevation of FMR1 mRNA is associated with 
increased psycho logical symptoms such as anxiety, depression and irritability. Thus, increased 
psychopathology is not confined to FXTAS patients, but can occur in all adult PM carriers, although 
especially in males 85,90,100,101. However, the observed neuropsychiatric phenotypes do not show a very 
consistent pattern, due to methodological limitations. Therefore, very recently a controlled study 
into neuropsychiatric functioning was conducted in male PM carriers, who did not show any signs 
of FXTAS, who were compared to controls who have a similar family environment (care of a family 
member with fragile X) and other non-PM carrier controls. This study did not find significant differences 
in psychopathology between PM carriers and non-PM carrier family and other controls, except that PM 
carriers were impaired in utilising working memory and accessing recall check. Also, when comparing 
PM carriers with normal controls, but not family controls, PM carriers showed more alcohol abuse 102. 
A recent study investigated the prevalence of mood and anxiety disorders in PM mothers of at least 
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one child with fragile X syndrome. The most prominent finding was a higher rate of lifetime major 
depressive disorder (MDD). This did not appear to be fully explained by the stress of raising a child with 
fragile X syndrome. Interestingly, a longer (CGG)n was associated with less likely occurrence of lifetime 
MDD. Preliminary analysis might suggest a non-linear relationship between (CGG)n length and MDD, 
such that women with mid-range lengths are at increased risk, while females that carry the longest 
repeats have a lower risk 103. Although speculative, this is in line with recent findings for POI prevalence 
in PM females 81,104. As yet, no controlled study has been performed for PM carriers with FXTAS. A study 
which thoroughly investigated cognitive functioning in PM carriers with and without FXTAS, found 
substantial executive impairment and dysfunction in a wide range of aspects of cognitive functioning 
in patients with FXTAS, while unaffected PM carriers performed worse than controls on executive 
cognitive functioning and declarative learning and memory 105. All relevant clinical aspects of FXTAS 
have been nicely summarised in a recent review by Berry-Kravis and colleagues 106.
In 2004, the first female cases with FXTAS were described. Female PM-carriers are much less 
likely to develop FXTAS, probably because of a protective effect due to the expression of the normal allele 
in part of their neurons. Also, oestrogen might have an alleviating effect on the disease mechanism 107. 
The diluting effect of the presence of a normal FMR1 allele is also the likely cause of the less severe 
clinical outcome seen in female FXTAS patients, as compared to male patients with FXTAS 107,108. Positively 
skewed X-inactivation, wherein the normal allele is preferentially active, could lessen the toxic effects 
of elevated FMR1 mRNA levels. In these first known females with FXTAS, no skewed X-inactivation was 
seen 107. However, another study described two sisters who are both PM-carriers, displaying a different 
degree of clinical involvement, which correlated with the pattern of X-inactivation. The sister who had a 
skewed X-inactivation pattern, favouring a higher percentage of cells expressing the PM-allele, suffered 
from more severe symptomatology. Although genetic background may influence severity of FXTAS, 
this is not likely a major factor in these sisters. Thus, this study provides a clear view on the effect of 
X-inactivation on the clinical outcome in FXTAS 109.
Diagnostic criteria for FXTAS  |  1.6 
MRI studies of the first patients identified to suffer from FXTAS revealed generalised brain atrophy and 
enlarged ventricles 83. Later, neuropathological post mortem studies of patients with manifestations of 
FXTAS generally showed global brain atrophy, as well as cerebellar and subcortical cerebral white matter 
disease. Also substantial Purkinje cell dropout with Bergmann gliosis is seen 110. Another prominent 
feature is the so-called MCP sign, namely increased signal intensities in T2-weighted MRI recordings 
of the middle cerebellar peduncles (MCPs), which is caused by spongiosis of the deep cerebellar white 
matter 84,111. This MCP sign is observed in about 60% of PM carriers with tremor and/or ataxia and was 
therefore included in the diagnostic criteria for FXTAS. Diagnosis is based on the following criteria, 
presented in table 1.1, on top of the mandatory criterion of a (CGG)n length between 55 and 200 
112. 
Testing guidelines for FXTAS, as well as the proposed diagnostic criteria have recently been described 
and summarised in a review by Berry-Kravis et al. 106.
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Criteria Clinical Radiological Neuropathological
(post mortem) 
Diagnosis major minor major minor
Definite FXTAS 1: intention
tremor OR gait
ataxia
                 AND:
MCP sign
                                   OR:
Presence of intra-
nuclear inclusions 
Probable FXTAS 2: intention
tremor AND gait
ataxia
                    OR:
Parkinsonism
                               AND: 
MCP sign
Possible FXTAS 1: intention
tremor OR 
gait ataxia
                 AND:
Cerebral white-
matter lesions, 
generalised atrophy       
Table 1.1 |  Diagnostic criteria for FXTAS (mandatory criterion: 55-200 CGGs in FMR1) (adapted from: 112). The table should be read from left to right, for 
each level of probability of the diagnosis.
Molecular correlates of FXTAS  |  1.7 
The development of FXTAS is restricted to carriers of the premutation, who have a transcriptionally fully 
active FMR1 gene 113. PM carriers, irrespective of showing signs of FXTAS, have been shown to have up 
to eight-fold elevated FMR1 mRNA levels in peripheral blood leucocytes, despite close to normal FMRP 
levels 86,114-116. Relative FMR1 mRNA levels in peripheral blood leucocytes are more elevated in comparison 
with normal controls than are relative FMR1 mRNA levels in brain 97. The level of FMR1 mRNA in blood 
leukocytes is highly and positively correlated to (CGG)n length in the PM range 
86,114,115,117. The mechanism 
underlying the elevated FMR1 mRNA levels is unknown. The observation that increased transcript 
levels were also measured when constructs bearing the FMR1 5’UTR with PM-sized (CGG)n, fused to a 
luciferase reporter were transfected into two different cell lines 15, suggests that the expanded (CGG)n 
itself, rather than the reduced FMRP levels, is responsible for increased transcription 75,114,115. Multiple 
FMR1 transcriptional initiation sites have been identified, with different efficiencies, dependent on the 
length of the (CGG)n in the 5’UTR downstream of the initiation sites. Thus, it appears that the (CGG)n 
exerts some effect at the level of transcription initiation 118. Cell culture studies on the decay of FMR1 
mRNA indicated that increased stability is not the cause of elevated FMR1 mRNA levels 86. Later, it was 
shown that increased FMR1 mRNA levels are due to increased transcriptional activity of both spliced 
and unspliced mRNA. Also, the majority of FMR1 mRNA was found to be localised in the cytoplasm, 
thus excluding the possibility that nuclear retention of FMR1 mRNA contributes to the higher levels (as 
occurs in myotonic dystrophy, which will be discussed later)113.
Although different methods and different repeat ranges tested show somewhat 
different results, it seems that within the PM range, FMRP levels gradually decrease with increasing 
(CGG)n length 
86,114-116. The reduced levels have been found to reflect impaired translational efficiency 
of the (CGG)n containing FMR1 mRNA 
119. Since none of the characteristic features of FXTAS have been 
observed in FM carriers, who express little or no FMRP, it is very unlikely that this syndrome originates 
from a protein-deficiency.
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The neuropathological hallmark of FXTAS  |  1.8 
As can be seen in table 1.1, apart from generalised atrophy, another neuropathological feature has 
been found to be characteristic for FXTAS brain pathology. Neurohistological examination of brains 
of PM carriers who displayed the neurological phenotype which would later be diagnosed as FXTAS, 
revealed the presence of eosinophilic, intranuclear inclusions in neurons and astrocytes (figure 1.2). 
These inclusions are discrete, round bodies, 2 to 5 µm large, and were seen in various regions throughout 
the cerebrum and brain stem 110. They are most numerous in the hippocampus. A strong correlation was 
found between repeat length and number of intranuclear inclusions, in neurons as well as astrocytes 95. 
The intranuclear inclusions stain positively with antibodies against ubiquitin. No positive staining in 
inclusions was obtained with antibodies against tau, cytokeratin, desmin, αB-crystallin, vimentin, GFAP 
or neurofilament. The antibody against neurofilament, however, showed swollen axons in the granular 
cell layer of the cerebellum (Purkinje axonal torpedoes). The GFAP-antibody revealed Bergmann 
gliosis. Furthermore, Purkinje cell drop out was seen in the cerebellum. No inclusions were observed in 
Purkinje cells. Brains of two female PM carriers unaffected by FXTAS were also examined; none of the 
neuropathological changes associated with FXTAS were observed 110.
Figure 1.2  |  Ubiquitin-positive intranuclear inclusions, the neuropathological hallmark of FXTAS in A: human neurons, B: human astrocytes, C: murine 
neurons. No inclusions have been seen in murine astrocytes.  See page 163 onwards for colour version of this figure. 
Previous neuropathological examinations of brains of elderly carriers of the FM did not show 
inclusions 68,120. Some neuroanatomical changes do, however, overlap between PM carriers with FXTAS 
and FM carriers; Purkinje cell loss and Bergmann gliosis have also been described in an older male with 
the FM 120. Also, shrinkage of the temporal lobe 121 and enlarged ventricles 122 have been seen in FM 
carriers. However, overall brain volume tends to be greater in FM carriers 121,123. Thus, the intranuclear 
inclusions seem to represent a neuropathological hallmark specific for FXTAS and their presence is 
therefore used as a post mortem diagnostic criterion (table 1.1).
Based on the toxic RNA gain-of-function model proposed for FXTAS, which will be described 
in detail later, it was predicted that FMR1 mRNA is present within the intranuclear inclusions. Indeed, 
FMR1 mRNA was detected in inclusions isolated from brain of a 70-year old patient. This finding serves 
as evidence for an association between elevated FMR1 transcript levels and formation of intranuclear 
inclusions. Since the presence of inclusions is associated with the development of FXTAS, these results 
strongly point towards an RNA gain-of-function mechanism 97. Another prediction of the model is 
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that RNA-BPs interfere with the abundant (CGG)n containing mRNA which then ultimately leads to the 
clinical phenotype 124. To investigate which proteins might mediate the toxic effects of the expanded-
repeat FMR1 mRNA, a systematic analysis was undertaken into the composition of purified intranuclear 
inclusions of FXTAS brain. Over twenty proteins were found to co-localise with ubiquitin-positive 
inclusions, among which αB-crystallin, Hsp27 and Hsp70, muscleblind-like protein 1 (MBNL1), several 
intermediate filaments and microtubule components, as well as myelin associated proteins and the RNA-
BP heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP A2/B1) 124. Another group demonstrated 
co-localisation of Pur-α and ubiquitin in intranuclear inclusions in human FXTAS brain 125, which had not 
been identified in the purified inclusions in the study by Iwahashi and colleagues 124. Thus, the exact 
composition and formation of inclusions is as yet unknown as well as how they are related to the clinical 
symptoms seen in FXTAS. 
The pathogenesis of FXTAS  |  1.9 
Most studies on the pathogenesis of FXTAS currently focus on the proposed RNA toxic gain-of-function 
model (figure 1.3). The evidence for this pathogenesis model, in which the FMR1 mRNA itself is the 
cause of the neurological disease, originates from the observations that FMR1 mRNA levels are elevated 
in peripheral blood leucocytes of PM carriers, that FMR1 mRNA is present in the intranuclear inclusions 
in brain and that no symptoms of FXTAS are seen among older carriers with the FM (83,84,110, reviewed 
in 112). This model parallels the RNA toxic gain-of-function model proposed for another non-coding 
expanded repeat disorder, myotonic dystrophy (DM: described in more detail in chapter 2). Myotonic 
dystrophy is either caused by expansion of a (CTG)n in the 3’UTR of the myotonic dystrophy protein 
kinase (DMPK) gene (DM1: mostly congenital), or by expansion of the (CCTG)n in intron 1 of the ZNF9 
gene (DM2: late onset form). In both forms of DM, RNA-BPs are sequestered to the mRNA that bears long 
C(C)TG-repeat tracts. One of these proteins is MBNL1. Nuclear foci are seen in DM, similar to intranuclear 
inclusions in FXTAS (reviewed in 126,127). These foci contain the repeat-containing RNA involved in DM, 
as well as MBNL1. The effect of the sequestration of MBNL1 into the nuclear foci is dysregulation of 
splicing of several target mRNAs, which in most cases can explain symptoms seen in DM 128,129. The toxic 
gain-of-function effect has been confirmed in transgenic mouse models in which either an expanded 
(CTG)n was placed within a non-coding region of a heterologous gene 
126 or by introducing a transgene 
containing the human DMPK gene with an expanded (CTG)n 
130; both transgenic mouse lines developed 
myotonia. Thus, it has been proposed that the situation in FXTAS is similar to DM, based on the 
previously described observations. It has furthermore been considered that POF in female PM carriers 
might also arise from an RNA-mediated toxicity 131. Cellular and animal models, which will be described 
in more detail hereafter, provide further evidence that indeed an RNA gain-of-function mechanism 
underlies the clinical syndromes in FXTAS. However, the protein targets that are sequestered by the 
(CGG)n containing mRNA remain to be elucidated, as well as the downstream effects. It will be difficult 
to answer these questions when solely investigating human samples, because in the case of the most 
interesting organ, the brain, one is limited to using patient material only at the end stage of the disease. 
Naturally, it is important to know about the onset and the course of the disease as well. Therefore, in 
vivo models as an alternative to conducting research in humans are necessary. Animal models have 
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proven and will continue to prove very helpful in answering questions about different stages of the 
disease and will be discussed in detail below. 
Also cellular in vitro models can give valuable insight into the mechanisms of toxicity. Inducible 
expression of constructs with non-coding (CGG)n of different lengths in HEK293 cells showed higher 
levels of apoptosis with increasing repeat length. Non-induced cells, thus only expressing endogenous 
levels of FMR1 mRNA, showed reduced cell death in comparison to the induced cells, suggesting that 
cell death is related to the amount of (CGG)n RNA that is transcribed 
132. Another cellular model mimics 
another aspect of FXTAS, namely the formation of inclusions, which occurred in human neuroblastoma 
cells after introduction of an expanded (CGG)n. Another result of the expression of the (CGG)n containing 
RNA is disruption of lamin A/C architecture 133. Lamin A/C was one of the intermediate filaments found 
to be a component of the intranuclear inclusions in FXTAS brain 124. Controlled expression of (CGG)n 
tracts in cellular models might provide further insight on the altered cellular function as a result of toxic 
RNA species. 
Figure 1.3  |  A schematic representation of the RNA gain-of-function mechanism proposed for the pathogenesis of FXTAS. The FMR1 gene is 
transcribed in the nucleus and transported to the ribosomes. The expanded (CGG)n present in the 5’UTR of the FMR1 gene hampers translation, leading to 
lower FMRP levels. Through an as yet unknown mechanism, transcription is upregulated, leading to increased FMR1 mRNA levels. In an attempt to get rid 
of the excess of FMR1 mRNA, the cell might attract chaperones or elements of the ubiquitin/proteasome system. Also (CGG)n-binding proteins might be 
recruited. These processes could lead to formation of intranuclear inclusions. Sequestration of proteins into the inclusions might prevent them from exerting 
their normal function, thereby disturbing cellular function, which in the end might cause neurodegeneration. Also, it cannot be excluded that neuroprotection 
takes place, such that cells that are capable of capturing the toxic transcripts in the inclusions are the cells that survive. See page 163 onwards for colour version 
of this figure. 
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Animal models for FXTAS | 1.10 
Several animal models have been generated in the past, in an attempt to mimic repeat instability as well 
as neurodegeneration associated with (CGG)n expansion in the FMR1 gene. The different existing animal 
models and their contributions to our understanding of the pathogenesis of FXTAS are discussed.  
Drosophila Melanogaster models for FXTAS  | 1.10.1
A Drosophila model generated by Jin and co-workers 134 provided useful insight into the effect of 
ectopic expression of different amounts of different (CGG)n lengths in the fly. Strong expression of a 
construct with 90 CGGs in all neurons of the peripheral and central nervous system caused lethality, 
as did ubiquitous expression in the embryo. Epithelial expression of this construct did not cause any 
effect, which shows that neuronal cells suffer more from the toxic effect of the long (CGG)n containing 
RNA. Moderate or strong expression of constructs containing part of the human FMR1 5’UTR with either 
normal or PM-sized CGG-tracts was also specifically directed to the retina. Moderate expression of a 
tract of 60 CGGs hardly caused an aberrant phenotype in the eye, whereas 90 CGGs led to rough eye, 
loss of pigmentation and disturbed architecture. Strong expression of either repeat length caused a 
more severe phenotype, with an even stronger effect for the (CGG)90, including major cell death. These 
experiments show that both the length of the CGG-tract and the expression level play a role in the 
severity of the neurodegenerative eye phenotype in Drosophila. Furthermore, disruption of the eye 
morphology increased with age in transgenic flies expressing 90 CGGs, mimicking the progressive 
nature of FXTAS. It was also shown that the phenotypes represent late onset symptoms rather than 
developmental defects. Immunohistochemical studies of the retina of flies strongly expressing the long 
repeat demonstrated the presence of inclusions, positive for ubiquitin, hsp70 and proteasome. These 
inclusions were found both in nuclei and cytoplasm, which is different from what is seen in humans and 
mice. Also, they were not as consistent in size and shape as in humans and mice. None of the aspects of 
the neurodegenerative phenotype could be induced with expression of a control construct containing 
EGFP (enhanced green fluorescent protein) only. Since hsp70 has been shown to be a universal 
suppressor of many neurodegenerative models caused by mutant proteins, for example polyglutamine-
containing proteins due to an expanded (CAG)n in the coding region of a gene, flies were generated 
that co-express the (CGG)90 and hsp70. Hsp70 was found to be capable of suppressing the (CGG)n 
RNA induced degeneration, despite the absence of a mutant protein, like in other neurodegenerative 
disorders where hsp70 could act as a chaperone in refolding mutant proteins. Thus, these results are 
promising since they provide a proof-of-principle that the RNA-induced phenotype can be rescued 134.
Subsequent studies in this model were aimed at testing the hypothesis that FXTAS is an RNA-
mediated neuro degenerative disease caused by the titration of RNA-BPs by the (CGG)n. A genetic screen 
of candidate RNA-BPs identified CUG binding protein (CUGBP1) as a modifier of the eye phenotype 
induced by the repeat tract of 90 CGGs. Overexpression of CUGBP1 was capable of suppressing the 
(CGG)n RNA-induced neuro dege n e ra tive eye phenotype. CUGBP1 was found to interact with the 
(CGG)n via hnRNP A2/B1 
135, a ribo-CGG binding protein, of which the presence has been demonstrated 
in inclusions in human FXTAS brain 124. A paper published simultaneously demonstrated that hnRNP A2/
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B1 directly binds to the (CGG)n 
125 and overexpression of this protein and its two Drosophila homologues 
also suppresses the repeat RNA-induced eye phenotype 135. In addition, Pur α, an RNA-BP expressed in 
neuronal cytoplasm, that is involved in dendritic mRNA transport, was also found to be associated with 
(CGG)n RNA and overexpression of Pur α suppressed the eye neurodegeneration phenotype. Pur α was 
also present in the inclusions in Drosophila 125, as well as in human FXTAS brain 124. Thus, these findings 
strongly support the current pathogenesis model for FXTAS, namely that PM-sized (CGG)n sequester 
RNA-BPs, which leads to altered cellular function and ultimately neuronal cell death 125. 
More evidence for the hypothesis that the levels of repeat RNA are important in inducing a 
neurodegenerative phenotype comes from the observation that simultaneous expression of a (CGG)n 
and a (CCG)n, which is present in the 5’UTR of the FMR2 gene, in Drosophila suppress their independent 
toxicity. The FMR2 gene is located about 600 kb distal to the FMR1 gene and is involved in non-syndromic 
X-linked mental retardation. Expression of only a (CCG)n of 90 CCGs also induced a neurodegenerative 
phenotype of the eye. The protective effect of co-expression was found to be dependent on the RNAi 
pathway; toxicity was reversed through a reduction of transcript levels, possibly through formation 
of double stranded RNA, which is then processed and cleaved. This is hopeful in light of potential 
therapeutical strategies involving complementary RNA molecules targeting mutant mRNAs carrying 
expanded trinucleotide repeats 136.
Mouse models for FXTAS  |  1.10.2
Initial attempts to make transgenic mouse models expressing expanded (CGG)n tracts focused on 
investigating the mechanisms underlying (CGG)n instability, since FXTAS had not been discovered at 
the time. The first transgenic mouse model expressed a (CGG)81, with two interruptions, but with a 
pure tract of 60 CGGs. Although in humans this repeat length is sufficient to cause instability upon 
transmission to the next generation, all transgenic mice showed exactly the same repeat length. Thus, 
the repeat was stably inherited in all animals tested 137. In another transgenic mouse line, a randomly 
(autosomally) integrated FMR1 PM allele ((CGG)22TGG(CGG)43TGG(CGG)21) was also stably transmitted 
138. 
(CGG)n tracts usually have a few AGG interruptions. Expansion of the (CGG)n appears to be initiated 
upon loss of the interruptions of the otherwise pure (CGG)n-tracts. Interruptions are predominantly lost 
at the 3’ end of the repeat tract, causing a long pure (CGG)n-tract 
9,139. Therefore, Lavedan and co-workers 
created new transgenic mouse lines with even longer uninterrupted (CGG)n. In addition, because it 
was recognised that chromosomal context might be important for (CGG)n instability to take place, they 
situated the (CGG)n tract within the context of the first exon of the human FMR1 gene and included 
the flanking CpG island. However, including nearby cis-acting elements in the transgene proved not 
to be sufficient to reproduce repeat instability as seen in humans, since only minor intergenerational 
instability was observed in these mice 140. 
Another approach was taken with the use of yeast artificial chromosomes (YACs), which 
can contain large fragments of exogenous DNA. YACs in transgenic mice have been demonstrated 
to appropriately express the genes present on the YAC, as all splice isoforms and other regulatory 
elements can be included 141,142. Several transgenic lines were created using YAC transgenes carrying 
(CGG)n of different lengths and with varying amounts of flanking sequences. Length-dependent 
intergenerational instability (small expansions and contractions) was seen. Parental origin of the repeat 
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allele did not influence the magnitude or direction of instability 143. To investigate the effect of potential 
cis- and trans- factors promoting expansions, the transgenic mice described by Lavedan et al. (1998) 
were subjected to a low-folate or folate-free diet, or crossbred with mice deficient in genes involved 
in DNA replication (Wrn helicase) and repair (p53). Also, the potential effect of parental age was taken 
into consideration. Small changes in repeat length were seen in almost all allele transmissions. Large 
deletions occurred about 10% of transmissions. No large expansions were seen, neither somatic 
instability. The pattern of intergenerational instability was not affected by the absence of the proteins 
involved in DNA replication and repair, nor by folate levels or the parental age 144. 
Since flanking of the (CGG)n with part of the FMR1 gene proved not to be sufficient to 
recapitulate all aspects of repeat instability in humans, another approach was taken by Bontekoe and 
colleagues (2001) 145. They generated a knock-in mouse model in which the endogenous murine (CGG)8 
was exchanged with a human (CGG)n of 98 trinucleotides. When cloning the human expanded repeat 
into the murine FMR1 promoter, minimal changes were made. Comparison of the promoter sequence in 
mice and humans showed that all known regulatory elements are conserved. After the initial breedings, 
infrequent (15 out of 155 transmissions studied) and minor instabilities were observed, two of which 
were contractions, both of paternal origin. Expansions occurred upon transmission of either one of the 
parental alleles 145. 
After FXTAS was first recognised and described, the aging expanded (CGG)n knock-in mouse 
(from now on called (CGG)n mouse) was analysed with respect to neurohistology, biochemistry and 
molecular aspects. The main findings were that Fmr1 mRNA levels in brain were increased throughout 
life, as compared with wild type animals 146, which mimics the human situation 86,115. Importantly, 
also intranuclear inclusions were found in many different areas throughout the brains of the (CGG)n 
mice (figure 1.2). Numbers and size of the inclusions increase with age; the first appearing around 30 
weeks, with percentages up to 55% in certain brain regions at 72 weeks of age, which parallels with the 
progressive nature of the disorder in humans. In addition, a correlation was recognised between the 
presence of inclusions in certain brain areas and clinical features in patients with FXTAS. This clearly 
suggests a role for the formation of intranuclear inclusions in the development of the tremor/ataxia 
syndrome in elderly PM carriers. Interestingly, inclusions were only seen in neurons 146, while in humans 
also astrocytes bear inclusions 110. Other neuropathological features observed in patients with FXTAS 
like neuronal loss, gliosis and Purkinje cell dropout have not been seen in the (CGG)n mice. Molecular 
chaperone Hsp40 and the 20S proteasome complex were found to be present in the inclusions. Among 
many other proteins, Fmrp, α-synuclein, poly-glutamine and tau were not present in the inclusions. 
Minor somatic repeat instability was seen in some organs at 52 weeks of age, as compared with in tail 
DNA taken 10 days postnatally 146. 
The (CGG)n mice were subjected to several behavioural tests. No severely aberrant behavioural 
phenotype was seen, only mild age-dependent learning disturbances and decreased performance in 
a neuromotor task 147. Thus, although the progressive character of the disorder is also seen in mice, the 
mouse appears to be less affected by the expression of the expanded (CGG)n than humans are, both 
with regard to neurodegeneration (neuronal cell loss) and the clinical and behavioural phenotype. The 
origin of these differences remains to be elucidated. 
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This first knock-in mouse model later turned out to be more promising in light of repeat instability 
than the earlier models with non-targeted autosomal (CGG)n, when considerable repeat instability 
was reported. The (CGG)n in these mice has been expanding over generations since it was generated 
and now has reached lengths, which in humans represent the full mutation range. Despite (CGG)n 
lengths over 200 CGGs, no methylation of the promoter region has been detected in these mice thus 
far (chapter 3, 6, 148). Furthermore, cell lines were derived from these mice expressing the expanded 
(CGG)n, which were investigated further with regard to altered cellular morphology and function, as is 
described in chapter 4. Also, alterations in hypothalamo-pituitary-adrenal (HPA) axis physiology, among 
which increased glucocortoid levels, have been observed in this mouse model, which might explain the 
increased psychopathology seen in PM carriers, as is outlined in chapter 5 149. 
Another, similar knock-in mouse model was generated by Entezam and colleagues 150, which 
had an initial repeat tract of ~118 CGGs. Similar to what is described in chapter 3, these mice show high 
repeat instability with a bias towards expansions. They show an increase in FMR1 mRNA levels with 
increasing (CGG)n length and an inverse correlation with Fmrp levels. Also, they reported area-specific 
decreases in Fmrp expression throughout the brain in mice with expanded (CGG)n. For the first time, 
large expansions into the full mutation range were seen within a single generation in a mouse model, 
but the gene was not found to be methylated, nor silenced, as Fmrp was still present 150. 
Thus, animal models have proven useful and will continue to prove useful in elucidating 
the molecular mechanisms underlying the clinical symptoms in FXTAS and thus might also provide 
potential therapeutical targets.
The overall aim of this PhD research was to further characterise the expanded (CGG)n knock-in 
mouse model and to study the role and formation of the intranuclear neuronal inclusions in FXTAS. 
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Abstract  | 
About twenty unstable microsatellite repeats have been identified as the cause of neurological disease 
in humans. The repeat nucleotide sequences, location within the genes, as well as the normal and 
disease-causing repeat length ranges differ, as much as the clinical outcomes. Unstable repeats can be 
located in the coding or the non-coding region of a gene. Different pathogenic mechanisms that are 
hypothesised to underlie the diseases are discussed, for which evidence is given both from studies in 
simple model systems, as well as from studies on human material and in animal models. Since somatic 
instability might affect the clinical outcome, this is briefly touched on. Available data and theories on 
the timing and mechanisms of the repeat instability itself are discussed, along with factors that have 
been observed to affect instability. Finally, the question of why the often harmful unstable repeats have 
been maintained throughout evolution is addressed.
CHAPTER 2
Microsatellite repeat instability and neurological disease
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In 1991, two different unstable and expanded trinucleotide repeats were identified as the genetic cause 
of two different neurological diseases. The (CGG)n in the FMR1 gene was found to be responsible for 
fragile X syndrome 1-4. Furthermore, an expanded polymorphic tandem (CAG)n in the coding region of 
the androgen receptor gene was strongly linked to X-linked spinal and bulbar muscle atrophy (SBMA: 
Kennedy’s disease) 5. These repeat expansions were recognised as a distinct class of mutations, based on 
their unusual properties. Since the repeat unit number is variable and the mutation rate depends on the 
repeat length, the risk of mutation of an allele in each subsequent generation is different from the risk of 
its predecessor. Therefore, this mechanism was termed ‘dynamic mutation’ 6. Since instability increases 
with expanding repeat length, the risk of getting the disorder is greater in successive generations. In 
addition, age at onset is likely to be lower and severity of the disorder may be worse with increasing 
repeat length. This unusual genetic property of the unstable trinucleotide repeats has become known 
as ‘anticipation’. In fragile X syndrome, this used to be referred to as the ‘Sherman paradox’ 7. 
Since the initial discovery of the dynamic mutations involved in fragile X and SBMA, almost 
twenty other unstable repeats have been found to be associated with neurological disorders. This list 
is likely to grow in the near future. Although the vast majority of repeats consist of trinucleotides, also 
tetra- and pentanucleotide repeats can expand and cause disease, for example in myotonic dystrophy 
type 2 (CCTG)n and spinocerebellar ataxia 10 (SCA10: (ATTCT)n). For clarity, all repeats will be referred to as 
trinucleotide repeats in this chapter, not meaning to exclude the tetranucleotide and pentanucleotide 
repeats. Clinical consequences range from congenital syndromes to late-onset neurodegenerative 
disorders. 
Another group of disorders is caused by expression of polyalanine repeats, coded for by 
(GCU)n, (GCC)n, (GCA)n or (GCG)n. Nine genes with expanded alanine tracts have been described thus far, 
most of which are transcription factors. These expansions predominantly cause congenital malformation 
syndromes and are not discussed in this chapter 8. 
Most trinucleotide repeats are polymorphic and show a normal range, seen in healthy people, 
and a threshold length above which the repeat causes serious clinical problems. For instance in fragile 
X, individuals carrying up to 55 CGGs show no clear-cut clinical consequences 1, although in the range 
of 45 to 55 there is a slight risk for the repeat to become unstable, which has been termed ‘grey zone’ 1,9. 
The fragile X locus also has an intermediate repeat length range that poses the carrier at risk of a distinct 
syndrome, namely fragile X-associated tremor/ataxia syndrome (FXTAS) or premature ovarian failure 
(POF) in carriers of alleles with between 55 and 200 CGGs. This repeat length range has been named the 
premutation (PM) 10-13. 
Although this chapter mostly focuses on intergenerational repeat instability, somatic 
instability also occurs in some of the disorders, which might have clinical consequences. Thus, somatic 
instability will be touched on briefly. Pathogenic mechanisms through which different repeat tracts 
may cause disease will be discussed, as well as the timing of the events and the factors that are thought 
to play a role in instability of the repeat tracts.  
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Various pathogenic pathways can underlie trinucleotide repeat-induced disorders. Both loss-of-function 
and gain-of-function mechanisms have been recognised to result from expanded trinucleotides repeats. 
When a disease is associated with an mRNA or protein that has attained a new cellular function, it is 
referred to as a gain-of-function mechanism. A gain-of-function occurs at the RNA or at the protein 
level, depending on the location of the trinucleotide repeat within the gene. If an expanded repeat is 
translated, because it is within the coding sequence, it is likely to affect protein structure and thereby 
function (reviewed in: 14-17). When a repeat is located in a non-coding region, it will not change protein 
structure or function directly. However, as the repeat is transcribed, mRNA function might be altered. All 
diseases and their proposed pathogenic pathways discussed in this chapter are summarised in figure 
2.1 and table 2.1. 
Loss-of-function at the protein level  |  2.1.1
The most common syndrome in which protein function is lost, is fragile X syndrome (FRAXA), which 
occurs when the (CGG)n in the 5’UTR of the fragile X mental retardation 1 (FMR1) gene exceeds 200 
CGGs (full mutation: FM) 2,18. Beyond this length, the CpG island within the promoter region as well 
as the repeat become methylated and histone acetylation decreases, which leads to transcriptional 
silencing. The gene product FMRP is normally highly expressed in neurons of the brain 19,20 and is 
involved in mRNA translation in the dendrites. FMRP is able to regulate synaptic function by regulation 
of the translation of these mRNAs at the synapse. As a result, its absence leads to the mental retardation 
seen in fragile X syndrome 21. 
Figure 2.1  |  Location of repeats within genes in relation to pathogenic mechanism. This schematic gene shows all microsatellite repeats described 
in this chapter, with their location within the gene. The greyscale indicates which pathogenic mechanism is thought to underlie the associated diseases. All 
repeats depicted above the gene are located in a coding sequence of the gene, while all repeats below are in non-coding regions. Please refer to the text and 
table 2.1 for further information regarding these repeats, genes and associated disorders. See page 163 onwards for colour version of this figure. 
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A closely related disease is due to a (CCG)n at the FRAXE locus, which lies just downstream of the 
FRAXA locus. Patients with a repeat length exceeding 200, suffer from mild mental retardation and 
developmental delay 22-24. The expanded (CCG)n lies in the 5’UTR of the fragile X mental retardation 2 
(FMR2) gene. Like in FRAXA, the region upstream of the repeat becomes methylated when the (CCG)n 
expands beyond 200 units, which silences the gene, thus protein function is lost 25. The FMR2 protein is 
a nuclear protein thought to act as a transcription factor 26, but its cellular function and the role in the 
disease remains to be elucidated. 
Expansion of a (GAA)n in the first intron of the FDRA gene is the cause of Friedreich ataxia 
(FRDA) 27, which is the most common inherited form of ataxia 28. FRDA is an autosomal recessive 
disorder, where repeats in the range of 66 to 1700 GAAs cause disease 29. PM-sized (34-100 GAA) alleles 
are recognised, due to their propensity to expand to their up to ten-fold expanded disease-causing 
counterparts. It is largely unclear how this happens, since patients with FRDA generally inherit alleles 
that already have disease-causing lengths from their heterozygous parents 30. In FRDA, the gene is 
not silenced. Instead, the (GAA)n expansion interferes with transcriptional elongation such that the 
level of the gene product, Frataxin, is greatly decreased 31. Frataxin appears to control iron availability 
in mitochondria and to have a role in biogenesis of iron-sulfur clusters and haem. This decreases 
production of cellular energy and prevents the production of free radicals 32-34.
RNA gain-of-function  |  2.1.2
An expanded repeat located in a non-coding region of the gene causes cellular toxicity in myotonic 
dystrophy (DM), FXTAS and likely in spinocerebellar ataxias type 8, 10 and 12 (SCA8, -10 and -12). Since 
the repeat is transcribed, but not translated, the proteins do not play a central role in the development 
of the disease. 
Myotonic dystrophy
Two forms of DM exist: DM1 is caused by a (CTG)n in the 3’UTR of a gene encoding a protein kinase 
(DMPK), while DM2 is the result of an expanded tetranucleotide repeat ((CCTG)n) in intron 1 of the zinc 
finger protein gene ZNF9. Myotonic dystrophy is a multisystem disorder, in which patients not only suffer 
from myotonia (muscle hyperexcitability) and muscle degeneration, but also develop cataracts, cardiac 
conduction defects, insulin resistance, sleep disorders, testicular atrophy, hypogammaglobulinaemia 
and frontal balding 35,36. The types are clinically similar, although DM2 is a milder disorder than DM1. Both 
DM1 and DM2 show childhood and adult onset, although most patients with DM2 have adult-onset 
disease. An important difference is that congenital forms only occur with DM1. Also, muscle weakness 
shows a distal pattern in DM1, while patients with DM2 suffer from proximal muscle weakness 36,37. 
DMPK mRNA levels are decreased in adult DM1 tissue. Hence, DMPK deficiency was initially 
proposed to be the underlying pathogenic mechanism in DM1. The decreased levels were attributed 
to the retention in nuclear foci, because transcription of DMPK does not seem to be altered when an 
expanded (CUG)n is present 
38-40. Although initial studies of DMPK-deficient mice only showed muscle 
weakness 41,42, later it was suggested that DMPK haploinsufficiency causes skeletal and cardiac muscle 
abnormalities through changes in sodium and calcium channels 43,44. However, reduced DMPK activity 
cannot account for all aspect of DM, thus other pathogenic mechanisms must also exist.
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Although the two genes involved in DM1 and DM2 are functionally different, the syndromes share a 
toxic RNA gain-of function mechanism. The first evidence pointing in this direction was that almost all 
of the expanded repeat-containing mRNAs were retained in nuclear foci 38. It is now known that the 
expanded RNA (CUG)n molecules can form secondary structures, like hairpins 
45,46, which is thought to 
be the cause of their retention in nuclear foci. In these foci, they sequester RNA-binding proteins (RNA-
BPs), which bind specifically to (CUG)n (CUG-BPs) 
45,47,48. Since mRNA processing, including splicing, is 
normally regulated by a dynamic complex of RNA-BPs, the function of these proteins in the presence 
of expanded (CUG)n was investigated. Splicing of the repeat-containing DMPK and ZNF9 mRNAs occurs 
normally. However, expanded C(C)UG-repeats in DM were found to affect splicing of certain other mRNAs 
in a trans manner 17. For instance, the expanded C(C)UG-repeats induce misregulation of alternative 
splicing of a muscle-specific chloride channel (CLCN-1) and the insulin receptor. This has clear clinical 
consequences, as DM1 patients have lower CLCN-1 levels and an insulin-resistant diabetes that is due 
to a skeletal muscle defect in insulin signalling. Thus, these two examples of splicing misregulation 
provide a strong molecular basis for the clinical symptoms 17.  
CUG-BP1 and Muscleblind-like protein 1 (MBNL1) were found to bind (CUG)n. CUG-BP1 is 
an hnRNP and a member of the CUG-BP/ETR-3-like (CELF) family of proteins that regulate alternative 
splicing, editing and translation 49,50. Binding of MBNL1, but not CUG-BP1, is proportional to (CUG)n 
length. Timchenko and co-workers proposed a model in which (CUG)n-BPs are sequestered to expanded 
DMPK-(CUG)n, which then causes aberrant expression of other transcripts that need these proteins for 
normal gene expression 49. MBNL1 is a specific (CUG)n-BP, homologous to the Drosophila muscleblind 
proteins, which are essential in terminal differentiation of muscle and photoreceptor cells. The human 
homologue of muscleblind is also involved in mammalian myoblast differentiation. It accumulates in 
the nuclear foci in DM1 cells. Miller and colleagues expanded the protein sequestration hypothesis 
such that the mutant DM1 mRNA provides a competing alternative substrate for the MBNL1 protein. In 
this way it might be sequestered away from its normal RNA-binding sites during a critical period of cell 
differentiation 48. 
MBNL1 and CUG-BP1 have been described as antagonistic splicing regulators of specific 
transcripts affected in DM 51-54. Relative activities of CELF proteins and human Muscleblind control an 
important developmental switch in splice pattern. CELF proteins promote an embryonic splice pattern 
for certain transcripts, while an adult pattern is seen when MBNL1 activity predominates. In DM, the 
switch to an adult splice pattern does not occur. Thus developmentally programmed alternative splicing 
may be perturbed due to a loss-of-function mechanism for MBNL1, while a (CUG)n-BP gain-of-function 
mechanism must be underlying the maintenance of the embryonic pattern (summarised in 55).  
Evidence supporting this hypothesis is now accumulating from murine models. For instance, 
deletion of Mbnl1 exon 3, which prevents formation of (CUG)n-binding isoforms, results in a DM-like 
phenotype, including splicing abnormalities similar to those seen in human DM. Kanadia et al. suggested 
that muscleblind-like proteins may play a direct role in splice-site selection 53. The Mbnl1 mutation did 
not reproduce all aspects of DM seen in humans, thus additional muscleblind proteins (Mbnl2 and 
Mbnl3), which are also recruited to nuclear RNA foci in DM 47, might also be involved. Alternatively, the 
repeat expansion may have other effects that contribute to the broad manifestation of the disease 53. In 
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contrast, transgenic mice overexpressing CUG-BP1 in heart and skeletal muscle share disrupted tissue 
architecture with tissues in DM, as well as dysregulated splicing of transcripts known to be aberrantly 
regulated in DM. These results confirm the postulated gain-of-function activity for CUG-BP1 in the 
presence of expanded repeats, resulting in maintenance of the embryonic splice patterns, as well as a 
trans-dominant effect on specific pre-mRNA targets 51. 
In addition, Drosophila models have provided evidence for the above outlined model. Flies 
expressing a non-coding expanded (CUG)n show several DM features, among which muscle wasting 
and altered CUG-bp1 and mbnl1 levels and distribution. Overexpression of human MBNL1 suppressed 
the (CUG)n-induced toxicity, while higher levels of human CUG-BP1 worsens the phenotype 
56. It is, 
however, still unknown how expansion of the C(C)UG-repeats can alter the activities of CUG-BP1 and 
MBNL. 
Fragile X-associated tremor/ataxia syndrome
In FXTAS, as described extensively in chapter 1, a (CGG)55-200 is present in the 5’UTR of the FMR1 gene 
57. 
Elevated FMR1 mRNA levels and mildly reduced FMRP levels suggest that toxicity originates at the RNA 
level (reviewed in 58). Also, the fact that no symptoms of FXTAS have been observed in elderly carriers 
with the full mutation (>200 CGGS, which silences FMR1), indicates that a lack of FMRP is not likely 
the cause of the clinical symptomatology seen in FXTAS. Post mortem immunohistochemical studies 
on FXTAS brain revealed the presence of ubiquitin-positive intranuclear inclusions in neurons and 
astrocytes in many brain regions, which also contain FMR1 mRNA 59-61. 
FXTAS has been proposed to be the result of a pathogenic RNA gain-of-function mechanism 
similar to what happens in myotonic dystrophy 62. Interestingly, MBNL1, among many other proteins, 
has been identified in the intranuclear inclusions in human FXTAS brain 63. No downstream effects on 
splicing patterns like in DM have been described to occur in FXTAS yet. Although some signs of cellular 
toxicity (reduced viability, disrupted lamin A/C architecture) have been observed in cellular models 60,64, 
it remains to be elucidated how the expanded (CGG)n leads to altered cellular function and ultimately 
to clinical symptoms. 
Studies are currently focussing on finding possible (CGG)n-BPs that are depleted from their 
normal functions, thereby causing cellular dysfunction. Indeed, studies in Drosophila have identified 
hnRNP A2/B1 and pur α as (CGG)n-BP. Expression of expanded (CGG)n-containing constructs in flies 
induces a neurodegenerative eye phenotype, which could be suppressed when hnRNP A2/B1 or 
pur α was overexpressed. Also CUG-BP1 was found to interact with the (CGG)n, via hnRNP A2/B1, and 
overexpression of CUG-BP1 suppressed the eye phenotype as well 65,66. Thus, these findings support 
a pathogenesis model that predicts that PM-sized (CGG)n sequester RNA-BP, which leads to altered 
cellular function. However, a role for these proteins in humans remains to be confirmed, as well as the 
precise mechanism through which they cause the neuropathological features seen in FXTAS. 
A clear difference in the pathogenesis of FXTAS and DM is that in FXTAS FMR1 transcript levels are 
increased, while DMPK and ZNF9 are normally expressed. The syndromes are, however, believed to 
result from similar downstream RNA-BP-mediated pathways. The explanation for this discrepancy 
might lie in the fact that disease-associated C(C)UG-repeats are much longer (DM1: ranging from 50 to 
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thousands of CUGs, DM2: between 75 and 11.000 CCTGs), as opposed to 55-200 CGGs in FMR1. MBNL1-
binding was found to increase with repeat length 48. The same toxic effect might, however, be exerted 
by shorter, but more abundant repeat tracts in FXTAS. In Drosophila models for FXTAS, the severity of 
a (CGG)n-induced eye neurodegeneration phenotype was found to be dependent on both expression 
level and length of the (CGG)n-containing transgene 
67. Interestingly, penetrance of FXTAS appears to 
be dependent on (CGG)n length 
57; a threshold might exist for the number of RNA-BPs bound to the 
expanded repeat, for cellular toxicity to become apparent.
Another difference lies in the fact that all carriers of expanded C(C)UG-repeats in DMPK and 
ZNF9 will develop DM, while only a part of carriers of (CGG)55-200 will suffer from FXTAS. It remains to 
be solved why some PM carriers are at higher risk of developing this syndrome than others, although 
additional aging factors might play a role.
mechanism repeat 
sequence
gene chromosomal 
localisation
position within 
gene
normal 
range
disease 
range
disease
 
reviewed 
in:
protein
loss-of-
function 
(CGG)n FMR1 Xq27.3 5’UTR 5-55 >200 FXS Fragile X syndrome  21
(GGC)n FMR2 Xq28 5’UTR 6-25 >200 FRAXE FRAXE associated mental 
retardation
 26
(GAA)n FDRA 9q13-21.1 intron 1 34-100 200-1700 FRDA Friedreich ataxia  31, 32
RNA
gain-of-
function
(CTG)n DMPK 19q13 3’UTR 5-37 50-3000 DM1 Myotonic dystrophy type 1 35, 37
(CCTG)n ZNF9 3q21 intron 1 <27 75-11000 DM2 Myotonic dystrophy type 2  35, 37
(CGG)n FMR1 Xq27.3 5’ UTR 5-55 55-200 FXTAS Fragile X-associated tremor ataxia 
syndrome
 58, 70
uncertain (CTG)n SCA8 19q13 3’ UTR 16-34 >100 SCA8 Spinocerebellar ataxia type 8  77
(ATTCT)n ATXN10 22q13 intron 1 <29 >800 SCA10 Spinocerebellar ataxia type 10  78
(CAG)n PPP2ABb 5q32 5’ UTR <32 51-78 SCA12 Spinocerebellar ataxia type 12  79, 80
protein 
gain-of-
function
(CAG)n AR Xq13-21 coding region 9-36 38-62 SBMA Kennedy’s disease / Spinobulbar 
muscular atrophy
93, 97
(CAG)n Huntingtin 4p16.3 coding region 6-35 40-121 HD Huntington’s disease 104
(CAG)n SCA1 6p23 coding region 6-44 39-82 SCA1 Spinocerebellar ataxia type 1  17
(CAG)n SCA2 12q24.1 coding region 14-31 34-62 SCA2 Spinocerebellar ataxia type 2 17
(CAG)n SCA3 14q32.1 coding region 12-~43 >60 SCA3 Spinocerebellar ataxia type 3/
Machado-Joseph disease
17
(CAG)n CACNA1A 19p13 coding region 5-18 20-33 SCA6 Spinocerebellar ataxia type 6 17
(CAG)n SCA7 3p12-21.2 coding region 7-34 >37 SCA7 Spinocerebellar ataxia type 7 17
(CAG)n TBP 6q27 coding region 25-44 45-66 SCA17 Spinocerebellar ataxia type 17 17
(GCG)n PABP2 5q32 coding region 6 8-13 OPMD Oculopharyngeal myotonic 
dystrophy
108 
(CTG)n JPH3 16q24.3 coding region 6-28 40-58 HDL2 Huntington’s disease-like 2  111
Table 2.1  |  Characteristics of all microsatellite repeats described in this chapter and the diseases that they cause, categorised by the pathogenic 
mechanism thought to underlie these neurological trinucleotide repeat disorders.
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Uncertain pathogenic mechanisms in the spinocerebellar ataxias
Expanding repeats furthermore cause a group of disorders referred to as the spinocerebellar ataxias 
(SCAs). Nine SCAs have been described to date, of which three (SCA8, -10 and -12) are caused by repeats 
in non-coding regions of different genes. SCA8 is the result of a (CTG)n in the 3’UTR of the gene coding 
for Ataxin-8, while SCA10 involves an (ATTCT)n in intron 1 of the ATXN10 gene. SCA12 is caused by 
a (CAG)n in the 5’UTR of the gene for phosphatase PP2ABb. The other SCAs involve (CAG)n in coding 
regions of genes and will be discussed hereafter. Even though the repeats are non-coding, it is not yet 
certain that these SCAs results from an RNA gain-of-function mechanism. Many questions concerning 
these syndromes remain unanswered to date. 
Patients with SCA8 usually present with a slowly progressive ataxia that largely spares 
brainstem and cerebral functions. Speech is affected and oculomotor problems are common, among 
other symptoms. (CTG)>100 in the SCA8 locus is associated with the disease. However, some individuals 
show largely expanded alleles, while they are devoid of any clinical symptoms associated with SCA8. 
Thus, it seems likely that additional environmental or genetic modifiers influence disease penetrance. 
Based on observations in transgenic mice and flies, which show parallels to aspects of DM and FXTAS, 
an RNA gain-of-function mechanism has been proposed to underlie SCA8, although further studies will 
have to confirm this 69.
SCA10 is the only human disease known to be caused by an expansion of a pentanucleotide 
repeat. The clinical picture can range from pure cerebellar ataxia to a more complex syndrome also 
involving epilepsy, neuropsychological disturbances, sensory neuropathy and corticospinal tract 
signs 70. Pentanucleotide repeats shorter than 29 units are present in normal alleles of the ATXN10 gene. 
(ATTCT)>800 are considered SCA10 mutations. It is currently uncertain what risks the intermediate repeat 
range pose on the carrier. The function of the ATAXN10 protein product is unknown and the pathogenic 
mechanism that causes SCA10 remains to be elucidated. Since transcript levels are not reduced in 
patient cell lines, an RNA gain-of-function mechanism has been proposed 36. 
SCA12 is a very rare disease. Normal alleles have up to 32 trinucleotides in the gene coding for 
phosphatase PP2ABb. The lower border of disease-causing repeat length is unclear, but clearly affected 
patients have alleles in the range of 51-78 CAGs. Early clinical signs are action tremor of arms and the head, 
which typically start in the third or fourth decade of life. Over the next 20-30 years the clinical pattern 
aggravates. Late stages of SCA12 may also involve cognitive decline. The gene PPP2ABb encodes one 
of the brain-specific regulatory subunits of the trimeric phosphatase PP2A. The repeat seems to affect 
transcriptional efficiency, as transcript levels are increased. Protein levels are also elevated. Many splice 
isoforms exist and it is conceivable that the SCA12 repeat expansion could disrupt splice regulation, 
thereby altering the function of PP2A. PP2A is an enzyme ubiquitously expressed and involved in many 
cellular processes, including apoptosis. The slow clinical course of SCA12 might suggest a gene dosage 
effect under the influence of modifying factors. A role for a toxic (CAG)n-containing transcripts can, 
however, not be excluded in the development of SCA12 71, neither a toxic polyQ-containing protein 72.
Gain-of-function at the protein level  |  2.1.3
The most common trinucleotide repeat in coding regions causing disease by altering protein physiology 
is the (CAG)n. When translated, this results in a polyglutamine (polyQ)-tract in the protein, obviously 
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affecting its structure and function. Although expansion sizes, structures, cellular localisation and 
functions of the resulting proteins differ, all (CAG)n-induced diseases are neurodegenerative disorders, 
involving the central nervous system 78-80.  
All disorders are associated with neuronal intranuclear aggregates that contain the disease-
causing gene product. In some cases polyQ-containing aggregates may also form outside the nucleus 81-84. 
In vitro studies demonstrated that polyQ-stretches have an inherent ability to aggregate. Apart from 
binding to many other proteins, glutamine also shows self-interaction, which may to a large extent 
account for the tendency of polyQ to aggregate 85. Once polyQ-stretches exceed a certain length, 
they are no longer soluble and form aggregates in solution. The threshold length above which in 
vitro aggregation takes place, is strikingly similar to the threshold causing disease 86. Nine expanded 
(CAG)n disease-associated genes have been identified. However, these are not the only polyQ-encoding 
sequences in the genome. Stretches above as well as below the threshold length for disease (~35-
40 CAGs) are seen. Knowing the normal function of polyQ-tracts might facilitate understanding how 
expansion of the (CAG)n-tracts and loss of the normal protein function causes disease, but to date not 
much is known about this 85.
In vivo protein aggregates also contain molecules other than the proteins containing the 
expanded polyQ-repeats. It is tempting to hold the aggregates responsible for the development of 
disease, some evidence exists however that large aggregates are not the primary cause of cell toxicity. 
Some disease models have indeed shown cell toxicity in the absence of aggregates, or toxicity was 
found to decrease as aggregate density increased 87.
Kennedy’s disease (spinobulbar muscular atrophy)
Kennedy’s disease (or spinobulbar muscular atrophy: SBMA) was the first disorder that was described 
to result from expansion of a polymorphic (CAG)n in the coding region of the androgen receptor gene 
located on the X-chromosome 5. Patients have 38-62 CAGs as opposed to 9-36 in normal controls. 
Affected males suffer from muscle cramps and develop proximal muscle weakness from their forties 
onwards 88. The androgen receptor is a nuclear receptor, which gets translocated to the nucleus upon 
androgen binding in the cytoplasm, in order to regulate transcription of hormone-responsive genes. 
The polyQ tract is located in the trans-activation domain 73,89. Presence of an expanded (CAG)n results 
in decreased receptor expression and altered transcriptional activation 90-92. This may account for the 
androgen insensitivity seen in SBMA patients, but it does not seem to explain motor neuron toxicity. 
Therefore it has been proposed that the mutant androgen receptor causes motor neuron dysfunction 
by a toxic gain-of-function 74.
Huntington’s disease
George Hungtington described the clinical features of what would later be named Huntington’s Disease 
(HD), including progressive involuntary movements (chorea), incoordination, general motor disability 
and several mental and personality problems already in 1872. Despite intensive efforts to find the gene 
for HD, identification of the coding (CAG)n in Kennedy’s disease did not prompt the HD Collaborative 
Research Group to focus on this mechanism 93. Only after myotonic dystrophy was recognised to 
result from an expanded trinucleotide repeat, such a repeat responsible for HD was searched for and 
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found. The expanded (CAG)n is located at the N-terminus of the gene that codes for a protein named 
Huntingtin 94. The precise function of normal Huntingtin remains to be established, although it is 
known to be involved in several cellular processes such as vesicular transport, cytoskeletal anchoring 
and clathryn-mediated endocytosis 95. Although loss-of-function of Huntingtin may account for some 
of the pathogenesis seen in HD, evidence points to a more prominent role for a toxic gain-of-function of 
the mutant Huntingtin protein. Inclusion bodies containing N-terminal Huntingtin and ubiquitin have 
been found in neuronal nuclei and neuronal processes of post-mortem brain material of HD patients. 
The clear correlation between the threshold of Huntingtin aggregation and the (CAG)n length which 
causes disease, suggests that aggregated (CAG)n-containing Huntingtin is a major toxic mechanism 
underlying HD 96. Abnormal protein interactions with mutant Huntingtin could take place, possibly 
leading to co-aggregation of other proteins. However, the precise mechanism by which inclusions lead 
to pathology, and whether they are a prerequisite for pathology remains to be elucidated 97,98. Also, 
evidence exists that inclusions might exert a neuroprotective effect by sequestering more toxic forms of 
the aggregated protein 75,97. However, transgenic mouse models have provided clear evidence that the 
presence of inclusions in the nucleus and neuronal processes is correlated to disease pathogenesis 99. 
A conditional mouse model showed reversal of neuropathology and disappearance of inclusion bodies, 
when mutant Huntingtin expression was turned off 100. 
Spinocerebellar ataxias
Expanded (CAG)n in coding regions are furthermore the cause of SCA1, 2, 3, 6, 7 and 17. These SCAs 
share many clinical and pathological features, which makes it difficult to distinguish them based on 
clinical symptoms, although some features may be more common in a specific SCA subtype. SCAs 
typically become evident around middle age, to progress to early death within 10 to 20 years. Cerebellar 
atrophy as seen in neuro-imaging studies is observed in all SCAs, as well as Purkinje cell loss. Loss of 
brain stem neurons, such as the inferior olive, is commonly seen in all SCAs, although milder in SCA6 
and not in SCA3. SCA3 also seems to be relatively spared with regard to cerebellar neurodegeneration. 
In SCA3 basal ganglia, brain stem and spinal cord are most affected (summarised in 17). Other than 
sharing a polyQ-tract, the gene products of the different SCA-genes bear no homology. SCA1-3 and 
-7 are caused by Ataxin-1 through -3 and -7 respectively, while SCA6 involves the α1A-subunit of the 
voltage-dependent calcium channel (CACNA1A), and SCA17 is the result of an expanded polyQ-tract in 
the gene coding for TATA-binding protein (TBP). Each disease has different normal and disease-causing 
(CAG)n length ranges and different pathways through which they cause disease, but for all is true that 
the age at onset of symptoms gets earlier as the repeat tract gets longer 17. 
All these (CAG)n-induced diseases suggest that the pathogenic polyQ-containing proteins escape the 
otherwise strict protein quality control mechanisms. PolyQ-elements likely impair a protein to fold into 
its functional native conformation. Heat shock proteins (hsp) such as Hsp40 and Hsp70 act as chaperones 
by recognising misfolded proteins and facilitating refolding. When refolding is unsuccessful, a few 
ubiquitin monomers will be attached to the protein, which is the signal for degradation by the ubiquitin 
proteasome system (UPS). Formation of inclusions in many polyQ-associated diseases suggests that 
these cellular quality control mechanisms fail to deal appropriately with mutant polyQ-containing 
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proteins. Research focussing on the precise role for chaperones and the UPS in these diseases could 
lead to promising therapeutical strategies 96. However, despite overlapping characteristics of the 
expanded polyQ diseases, it is clear that they all differ, depending on how the expanded (CAG)n affects 
the protein. It cannot be ruled out that in some cases loss-of-function of the polyQ-containing protein 
contributes to the pathogenesis 17. Alternatively, one could wonder whether the repeat-containing RNA 
also contributes to pathogenesis in polyQ-mediated disease 101.
Other trinucleotide repeats in coding regions
Other coding repeats that cause neurological disease include a (GCG)n, coding for a polyalanine-tract, 
in the poly(A)-binding protein 2 (PABP2), which causes oculopharyngeal myotonic dystrophy (OPMD). 
It is interesting to note that these (GCG)n are short, namely 8-13 repeat units in the OPMD families, as 
opposed to the normal allele which is 6 GCGs long. The (GCG)n represents the first short trinucleotide 
repeat discovered, which causes human disease. Furthermore, the (GCG)n does not show the features of 
a dynamic mutation. For instance, it is meiotically quite stable 76. The polyalanine-tract was postulated 
to cause pathologically expanded PABP2 to accumulate as filament inclusions in nuclei, which are seen 
in OPMD patients 102. 
Furthermore, an expanded (CTG)n in an alternatively spliced exon of the junctophilin-3 (JPH3) 
leads to Huntington disease-like 2 (HDL2). Two of three splice isoforms result in the presence of the 
repeat in the coding region, leading to a polyalanine or a polyleucine tract 103. Intranuclear protein 
aggregates have been seen in brain, but the polyalanine and polyleucine tracts do not seem to play a 
major role in the formation of the aggregates, nor in the pathogenesis of HDL2 in general. It has also 
been postulated that HDL2 expansions can lead to formation of RNA inclusions, which might suggest 
that HDL2 pathogenesis might originate at the level of toxic transcripts 77. 
Timing of repeat instability  |  2.2
When trying to elucidate the mechanism of repeat instability, timing of the event is a major aspect that 
remains surrounded by question marks. The fact that repeat length changes between generations, tells 
us that instability occurs at some point between gametogenesis in the parent and early embryogenesis. 
Attempts have been made to gain insight into what happens around fertilisation, although availability of 
human material is limited. Some of the findings that shed light on when the fragile X dynamic mutation 
takes place will be discussed, as well as the timing of events in other trinucleotide repeat disorders.
Timing of expansion in the dynamic fragile X mutation  |  2.2.1
Remarkable observations that expansions to a fragile X FM occur only upon maternal transmission of 
a PM allele, and that daughters of FM males are clinically and cytogenetically normal, were explained 
when it was observed that male fragile X patients only have PM alleles in their sperm 104. Two models 
have been proposed to explain this finding. 
First, the prezygotic model predicts that an expansion of PM to FM could occur during maternal 
meiosis (figure 2.2). This means that the FM must contract to a PM in gametes of male offspring. PM 
gametes might have some selectional advantage either due to the presence of FMRP, or against the 
presence of an expanded (CGG)n. However, FMRP is not required for spermatogenesis 
105,106. FMRP 
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expression might still be beneficial to the spermatogonia as they mature. A selective advantage for 
cells expressing FMRP was indeed seen in cell culture studies 107.
In 13-week old FM foetuses, no PM alleles were detected in testes, while in 17-week old FM 
foetuses some primordial germ cells expressing FMRP were observed. This suggests that contraction 
from FM to PM occurs in the maturation process of the testis, after the initial replication event 108. 
Paternally derived alleles have been shown to undergo rapid demethylation in murine zygotes, before 
the first round of replication, while CpG methylation is maintained in maternally derived alleles 109. 
CpG methylation appears to stabilise the DNA. Hence, paternally derived alleles could be prone to 
deletions upon demethylation 110. Furthermore, FMs are responsible for a delay in replication of the 
FMR1 gene during the cell cycle 111,112. The large number of cell cycles associated with spermatogenesis 
might enhance a selectional effect 113. Thus, primordial germ cells with a PM might have a proliferative 
advantage, thereby overgrowing FM cells. However, if multiple contraction events can take place, it is 
puzzling why only one distinct PM band is mostly seen in sperm of FM men 104. 
The other model considers a postzygotic expansion, after separation of the germ line. It 
assumes that the FM allele has never been present in male or female gametes 114,115. However, oocytes of 
a foetal female FM carrier had only FM alleles 108. It is however unknown whether oocytes of a female PM 
carrier bear PM or FM alleles. A postzygotic expansion mechanism occurring only for a PM allele on the 
maternal X-chromosome, would require an imprinting mechanism to distinguish it from a paternally 
derived PM, which would not expand 104,116.
Figure 2.2  |  The prezygotic model of expansion of 
the fragile X mutation. This model assumes that an 
expansion of a maternal PM to an FM takes place during 
meiosis. The fertilised oocyte carries an FM allele. After 
separation from the embryo proper, the primordial germ 
cells (PGCs) have an FM. Some alleles will contract to PMs. 
To explain why FMs are only transmitted through females, 
some selection must exist agains FMs in the male germ line 
during spermatogenesis. In the mature testes, PM alleles 
predominate. In somatic cells and the female germ line, 
this selection did not take place. Cells with a PM are shown 
in black and cells with an FM are depicted in grey. See page 
163 onwards for colour version of this figure. 
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Based on a simulation study and analysis of tissues of affected foetuses, Moutou and co-workers favour 
a prezygotic model, whereby a selection mechanism accounts for the sole presence of PM alleles in 
sperm of male offspring. However, they cannot exclude a postzygotic model in which a transition occurs 
at the early morula stage 117. Naturally, a final conclusion can only be drawn after analysis of oocytes 
in ovaries from an embryo carrying a PM allele. Unless the embryo suffers from a different detrimental 
defect, this material is not available for obvious reasons. Also, oocytes from an adult PM carrier would 
provide useful information. However, the most likely reason for an ovarium to become available is when 
a female PM carrier suffers from POF. In this case, naturally, almost no oocytes are present anymore. 
Expanded (CGG)n knock-in mouse models have been developed 
118,119, that show intergenerational 
repeat instability 119,120. These models will be valuable in answering remaining questions.
Timing of expansion in other trinucleotide repeat disorders  | 2.2.2 
Also for other trinucleotide repeat disorders, the exact timing of expansion is still under debate. 
Intergenerational expansion in DM1 was suggested to result from initial expansion, followed by 
somatic instability 121. This initial instability was first suggested to occur between week 13 and 16 of 
gestation 122-125. However, the youngest foetuses that were investigated were obtained at 10-12 weeks 
of gestation and they already showed major expansion as compared to the parental allele 121,122,124. 
Furthermore, studies in tissues of monozygotic twin pairs showed identical expansion patterns 121,126,127. 
Monozygotic twinning occurs at the latest on day 10.5 of embryonic development 128, thus this first 
wave of instability is likely to happen in very early embryonic stages. Interestingly enough, analysis of 
expanded DMPK alleles has been done in oocytes and embryos of mothers with expanded (CTG)n, who 
underwent in vitro fertilisation (IVF) with pre-implantation diagnostics for DM1. This study revealed that 
expansions are already detectable in oocytes, including an immature oocyte (germinal vesicle stage) 
and embryos, as early as the three-cell stage 129. An earlier study had also observed that enlargement 
of a (CTG)n had occurred at the germinal vesicle stage, that is, either during premeiotic proliferation of 
oogonia, or during prophase I of meiosis I 130. Similar to the fragile X dynamic mutation, although to a 
lesser extent, a selection mechanism against further expansion of long alleles in sperm has also been 
proposed for DM1 121. 
(CAG)n expansions have also been detected in oocytes in a transgenic mouse model for 
SCA1, thus after meiotic DNA replication and prior to fertilisation 131. Thus, oogenesis seems the most 
likely moment of (CTG)n expansion 
129,130. However, an asymptomatic male carrying a somatically stable 
(CTG)52, showed major instability in the germ line, with a bias towards expansion. The mean repeat 
length in this man’s sperm was (CTG)238, which was consistent with the large alleles inherited by two of 
his offspring 132. 
Transmission of normal alleles was also investigated in donated supernumerary IVF embryos. 
In individuals who carried both a (CTG)5-18 and a (CTG)19-37 allele, the (CTG)19-37  allele was transmitted 
to the offspring in 59% of cases. Of these transmissions, 7% was unstable when the (CTG)19-37  allele 
was of paternal origin, whereas no instability of maternal alleles was seen. Thus, instability of normal 
DMPK alleles can occur during male gametogenesis or early embryogenesis. It remains to be elucidated 
whether expansions in the normal range are the result of the same mechanism as that which yields 
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larger expansions. Also, further studies will need to clarify whether (CTG)n expansion continues after 
fertilisation, during embryonic cell division 129. 
The magnitude of intergenerational (CAG)n expansions increases greatly with the age of the 
transmitting father 133. The frequency of (CAG)n expansions in sperm was found to increase with length of 
the inherited repeat allele 134,135. Both increased magnitude and frequency with age are mimicked in mouse 
models for DM 136,137. Accumulation of expansions in sperm explains the positive correlation between 
age of the transmitting father and the repeat length in the offspring 137,138. However, another study in 
a DM mouse model did not show significant differences between spermatozoa and spermatogonia, 
implicating that germinal expansions are already present very early in spermatogenesis 136. Furthermore, 
a recent study did not find a correlation between (CAG)n length variation in sperm and age of HD 
patients 139.
Instability of repeats in coding regions has been less well characterised. Expansions of the 
(CAG)n  have been observed in sperm of HD patients 
134,135, as well as transgenic mouse models for HD 140. In 
the mouse model the (CAG)n  expansions in the male germ line seemed to occur in late spermatogenesis, 
in post-mitotic and post-meiotic cells (transition from round to elongated spermatids) 140. Analysis of 
testicular germ cells of two men who died from HD showed that repeat expansions were already present 
before the end of the first meiotic division, and in some cells even before the start of meiosis. However, 
the majority of the larger expansions was found in the postmeiotic cell population, suggesting that 
instability processes may continue after meiosis 141. 
Study of a possible age-effect of transmitting females has led to opposing results 142. A study 
in superovulated female transgenic SCA1 mice showed an age-dependent contraction-biased repeat 
instability in unfertilised mature oocytes. In oocytes harvested from mice of 7-weeks of age, very little 
repeat size heterogeneity was seen, which suggests that instability might occur during germ cell cycle 
arrest in meiosis I 131. Thus, different mechanisms appear to underlie the instability occurring in male 
and female gametogenesis.
Somatic repeat instability  |  2.3
Despite the intergenerational repeat instability that links all diseases described in this chapter, the 
extent of somatic instability varies. In fragile X syndrome, for instance, many patients show a smear 
of FM repeats on Southern blot, indicating a range of repeat lengths 2,143. A subset of patients also 
has a PM allele (mosaisics) 144-146. Repeat patterns of monozygotic twins of 9- and 30-year old showed 
extraordinary similarity 114. Thus very little, if any, somatic (CGG)n instability occurs over the course of life. 
The proposal that CpG methylation stabilises the repeat 110 might explain the lack of somatic instability 
in fragile X patients. Cell culture experiments with FM fibroblast lines showed remarkably stable 
transmission of the repeat to progeny cells. Thus, this contradicts that (CGG)n are mitotically unstable. 
Indeed, if they were, one would expect more random patterns of repeat lengths among different 
tissues 115. However, foetal female fragile X fibroblasts, which were cultured for many passages, showed 
dramatic instability, while male adult fragile X fibroblasts did not. Thus, further repeat expansion was 
observed during cell proliferation in female fibroblasts, outside the proposed time window of early 
embryonic development 147. 
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Minor somatic instability was observed in the expanded (CGG)n mouse model, when comparing 
tissues at 52 weeks of age with tail DNA obtained at 10 days postnatally. Increase in repeat length 
was never larger than 10 triplets, with kidney and testis showing more instability than brain. Somatic 
instability might contribute to tissue specificity and disease progression. Thus, it was concluded that 
somatic instability in the brain does not play a major role in this mouse model, although the influence 
of instability on individual neurons cannot be excluded 148.
Other trinucleotide repeat disorders show substantial somatic instability. In particular, 
the (CTG)n in DM1 is highly unstable in many tissues. Studies set up to investigate intergenerational 
instability, already revealed tissue heterogeneity of repeat length 122-125. (CTG)n length indeed appears 
to depend on the type of cell lineage 123,125,149-153. As it was found that the (CTG)n length in lymphocytes 
does not correlate well with the severity of the phenotype 154-158, somatic mosaicism was suggested 
as a possible explanation 123. Observations that muscle cells consistently show longer repeats than 
peripheral blood leukocytes, point in this direction 149-152. To date no studies have been published that 
correlate repeat length in several tissues from adult DM1 to the severity of the phenotype. However, it 
has been suggested that ongoing expansions in somatic cells may contribute to the progressive and 
tissue-specific nature of DM 153,159.
Somatic (CTG)n instability is repeat-size and age-dependent. Thus, older patients show a 
longer average repeat size 151,153. Since somatic expansion occurs in both post-mitotic and proliferating 
tissues, it must be a process independent of cell division 121. In a knock-in mouse model for DM1, which 
reproduces somatic instability of the (CTG)n, it was observed that once alleles had expanded, they 
continued to increase in length. In contrast, the portion of cells that did not show instability, remained 
constant. The researchers observed a bimodal profile for repeat length (i.e. two major repeat lengths), 
which became more pronounced with age. They considered aging and terminal differentiation to play a 
role 160. In liver cells, polyploidisation marks late differentiation 161. It was therefore investigated whether 
acquiring a greater than diploid DNA content affects hypermutability. Indeed, about 50% of liver cells 
became tetraploid-octaploid, and 80% of cells were binuclear. These changes were accompanied by an 
overall increase in expansion frequency, as compared with diploid, mononuclear cells. It is unknown 
how these factors affect somatic (CTG)n stability. These findings also serve as evidence for expansion 
to be a post-replicative event 160. To date, this has not been described for other mouse models for DM1, 
neither for other trinucleotide repeat disorders. The mouse model for FXTAS 118,120,148 does not show 
increased somatic instability in polyploidic or multinuclear hepatocytes (unpublished results). 
Mouse models for DM also show somatic instability throughout life 151,153. It is interesting to 
note that different individual mice of the same mouse line presented the same pattern of mosaicism, 
that is, more instability in some tissues and less in others. This means that somatic instability is not 
a random process, but that some, as yet unknown, deterministic processes underlie these tissue 
differences (reviewed in 142).
The observation that the (CAG)n length heterogeneity observed in HD offspring does not 
correspond to that in the transmitting parent, suggests somatic instability 134. Early studies demonstrated 
(CAG)n length heterogeneity within and between tissues, with the largest degree of mosaicism seen in 
brain and sperm 162,163. Interestingly, region-specific repeat length analysis revealed dramatic increases 
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in repeat length in the striatum, which is the brain region that is primarily affected in HD, both in a 
mouse model for HD 164 and in early-stage HD patients 165. 
In a mouse model for HD, a gender effect for direction of instability was seen in offspring 
from identical fathers, which shows that repeat length can change in the early embryo 166,167. No further 
somatic instability was seen in these animals, when testing several tissues and at later stages in life 167. 
Higher levels of (CAG)n length variation had been observed in buccal cell DNA as compared 
with DNA obtained from blood in patients with SCA7 168. Analysis of buccal cell DNA of HD patients 
showed that (CAG)n length variability depends on the size of the inherited allele, where larger repeats 
lead to a higher degree of somatic mosaicism. No large length gains were seen in buccal cells, as 
opposed to the previously detected large expansions in brain. No effect of age on repeat instability in 
buccal cells was seen 169. Somatic (CAG)n instability has also been seen in SCA1, SCA3, SCA7, SBMA and 
FRDA 142.
Molecular mechanisms of repeat instability  |  2.4
It remains to be solved whether intergenerational and somatic instability arise from the same 
mechanisms. Most studies that attempt to elucidate the molecular mechanisms of repeat instability 
deal with intergenerational instability. Evidence from these studies will be described.
One of the first proposed mechanisms involved in repeat instability at the molecular level 
was slippage of the replication fork during replication. Unpaired bases form loops, which result in 
expansions or contractions in a next round of replication, depending on whether the looped repeats 
are in the newly synthesised or template strand (figure 2.3,  170,171). However, slippage cannot explain all 
aspects of repeat expansions, for example, it would predict only limited expansions, rather than large-
scale expansions. 
New insights came from the realisation that the expandable repeats have unusual structural 
properties. Disease-causing trinucleotide repeats are almost exclusively formed of (CNG)n  triplets. 
Single-stranded (CNG)n can form hairpin-like structures that can have both Watson-Crick and 
mismatched base pairs 172. The leading and lagging strand have different tendencies to form hairpins, 
due to their different sequences. This makes the slipped-stranded DNA asymmetrical, which has 
important biological consequences. Hairpin formation on one strand might cause the slip-out on the 
other strand to be in random-coil state. The structure of the slip-outs is likely to affect recognition and 
subsequent repair or recombination of this structure 173. Most prominent instability occurs when the 
structure-prone strand serves as the lagging strand template 16. 
An alternative model is based on in vitro observations that unusual structures formed by 
expanded repeats stall DNA polymerases 174-176. In vivo studies showed that the orientation of the 
repeat relative to an origin of replication largely determines the stability of the repeat 177-180, which 
underscores the biological meaning of the asymmetrical conformation of the slipped-stranded DNA. The 
orientation-dependence of instability was hypothesised to be a result of temporary existence of single-
stranded DNA during lagging strand synthesis. This could allow formation of hairpins. The tendency 
to form hairpins is dependent on the exact sequence of the repeat of the lagging strand template. 
However, evidence that does not support this model exists. Thus, it is unclear why hairpins form in an 
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orientation-dependent manner, but most models agree that replication can generate small insertions 
and deletions 181. An origin of replication was recently identified adjacent to the FMR1 promoter. The 
position of this origin of replication with respect to the (CGG)n is such that it favours contraction. This is 
because the CGG sequence, which is more prone to form stable hairpins than is (CCG)n, is in the lagging 
strand template 182. However, usage of origins of replication might be different during early embryonic 
development. Use of an alternative origin of replication downstream of the repeat would cause the 
(CGG)n to be in the nascent Okazaki fragment, which could lead to expansions 
101. 
Evidence for replication-based mechanisms came from studies in yeast replication mutants, 
which showed a marked increase in frequency of repeat instability. Proteins involved in lagging strand 
synthesis, coordination between synthesis of the leading and the lagging strand and restarting of 
the replication fork play a role in the stability of microsatellite repeats (reviewed in 16). A model based 
on replication fork stalling and restarting was proposed 183, which can explain both contraction and 
expansion. Unusual secondary structures in the lagging strand template causes stalling of the DNA 
polymerase situated on this strand. DNA replication could deal with this obstacle in two ways, resulting 
in either contraction or expansion. In short, contraction would result from resuming lagging strand 
synthesis after skipping one Okazaki fragment. The gap between adjacent pieces of nascent DNA strands 
Figure 2.3  |  Replication fork  progression and repeat instability. During normal replication, helicases break the hydrogen bonds that keep the 
two DNA strands together, which yields the replication fork. DNA polymerase can only synthesise a new strand in a 5’ to 3’ direction. Hence, on one strand 
(leading strand) DNA polymerase reads the DNA and adds nucleotides to the nascent strand in a continuous matter. On the other strand (lagging strand) the 
complementary strand is synthesised in short segments (Okazaki fragments) at a time, that are later joined together by DNA ligase. Formation of secondary 
structures, such as hairpins can form in one of the strands. This can impair normal replication fork processing. The sequence of the strands, together with the 
position of the origin of replication with respect to the repeat sequence, determine which strand is more prone to form hairpins. Whether a hairpin is present 
in the template or nascent strand, in turn determines whether contraction or expansion results in the next round of replication. See page 163 onwards for 
colour version of this figure. 
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will be repaired, resulting in repeat contraction. The alternative route could lead to fork reversal. Briefly, 
this refers to a complex ‘chicken-foot’  structure, which contains a single-stranded repetitive extension 
in the nascent leading strand, which could cause extra repeats to be added when the reversed fork 
restarts replication (discussed in more detail in 183 and 184). This is the only model to date that can explain 
the observations on trinucleotide instability on a molecular level. For instance, the phenomenon of 
anticipation could be the result of progressively increased instability due to consecutive replication 
stalls and restarts within longer repeat tracts. Also, the threshold-length of the repeat tract for formation 
of secondary structures coincides with the length of the average eukaryotic Okazaki initiation zone 
(~200 bases), which might explain why various repeats show similar thresholds for expansion. Lastly, 
varying degrees of instability observed in different model organisms could be explained by different 
probabilities of fork reversal and fork bypass to occur 16
Modifiers of repeat instability  |  2.5
Initial studies into the dynamics of triplet repeat expansion were conducted in simple model systems 
such as Escherichia coli and Saccharomyces Cerevisiae. These studies have shed light on some factors that 
play a role in repeat dynamics. However, they are of limited value when considering that trinucleotide 
repeats have a tendency to contract in bacteria and yeast, while almost all repeats in humans show 
a bias towards expansions. In addition, germ line and somatic repeat instability cannot be studied in 
these simple model systems. Therefore, transgenic and knock-in mouse models have been generated 
to mimic human repeat dynamics more closely. The repetitive nature of the sequence of a trinucleotide 
repeat is a primary determinant of its unstable nature. However, given the fact that different repeats 
behave differently, and that the same repeat might act differently among individuals, other factors 
must also play a role. A commonly used categorisation of factors that influence repeat instability, is 
based on cis- and trans-acting factors, where cis-acting refers to factors that are directly associated with 
the repeat, whereas elements that interact with the repeat can be considered trans-acting elements. 
Many of the results obtained in the different model systems will be discussed below.
Cis-acting factors  |  2.5.1
The most obvious factor involved in repeat instability, is the length of the repeat tract. Most trinucleotides 
repeat disorders have distinct repeat categories for normal alleles, which are generally stable upon 
transmission to the next generation, and longer unstable alleles 142. Transgenic mouse models also 
show that a threshold repeat length exists, above which repeats become unstable across generations. 
In some mouse models, instability increases with longer repeat tracts 119,138,185. 
Repeat sequence
Apart from the length of the repeat tract, also the precise sequence plays a role. When a different 
trinucleotide interrupts a repeat tract, it is more stable than a pure repeat. Interruptions determine the 
chances of folding into hairpins and their stability 186,187. For example, AGG interruptions greatly stabilise 
expanded (CGG)n tracts 
186,188. Also the position of the AGG interruption influences stability, as most 
(CGG)n length variations are seen at the 3’ side of the repeat in the FMR1 gene 
189. In fragile X, FM (CGG)n 
tracts were found to have fewer AGG interruptions and longer pure (CGG)n stretches, when compared 
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with normal length FMR1 alleles 190. A similar stabilising effect of interruptions on (CAG)n has been 
described in men 191,192 and mice 131. Thus, when generating a mouse model to study intergenerational 
repeat instability, it is wise to introduce a repeat as long and pure as possible. 
A sequence-specific effect can also be concluded from observations that (CTA)n and (TAG)n did 
not show detectable expansions in a yeast model that did show (CAG)n and (CTG)n instability, possibly 
related to the impossibility of forming secondary structures for the former repeat sequences. Also, 
(CAG)25 was found to be much more stable than (CTG)25, which was explained as that (CAG)n are unlikely 
to form hairpins in this assay 180.
Flanking sequences
It has become evident that factors outside the repeat sequence itself also have an influence on repeat 
instability. Much of this insight has been obtained through animal studies. The first attempts to mimic 
intergenerational repeat instability in mouse models expressing expanded trinucleotide repeats 
failed. Transgenic models expressing (CGG)n of lengths that in humans cause instability, showed stable 
transmission to next generations 193,194. 
Database analysis of sequences of C/G-rich trinucleotide repeat-associated genes revealed 
that in almost all cases studied a CpG island was located close to the repeat. This was interpreted 
as a clue that flanking regions and chromatin structure near the triplets might play a role in repeat 
instability 195. The relative expandability of a repeat was found to be associated with the GC-content 
of the flanking region. GC-rich chromatin might affect the flexibility of the trinucleotide repeat and 
the stability of secondary structures that are formed by the repeat. This might have an effect on DNA 
processes 196. The observation that a fragile site can be induced at the FRAXA locus might also hint at an 
abnormal chromatin structure 197. It should be noted, however, that (CAG)n and (CTG)n expansions have 
not been associated with fragile sites. 
The importance of the flanking region also became evident when a transgenic mouse model 
was generated by introducing a 45 kb genomic segment with a (CTG)55 
185. In contrast to other mouse 
models, expressing (CAG)n in a cDNA context 
198-200, these mice showed moderate intergenerational 
and somatic repeat instability. No large expansions were seen. As the threshold for large increases in 
humans is thought to lie between 40 and 50 repeats, it was suggested that this threshold is higher in 
transgenic mice 185. Subsequent studies focused on differences in instability between transgenic mice 
expressing a large human genomic fragment (45 kb) with either a normal ((CTG)20), slightly expanded 
((CTG)55) or a large CTG-repeat ((CTG)>300). As expected, the normal allele showed no instability at all. Mice 
expressing the long repeat exhibited dramatically increased instability, as compared to the (CTG)55-line, 
again confirming that instability strongly depends on repeat length 138,201. 
Also in the case of (CGG)n instability, transgenic expression of a yeast artificial chromosome 
(YAC), which contained an expanded (CGG)n tract as well as some flanking sequences, resulted in 
moderate instability 202. But only when a knock-in mouse model was generated by substituting the 
endogenous murine (CGG)8 repeat in the Fmr1 gene with a human (CGG)PM tract, thus preserving the 
genomic context 193, substantial repeat instability was observed 119,120. Thus, not only the presence of a 
certain degree of flanking region, but also the insertion site is important for the occurrence of repeat 
instability. In the process of generating transgenic mice expressing expanded (CTG)n repeats, a few 
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similar mouse lines were obtained that expressed the same repeat tract, albeit integrated in different 
regions in the genome. The different integration sites resulted in slight variation in intergenerational, as 
well as somatic repeat instability 185,203,204.
Orientation of the repeat with respect to the replication fork
As mentioned above, the molecular basis of repeat instability is thought to lie at the replication fork 
machinery 16. Thus, it is not surprising that factors associated with this machinery influence instability. 
Studies on (CTG)n instability in E.coli  and yeast 
178,180 already showed that the direction of replication 
determines the frequency of expansions and deletions. When the (CTG)n template is on the leading 
strand, expansions predominate, whereas (CTG)n oriented the other way cause mostly deletions. 
Trans-acting factors  |  2.5.2
Not only characteristics of the repeat itself or the direct vicinity thereof play a role, but also other factors 
such as DNA metabolism or function of other genes have been described to affect trinucleotide repeat 
stability. 
Parental effects
Different trinucleotide repeat disorders have different patterns of transmission. A paternal bias for 
transmission of expansions is seen in HD, while expansions into the fragile X-range occur solely with 
alleles of maternal origin 204. In DM patients, a very specific transmission pattern is observed: the change 
from asymptomatic (PM: 38-50 CTGs) to clear DM1 often happens upon paternal transmission of an 
allele that expanded into the disease-causing range, whereas children with the severe congenital form 
are almost exclusively born if a mutated allele is transmitted by the mother 156. Paternal transmissions 
are usually smaller (not exceeding (CTG)1000), since size of parental (CTG)n is inversely correlated with the 
intergenerational expansion only upon paternal transmission 122. Despite the differences in the different 
repeat disorders, it is clear that there is a parental gender effect. Not all mouse models mimic the clear 
parental gender effects. Nevertheless, the observation that the intergenerational mutability of some 
repeats depends on the sex of the parent, suggests that sex-specific factors might induce mosaicism 
in the male and female germ line. This could be due to sex-specific differences in DNA metabolism or 
other factors, for instance the number of rounds of replication, during gametogenesis (summarised 
in 141). In females, it has been postulated that instability occurs when oocytes are arrested in meiosis I, 
after meiotic DNA replication, which gives a large time window of opportunity for DNA damage to 
occur 130. Cells at this stage have only undergone a limited number of cell divisions, which would point 
to a role for DNA repair in quiescent cells 129,205.
When considering the number of cell cycles, it is not surprising that age of the transmitting 
parent also appears to have an effect on instability. Magnitude of (CAG)n expansions has been shown to 
correlate with the age of the transmitting father 132. Expansions can accumulate in sperm over time 137,136. 
A transgenic mouse model for DM expressing (CTG)>300 showed a higher number of expansions with 
increasing age of the transmitting father, but not the transmitting mother 137. 
DNA replication and repair
Despite the abundant presence of repetitive DNA in the genome, no general microsatellite instability 
occurs in the diseases described. Thus, repeat instability is limited to the disease locus. It was therefore 
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concluded that expansions are not resulting from aberrant trans-acting factors involved in DNA 
replication, repair and recombination. However, evidence is currently accumulating that factors involved 
in DNA repair and replication are in fact influencing trinucleotide instability. Some of this evidence will 
be discussed.
Cell culture studies using foetal DM1 fibroblasts showed expansion of the (CTG)216 allele 
only in proliferating cells but not in quiescent cells. Addition of agents that interfere with DNA 
metabolism revealed that (CTG)n expansion was seen specifically at the disease locus when lagging 
strand synthesis alone, or simultaneously with leading strand synthesis, was blocked. This suggests 
that disturbed replication fork dynamics might play a role in (CTG)n instability 
207. Also observations that 
DNA polymerases in vitro 208, and replication forks in E.coli 209 and yeast 210 have difficulty processing 
trinucleotide repeats that have a high G/C content, pointed towards a role for these events in the origin 
of instability. Flap endonuclease 1 (FEN1) has endonuclease activities acting specifically on 5’ flaps that 
are created by strand displacement during Okazaki fragment maturation 211. Studies in yeast 212-214 and 
mice 215 showed that Fen1 deficiency led to increased (intergenerational) instability of (CAG)n/(CTG)n. 
However, another study in a mouse model for DM1 did not show an effect of Fen1 heterozygosity on 
(CTG)n instability 
216. Later these different outcomes could be explained by a repeat length dependent 
effect of Fen1 on instability, such that long (CAG)n/(CTG)n tracts need more Fen1 protein to ensure 
stability of the repeat 217.
Mosaicism has been seen in both proliferating and quiescent tissues, suggesting a 
replication-independent mechanism 121,123,149,150,152,206,218,219. Thus, if intergenerational instability is the 
result of the same mechanism as somatic instability, it cannot solely depend on replication-dependent 
mechanisms. 
DNA repair pathways ought to maintain genome integrity and stability, thus they are likely 
candidates for modifying trinucleotide repeat instability. Impaired mismatch repair (MMR) activity is 
highly correlated to genetic instability of simple DNA repeat sequences in hereditary nonpolyposis 
colorectal cancer (HNPCC). This suggests that aberrant or absent components of MMR systems may 
cause repeats to become unstable 220. In MMR, heterodimers are formed of MSH2 with either MSH3 
or MSH6, which can then recognise single-base mismatches or short unpaired regions, such as small 
insertions and deletions. This results in recruitment of other factors involved in DNA repair 221. Studies 
in Msh2-deficient yeast strains did not show altered (CTG)n expansion rates, as compared with Msh2-wt 
strains. Neither was an effect on instability seen for the recombination gene Rad52 180.
In an attempt to gain more insight into the possible role of DNA repair in repeat instability 
in vivo, transgenic mice expressing (CTG)>300 were crossed with mice knock out for Msh2. Lack 
of Msh2 changed the direction of instability, with only contractions taking place, as opposed to 
mostly expansions in a wt Msh2 background. This was true for both intergenerational and somatic 
instability 222. Mouse models for HD have also shown increased contraction frequencies in an Msh2-
deficient background 223-226. Msh3 deficiency also decreased the expansion frequency in a knock-in DM1 
mouse model, which carries (CTG)80 in the 3’ end of the Dmpk gene 
227. Another study confirmed the 
necessity of Msh3 in the expansion of (CTG)n. Heterozygous animals revealed that Msh3 is rate-limiting 
in the process, since this decreased the number of expansions. Msh6, a partner of Msh2 in MMR, did 
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not play a key role 228. Msh3 expression might provide a permissive environment for (CAG)n-instability, 
since in a mouse model for HD, Msh3 was almost exclusively expressed in neuronal cells, which showed 
clear somatic instability over time, as opposed to non-neuronal cells 219. It is unclear whether the same 
mechanism is responsible for expansions in Msh2-wt and contractions in Msh2-deficient animals, 
whereby the presence or absence of Msh2 determines the direction of instability. Another possibility is 
that, in the absence of Msh2, a distinct process takes place which leads to contractions 136. 
Since (CTG)n have been shown to induce length-dependent breakage in yeast, the influence 
of two genes involved in double strand break repair by homologous recombination (Rad52 and Rad54) 
were also investigated. These did not show a substantial effect on (CTG)n instability 
222. The influence of 
genes involved in replication and repair on instability of the (CGG)n repeat in the FMR1 gene has also 
been investigated in a mouse model for FXTAS. Neither a helicase (Wrn), which facilitates replication 
of the repeat, nor a protein (p53) with a function in DNA damage surveillance and repair affected 
instability 229. The same lab later investigated the effect of ATR deficiency on (CGG)n instability in their 
expanded (CGG)n mouse model 
230. ATR is the ataxia-telangiectasia and rad3-related kinase, which 
responds to stalled replication forks and bulky DNA adducts 231. Parental ATR heterozygosity led to 
an increased frequency of expansion of alleles only of maternal origin, in offspring wt for ATR. This 
suggests that expansion can occur prior to fertilisation of the oocyte. However, a higher prevalence 
of repeat expansion was seen in offspring heterozygous for ATR, in comparison with offspring wt of 
ATR, for alleles derived from mothers heterozygous for ATR. The most likely origin of the additional 
expansions in ATR heterozygous offspring is in the haploid oocyte 230. The authors propose that two 
mechanisms exist that might explain intergenerational instability: one that causes a higher expansion 
frequency in males, which is not so sensitive to ATR haploinsufficiency and a second that is affected 
by ATR haploinsufficiency, which occurs mostly in females. The authors point out, however, that ATR 
insufficiency might not be a prerequisite in humans, but that it might allow events to become visible in 
the lifespan of mice, which would have years to accumulate in humans 230.
Mutant screens have been conducted in yeast to search for genes that have a modulating 
effect on (CAG)n instability. This revealed Mrc1 as a mediator of instability. Mrc1, and associated proteins, 
have a role in preventing development of too long stretches of single stranded DNA (ssDNA), which 
are likely to form aberrant secondary structures, which impair replication. Mrc1 also has a function 
as a checkpoint protein after secondary structure formation, aiming at prevention of establishing the 
mutagenic event. Thus, at least two Mrc1-dependent mechanisms seem to act in an effort to reduce 
(CAG)n instability 
232.
Taken together, it is clear that disturbed replication and repair processes increase the frequency 
of repeat instability events. It is noteworthy that these two processes can be difficult to distinguish, as 
replication can be part of normal mitosis, or repair-dependent. It remains to be elucidated whether 
expansion in human disease is the result of normal or repair-induced replication 181. 
Combined pathogenic pathways
A Drosophila model for SCA3, expressing a polyQ-stretch, showed little repeat instability. However, 
when the transgene was expressed in the germ cells, substantial instability was seen in the progeny. 
This model was also used to investigate the influence of DNA repair pathways on (CAG)n instability. 
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The Mus201 protein is a fly orthologue of human Rad2/XP6, which is crucial for nucleotide excision 
repair (NER) and transcription-coupled repair function. In a Mus201 deficient background, flies 
showed a dramatic reduction in instability. Furthermore, as cyclic adenosine 3’5’-monophosphate 
(cAMP) response element binding protein (CREB)-binding protein (CBP) is found in polyQ-associated 
inclusions, which reduces soluble CBP levels, the effect of lower CBP levels on repeat instability was 
investigated. Toxic polyQ-containing protein might increase CBP-degradation, further decreasing 
soluble levels. It may, however, also inhibit CBP/p300 histone acetyltransferase (HAT) activity. Increased 
instability was seen when CBP levels were decreased, which was accompanied with increased polyQ 
toxicity. Instability levels could be reduced with CBP overexpression 233. Treating fly or mouse models of 
polyQ disease with histone deacetylases (HDAC) inhibitors normally protects against the toxic effects 
of the mutant protein 234. Treating flies expressing the polyQ protein in germ cells with HDAC inhibitors 
revealed that normalisation of acetylated histones also reduced repeat instability, most likely (at least 
partially) due to compensation for decreased dCBP and/or HAT activity. Thus, these studies suggest that 
repeat instability is not only dependent on what happens at the DNA level, but it might be affected by 
downstream effects of polyQ toxicity 233. Naturally, similar processes with several factors operating at 
different levels, all contributing to repeat instability could turn out to play a role in other trinucleotide 
repeat disorders. 
The studies in flies 233 also pointed toward a role for transcription of repeats in the origin of 
instability. These results together with studies in human cells expressing (CAG)n, suggest that transcription 
of repeats might promote formation of secondary structures in the repeat tracts, which then attract 
various DNA repair systems 233,235,236. This is in line with the stabilising effect of CpG methylation that is 
known for the (CGG)n in the FRAXA locus, since the methylation causes transcriptional silencing 
104,237-239. 
Also other epigenetic changes may occur in the vicinity of long (CTG)n, which can trigger formation and 
spreading of heterochromatin, affecting transcription. Thus, the effect of epigenetic changes on (CAG)n 
was investigated in a mouse model for SCA1. Heterozygosity for the maintenance DNA methyltransferase 
Dnmt1, which preserves the patterns of CpG methylation, indeed promoted intergenerational (CAG)n 
expansion 240. 
A transgenic mouse model expressing a construct containing an origin of replication of SV40, 
followed by a (CGG)26, showed large intergenerational expansions, into the FRAXA FM range 
241. SV40 
origin of replication is known to exclude nucleosomes, which is likely the cause of the large instability 
seen in these mice, since expanded (CGG)n have also been shown to exclude nucleosomes in in vitro 
experiments. This also hints at chromatin characteristics having an influence on repeat instability  242.
Concluding remarks  |  2.6
Since this chapter has dealt solely with the negative consequences of the presence of expanded 
trinucleotide repeats, it is interesting to wonder why these repetitive elements have evolved, and even 
more striking, been maintained. Transcriptome-wide database analysis has identified several hundreds 
of transcripts containing triplet repeat tracts (> 6 repeat units). The vast majority (67%) of the repeats 
are located in open reading frames, while 24% are situated in the 5’UTR and 9% in the 3’UTR. However, 
when considering the median length of these regions in human mRNAs, repeats are overrepresented 
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in 5’UTR and underrepresented in 3’UTR. 5’UTRs often play a role in regulation of translation, and 3’UTR 
are involved in mRNA stability, transport and cellular localisation. The preferential colocalisation of the 
repeats within the mRNA might hint at their biological role. Of the repeat-containing mRNAs with a 
known biological function, indeed a large amount is involved in intracellular and extracellular signalling 
or transcription and translation. The function of transcripts might be compromised due to the presence 
of an expanded repeat 243. This study only mainly found and analysed repeats of up to twenty triplets. It 
is conceivable that longer repeats impair the normal function to a greater extent. 
This does however not explain why these repeats have been maintained over the course of 
evolution. Concerning polyQ-tracts, it is noteworthy that glutamine is encoded for by both CAG and 
CAA. Therefore, if there were some selectional advantage for a polyQ-tract, it would not need a pure 
CAG tract, as is generally seen. Evidence exists that both (CTG)n and (CAG)nrepeats form a functional 
component of an insulator element, thereby having a role in the regulation of gene expression. 
Replacement of repeats with non-repeat sequence was shown to decrease insulator activity. (CTG)n and 
(CAG)n repeats have been found to act as strong nucleosome positioning elements in vitro 
244-247 as well 
as (CGG)n 
242.
Thus, it seems that trinucleotide repeats do not only sort negative effects. However, negative 
effects might prevail once they expand beyond a certain threshold. Future studies might shed light 
on beneficial characteristics, which will explain why they have been maintained over the course of 
evolution. Naturally, future studies should also focus on how instability, as well as the negative effects 
of expansion, can be prevented. 
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Abstract  | 
The human FMR1 gene contains a CGG repeat ((CGG)n) in its 5’ untranslated region. The repeat length 
in the normal population is polymorphic ((CGG)5-55). Lengths beyond 200 CGGs (full mutation) result in 
the absence of the FMR1 gene product, FMRP, through abnormal methylation and gene silencing. This 
causes Fragile X Syndrome, the most common inherited form of mental retardation. Elderly carriers 
of the premutation, defined as a repeat length between 55-200 CGGs can develop a progressive 
neurodegenerative syndrome: Fragile X-associated tremor/ataxia syndrome (FXTAS). In FXTAS, FMR1 
mRNA levels are elevated and it has been hypothesised that FXTAS is caused by a pathogenic RNA gain-
of-function mechanism. We have developed a knock-in mouse model carrying an expanded (CGG)n (98 
repeats), which shows repeat instability and displays biochemical, phenotypic and neuropathological 
characteristics of FXTAS. Here, we report further repeat instability, up to 230 CGGs. An expansion bias 
was observed, with the largest expansion being 43 CGG units and the largest contraction 80 CGGs. 
In humans, this length would be considered a full mutation and would be expected to result in gene 
silencing. Mice carrying long repeats (~230 CGGs) display elevated mRNA levels and decreased FMRP 
levels, but absence of abnormal methylation, suggesting that modelling the Fragile X full mutation in 
mice require additional repeats, or other genetic manipulation.
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Introduction  |  3.1
The Fragile X mental retardation gene 1 (FMR1), involved in fragile X syndrome, contains a (CGG)n in its 
5’-untranslated region (5’UTR). Depending on the length of this trinucleotide repeat, different clinical 
outcomes are possible. Repeats of normal individuals are within the range of 5 to 55 CGGs 1. Repeat 
lengths greater than 200 CGGs (full mutation: FM) typically leads to methylation of both the (CGG)n and 
the FMR1 promoter resulting in transcriptional silencing of the gene. The consequent absence of FMRP 
in neurons is the cause of the mental retardation in Fragile X patients. Fragile X Syndrome is the most 
common genetic disorder associated with mental retardation 2.  
The premutation (PM), comprising ~55 to ~200 unmethylated CGGs, was long thought to be 
associated only with a high risk of expansion to a full mutation upon maternal transmission. However, 
elevated FMR1 mRNA levels and normal or slightly reduced FMR1 protein (FMRP) were reported 3,4,5. 
Additionally, 20% of female PM carriers are at risk of developing premature ovarian failure 6. In 2001 the 
first evidence of a new neurological syndrome (Fragile X Associated Tremor/Ataxia Syndrome:  FXTAS) 
was published by Hagerman and colleagues, observed in five elderly male PM carriers. Patients presented 
with progressive intention tremor, leading to executive function deficits and generalised brain atrophy 
on MRI scans. Since this neurological syndrome is restricted to the PM range, reduced levels of FMRP 
are unlikely to be the underlying cause 7. However, since elevation of FMR1 mRNA levels seems to be 
correlated to the length of the (CGG)n 
5,8,9, and cognitive and functional impairment increases with the 
number of (CGG)n 
10, an RNA-gain-of-function effect has been proposed, in which elevated levels of 
FMR1 mRNA containing an expanded (CGG)n lead to progressive neurodegeneration 
7. 
Little is known about when and how (CGG)n instability takes place. In order to be able to 
elucidate the timing and mechanism of (CGG)n instability and methylation of the FMR1 gene, a mouse 
model was generated by Bontekoe and colleagues 11. In this model, the endogenous mouse (CGG)n (8 
trinucleotides) of a wild type mouse was exchanged with a human (CGG)98, which is in the PM range in 
humans. This ‘knock in’ CGG triplet mouse shows moderate repeat instability upon both maternal and 
paternal transmission and displays biochemical, phenotypic and neuropathological characteristics of 
FXTAS 11,12.
In this paper, we report further repeat instability, up to lengths above 200 CGG units. In humans, 
this would implicate a full mutation, thus silencing of the gene. Mice carrying these long repeats (~230 
CGGs) display elevated mRNA levels and decreased FMRP levels, but absence of CpG methylation, 
which would mean that in mice a full mutation has not occurred as yet. However, additional mice with 
long (CGG)n will be necessary to fully evaluate this issue. 
An unmethylated FM in a mouse model for FXTAS 69
Materials and Methods  |  3.2
Mice
Both the knock in CGG triplet mice and wild type (wt) mice (parent of the knock in mouse, with a mouse endogenous 
(CGG)8 repeat) were housed in standard conditions. All experiments were carried out with permission of the local 
ethical committee. Repeat lengths were determined for the whole mouse colony but only male mice were used for 
the experiments.
Isolation of DNA from mouse tails
DNA was extracted from mouse tails by incubating with 0.2 mg/ml Proteinase K (Roche Diagnostics) in 335 µl lysis 
buffer (50 mM Tris-HCl pH 7.5, 10 mM EDTA, 150 mM NaCl, 1% SDS) overnight at 55°C. After adding 100 µl saturated 
NaCl solution the next day, the suspension was centrifuged. Two volumes of 100% ethanol were added and gently 
mixed. The appearing DNA cloud was fished out with a plastic pipet tip and subsequently washed and centrifuged 
in 500 µl 70% ethanol. The DNA was then dissolved in 100 µl milliQ-H2O. 
Repeat length determination 
Following a method kindly provided by K. Usdin (personal communication), (CGG)n lengths were measured using the 
Expand High Fidelity PCR System (Roche Diagnostics). Approximately 300 ng of tail DNA was added to a PCR mixture 
with a total volume of 50 µl, containing 0.2 µM of each primer, 200 µM of each dNTP (Invitrogen), 2% DMSO (Sigma), 
2.5 M Betaine (Sigma), 5U Expand High Fidelity Plus PCR System Enzyme and 10 µl of the 5x Expand HF buffer with 
Mg (7.5 µM). As forward primer 5’- CGGAGGCGCCGCTGCCAGG-3’ was used and 5’-TGCGGGCGCTCGAGGCCCAG-3’ 
as reverse. PCR conditions were 10 minutes initial denaturation at 95°C, followed by 35 cycles of denaturation for 
1 minute at 95°C, annealing for 1 minute at 65°C and elongation for 5 minutes at 75°C, with a final elongation step 
of 10 minutes at 75°C. 25 µl of PCR product was mixed with an equal volume of loading dye (95% formamide, 0.1% 
brome phenol blue, 0.1% xylene cyanol) and loaded onto a denaturing 6% poly acrylamide (PA)(19:1) gel, which 
was run in 0.6x TBE at 18 Watts. Separated DNA was visualised on a UV-lamp after soaking the gel in 0.6x TBE with 
ethidium bromide. Approximate repeat lengths were determined using a standard curve, based on DNA samples of 
which repeat lengths were determined with an ABI-based Fragile X size polomorphism assay in the past 11.
As these primers are specific to the knock-in allele and do not detect wild type alleles, a separate PCR 
is necessary to distinguish females heterozygous or homozygous for the repeat. TaKaRa LA Taq was used with 
GC buffer II according to manufacturer’s instructions (Takara Bio Inc), with 5’-gctcagctccgtttcggtttcacttccggt-3’ as 
forward primer and 5’-agccccgcacttccaccaccagctcctcca-3’ as reverse primer.
Transmission pattern of repeat alleles
The mode of transmission of the repeat allele was investigated, by comparison of the repeat lengths present in 
the tails of the breeding couple with those of their offspring. Since the ability of the PA gels to resolve lengths of 
PCR products in this range is limited, relatively large bin sizes were chosen to describe repeat length. Comparisons 
between parents and offspring were made using PCR products run on the same gel. Frequencies of contractions, 
stable transmissions and expansions were tested with a one-sample T-test. Magnitude and direction (contraction, 
stable transmission or expansion) of the repeat instability, gender of the offspring and parental origin of the repeat 
allele were taken into account. Transmission groups were tested for differences in magnitude of contractions and 
expansion separately, using one-way ANOVA. Effect of gender of offspring, as well as effect of parental allele of 
origin was investigated with independent samples T-tests for both contractions and expansions. Because of small 
expected frequencies, Fisher’s Exact Test was performed to test for possible differences in frequencies of contractions, 
stable transmissions or expansions, among the different transmission groups. The same test was used to determine 
the significance of differences in frequencies of an allele fitting into the categories distinguishing magnitude of 
instability (categories shown in figure 3.2). A difference in absolute magnitude of contractions vs. expansions was 
investigated using an independent samples T-test. 
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RNA isolation, RT and Q-PCR analysis
Mouse brains were homogenised on ice in buffer (PBS with 1% NP-40, Complete protease inhibitor cocktail tablets 
(Roche Diagnostics), 3 mM DTT (Invitrogen) and 20U RNAsin (Promega). 1 ml RNA bee (Tel-Test) was added to 100 µl 
brain homogenate. 200 µl chloroform was then added and the mixture was then spun at 4°C for phase separation. 
1 Volume of isopropanol was added to the aqueous phase to precipitate the RNA. The pellet was washed with 80% 
ethanol and dissolved in DEPC-treated MilliQ-H2O. RNA concentration and purity was determined using a NanoDrop 
ND-1000 Spectrophotometer (NanoDrop Technologies). RT-PCR was performed on 2 µg RNA using iScript cDNA 
Synthesis Kit (BioRad) according to manufacturer’s instructions. 
For Q-PCR two primer sets for Fmr1 (transition exon 5/6 (5’-AGATCAAGCTGGAGGTGCCA-3’ as forward 
primer and 5’-CAGAGAAGGCACCAACTGCC-3’ as reverse) and transition exon 16/17 (5’-CCGAACAGATAATCGTCCACG-3’ 
as forward primer and 5’-ACGCTGTCTGGCTTTTCCTTC-3’ as reverse) and two primer sets for two distinct internal 
controls (Gapdh: forward: 5’-CCTGGAGAAACCTGCCAAGTAT-3’ and reverse: 5’-CCCTCAGATGCCTGCTTCA-3’) and 
Rpl13a: forward: 5’-TCTCAAGGTTGTTCGGCTGA-3’ and reverse: 5’-GTGGCTGTCACTGCCTGGTA-3’ were used. Since 
efficiencies of the different primer sets were not identical when tested, it was necessary to make a standard curve 
for each primer pair in every run. Input quantities were calculated by subjecting Ct values to the formula of the 
appropriate standard curves. A ratio of Fmr1 mRNA to the reference gene was then calculated for each mouse. This 
Fmr1/reference-ratio was standardised to 1 for wild type (wt) mice. Fmr1/reference-ratios were compared with the 
ratio in wt mice of the same age. 1/10 and 1/100 dilutions of RT product were used as input material. All dilutions 
were performed in duplicate.
Western blotting
Half brains (saggital) were homogenised in 500 µl HEPES-buffer (10 mM HEPES, 300 mM KCl, 3 mM MgCl2, 100 µM 
CaCl2, 0.45% Triton X-100 and 0.05% Tween-20, pH 7.6, with Complete protease inhibitor cocktail (Roche Diagnostics), 
while kept on ice. After incubating the homogenates on ice for 30 minutes, they were sonicated twice for 20 seconds. 
Cell debris was spun down and the supernatant was collected. Loading mix was added to 100 µg of protein, heated 
at 95°C for 5 minutes and loaded onto a 10% SDS-PAGE gel. After electroblotting the gel onto a nitrocellulose 
membrane, the membrane was incubated overnight at 4°C with the monoclonal 2F5-1 antibody specific for FMRP 13, 
in PBS-T with 5% milk powder. The lower part of the membrane was incubated, under the same conditions, with an 
antibody for synaptophysin. The next day the membrane was incubated with a horseradish peroxidase conjugated 
secondary antibody rabbit-α-mouse (DAKO), allowing chemiluminescence detection with an ECL KIT (Amersham).
Methylation status
DNA was checked for the presence of methylated CpGs in the promoter region in two ways. A quick screen 
consists of overnight digestion of 1 µg DNA with the methylation-sensitive enzyme BssHII (after pre-digestion 
with EcoRI to facilitate complete digestion with BssHII). The digested DNA is then subjected to PCR over the 
promoter region containing the BssHII-site (forward primer: 5’-AAATCTACCCAATGCCCCTCC-3’, reverser primer: 
5’-CCTGGGTACCTGCCTCAGG-3’). The PCR mixture contained 10x PCR buffer, W-1, 1 unit Taq Polymerase (all 
Invitrogen) and 50 mM Spermidine (Fluka BioChemika). The PCR program was as follows: 5 minutes denaturation 
at 95°C, 35 cycles of 30 seconds at 95°C, 30 seconds annealing at 56°C and 1.5 minutes at 72°C, followed by a final 
elongation step of 10 minutes at 72°C. A non-methylated BssHII site can be cut by BssHII, and hence will not produce 
a PCR product. Methylated DNA prevents BssHII digestion, thus a PCR product can be produced. 
The other method consists of subjecting 1.5 µg of DNA to bisulphite conversion, using the Qiagen Epitect 
kit, according to manufacturer’s instructions. 1.5 µl of converted DNA was then used for a PCR using forward primers 
5’-GAAGTGAAATCGAAACGTTTTTTAGCGTTT-3’ and 5’-GAAGTGAAATTGAAATGTTTTTTAGTGTTT-3’ and reverse primer 
5’-ATTTATCACTTTTTTTTTACTTCCCTCC-3’. In order to be able to amplify a fragment with unknown methylation 
status, it is necessary to use a combination of primers, one of which matches the sequence after conversion in the 
case where the DNA was methylated and another primer in case it was unmethylated. The PCR mixture was prepared 
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as described above for the PCR after methylation-sensitive digestion, except for that 50 mM MgCl2 was added. 
The PCR program was the same as described above with the exception of an annealing temperature of 63.5°C. 5 
µl of PCR product was then used for a semi-nested re-PCR, since no PCR product was seen on a 2% agarose gel 
initially. Primers used in the second PCR reaction were forward:  5’-TTTTGTAAATAGTTAAATGATGTTATGTGATTTG-3’ 
and 5’-TTTTGTAAATAGTTAAACGATGTTACGTGATTCG-3’ and reverse: 5’-TTTTTTACTTCCCTCCCACCAC-3’ and 
5’-TTTTTTACTTCCCTCCCGCCGC-3’. PCR products were visualised and cut out of a 2% agarose gel and the bisulphite 
converted PCR product was purified using an Illustra GFX PCR DNA and gel band purification kit (GE Healthcare). The 
resulting converted DNA was then sequenced as follows: amplification reactions were performed in 22 µl containing 
1x Invitrogen PCR buffer, 1.5mM MgCl2, 0.01% W-1, 250 µM of each dNTP, 1 µM forward primer,1 µM reverse primer 
(primers were the same as the ones used in the second PCR reaction), 0.75 units of  Platinum Taq DNA polymerase 
(Invitrogen) and 25 ng genomic DNA; DNA Cycle conditions: 7’30” 95oC; 10 cycles of 30” denaturation 94oC, annnealing 
68oC minus 1oC per cycle, 1’ extension 72oC followed by 25 cycles of 30” denaturation 94oC , annealing 58oC , 1’ 
extension 72oC; final extension 5’ 72oC. Templates for the Direct Sequencing reactions were cleaned from dNTP’s and 
primers using 1 ul ExoSAP-IT (USB) during 30 minutes at 37oC followed by a 15 minutes inactivation step at 80oC. 
Direct sequencing of both strands was performed using Big Dye Terminator chemistry ver.3.1 (Applied Biosystems) 
as recommended by the manufacturer. Fragments were loaded on an ABI3100 automated sequencer and analyzed 
with DNA Sequencing Analysis (ver.3.7) and SeqScape (ver.2.1) software (Applied Biosystems).
Immunocytochemistry
Mice were sacrificed by cervical dislocation, brains were dissected immediately and fixed overnight in 3% 
paraformaldehyde. The brains were embedded in paraffin according to standard protocols. Sections (7 μm) 
were deparaffinised, followed by antigen retrieval using microwave treatment in 0.01 M sodium citrate solution. 
Endogenous peroxidase activity blocking and immunoincubation was performed as described before using 
monoclonal antibodies against FMRP (1C3) 14. 
Results  |  3.3
The original knock in construct introduced (CGG)98 into the mouse Fmr1 locus and has been used as 
a model for the human premutation disorder, FXTAS 11,12,15. This line was initially developed to study 
repeat instability of long (CGG)n in the mouse Fmr1 locus and has been maintained for several years 
now. In the course of breeding, animals with longer repeats were born and selected for breeding in an 
attempt to further increase the size of the CGG array, with the hypothesis that repeat instability will be 
greater as the repeat tract gets longer. We previously reported expansions of this tract to sizes of 110 
CGG units 15. (CGG)n lengths in the mouse model have now expanded to above the threshold of human 
FMR1 full mutations. This study focuses on the characteristics of these mice, which are summarised in 
table 3.1.
Mouse Repeat length Western Q-PCR Immunohistochemistry
α-Fmrp
Id %Fmrp of wt category fold change vs. wt
1 >230 C 75 >230 5x  Fmrp: see figure 3.5
2 ~230 D 45 >200 2x  Fmrp: see figure 3.5
3 ~230 E 40 - -
4 ~215 - >200 2x -
Table 3.1  |   Main characteristics of the CGG-repeat knock-in mice described in this study.
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Repeat instability 
In order to investigate the mode of transmission of (CGG)n in the expanded (CGG)n mouse model, mice 
were bred and repeat lengths in the offspring were compared to repeat lengths in the breeding couple. 
The (CGG)n shows instability upon transmission to the next generation (figure 3.1). Both expansions 
and contractions occur in addition to stable transmissions. Predominantly small expansions are found 
along with stable transmissions. Both germ line and somatic mutations can be observed. In figure 3.1, 
for example, animal 2 is a mosaic for repeat length, showing two long repeat alleles (approx. 190 and 
200 CGGs) as well as a shorter allele (approx. 60 CGGs), which must represent a mitotic contraction, 
which was transmitted to one of her male offspring (animal 3).  Figure 3.1 also shows the mouse with 
the longest (CGG)n length (>230: animal d in figure 3.1) observed thus far, as well as the controls used 
for repeat length determination. 
Transmission pattern of repeat alleles
Mode of transmission of (CGG)n alleles was investigated by comparison of repeat alleles of breeding 
couples with those of their offspring and subjected to statistical analysis. Figure 3.2 shows instability 
of repeat alleles in three different transmission groups, based on gender of offspring and origin of 
the allele. Seventy-nine alleles, of which the parental allele of origin was known, were subjected to 
statistical analysis. Among all transmissions, 15 contractions (19%), 16 stable transmissions (20%) 
and 48 expansions (61%) were observed. A one-sample T-test revealed that these frequencies were 
statistically significantly different from expected frequencies (adjusted p-value for contractions=0.006, 
1a b c d 2 3 4 5 6 7 8
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Figure 3.1  |  PA gel with PCR products of an expanded (CGG)n litter and the breeding couple. The (CGG)n shows 
both expansion and contraction upon transmission to the next generation. A-d represent DNA samples with 
previously determined repeat lengths, which are used as a standard curve for approximation of repeat lengths 
of other samples. 
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for stable transmissions: padj=0.006 and for expansions padj<0.001). The largest contraction was of 80 
CGGs and the biggest expansion was 43 trinucleotide units. Comparing mean magnitude of instability 
between contractions (n=15, mean=15.93, sd=21.0) and expansions (n=48, mean=12.8, sd=10.5), 
among all alleles considered, with an independent samples T-test revealed no statistical significance 
(t=0.55, p=0.59). 
Figure 3.2  |  Histogram sum marising 
the observed in stability of (CGG)n alleles 
upon trans mission to the next generation. 
Bars represent the percentage of times 
a transmitted allele fits in an instability 
category (x=change in repeat length), 
within a transmission group (male offspring, 
maternal origin, or female offspring with 
either maternal or paternal origin). Fisher’s 
Exact Test revealed no statistically significant 
differences in frequencies of instability 
categories amongst the transmission groups 
(P=12.86, sd=0.09). 
Type of 
instability
n Largest 
instability
Mean 
Magnitude (sd)
Contractions 15 -80 16 (21,0)
Stable transmissions 16 - -
Expansions 48 +43 13 (10,5)
Statistically significant? SS NSS NSS
Table 3.2 summarises these data. One-way ANOVA revealed no statistically significant difference 
in magnitude of instability of contractions (F=3.28, p=0.07) between the different transmission 
groups, namely male offspring with a repeat allele of maternal origin (MM)(mean=-30.7, standard 
deviation (sd)= 11.3), female offspring with an allele of paternal origin (FP)(mean=-7.67, sd=4.7) and 
female offspring with a maternally derived repeat allele (FM)(mean=-5.33, sd=0.42). Neither was a 
difference found in magnitude of expansions (F=1.36, P=0.27) between MM (mean=11.32, sd=2.4), FP 
(mean=15.36, sd=2.5) and FM (mean=8.86, sd=1.9). When looking at the factors that determine the 
transmission groups, gender of offspring and parental allele of origin, separately, for both contractions 
and expansions, no specific transmission pattern is revealed with independent samples T-tests. 
Table 3.2  |  Summary of the observations on 
direction and magnitude of instability. SS: sta-
tistically significant, NSS: not statistically signi-
ficant (see text for test statistics and p-values).
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Considering contractions, no effect (t=-2.15, p=0.08) for gender of offspring (male: n=6, mean=-30.7, 
sd=27.8, female: n=9, mean=-6.1, sd=4.3). It must be noted that numbers are small, so that the largest 
contraction, which occurred in a male mouse, has a relatively big influence on the outcome. There was 
no difference (t=-7.96, p=0.43) between magnitude of mean male expansion (11.32, sd=10.4, n=19) 
and mean female expansion (13.79, sd=10.6, n=29). Testing for an effect of parental allele of origin 
revealed no statistically significant outcome for contractions (t=0.75, p=0.47) nor expansions (t=1.6, 
p=0.12) (contractions: mean(paternal origin)=-7.7, sd=8.4, n=3, mean(maternal origin)=-18.0, n=12, 
sd=22.9; expansions: mean(paternal origin)=15.4, sd=11.5, n=22, mean(maternal origin)=10.7, sd=9.2, 
n=26). Fisher’s Exact Test revealed no statistically significant differences in observed frequencies of 
contractions, stable transmissions and expansions (P=5.70, p=0.33) between the transmission groups. 
Neither were there statistically significant differences in frequencies of instability categories amongst 
the transmission groups (P=12.86, sd=0.09). Means of the magnitude of repeat instability are shown in 
table 2.3 for the different transmission groups. 
Instability category
Transmission groups Δrep < -15 -15<Δrep <0 Δrep=0 0<Δrep<15 Δrep>15 total
Male, maternal -51 (25.9), n=3 -11 (7.5), n=3 n=5 7 (3.9), n=15 28 (10.5), n=4 1 (21.9), n=30
Female, paternal -17, n=1 -3 (1.4), n=2 n=7 7 (4.0), n=12 26 (8.5), n=10 10 (12.9), n=32
Female, maternal n=0 -5 (1.0), n=6 n=4 8 (4.4), n=6 16, n=1 2 (7.2), n=17
total -42 (27.0), n=4 -6 (4.5), n=11 n=16 7 (3.9), n=33 26 (8.9), n=15 5 (16.5), n=79
Table 3.3  |  Summary of the mean repeat instability observed in mice specified for the different transmission groups. Displayed are the mean magnitude of 
instability (sd) and number of observations. See text for the outcome of statistical analyses.
Q-PCR analysis
Since human carriers of the premutation have elevated Fmr1 mRNA levels 3-5, we investigated mRNA 
levels of mice with different repeat lengths, to determine whether repeat length has an influence on 
mRNA abundance. mRNA ratios proved to be independent of the amount of input RNA, tested by using 
two dilutions of input material (data not shown). First we investigated wt mice of different ages and 
found a two-fold increase of Fmr1 mRNA in 100-week old wt mice, as compared with 25-week old wt 
mice. Next we tested Fmr1 mRNA levels in (CGG)n mice of different repeat lengths, with reference to 
age-matched wt mice. 100-week old mice with a (CGG)n of 110 and 130 trinucleotide units showed 
a two-fold increase of Fmr1 mRNA, with reference to age-matched wt mice (data not shown). Figure 
3.3 shows Fmr1 mRNA levels for mice around 25 weeks of age, with reference to 25-week old wt mice. 
Bars represent two mice in each category, with an exception of category >230, which represents 
a single mouse. Four combinations of two primer pairs within the Fmr1 gene and two primer pairs 
for two distinct reference genes, Gapdh and Rpl13a, were measured and calculated. Figure 3.3 shows 
comparison of Fmr1 mRNA levels as measured with a primer pair amplifying the transition of exon 
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16 to exon 17 and Gapdh as a reference gene (the ratio in wt mice is standardised to 1). This graph is 
representative for all combinations of primer pairs. Both Gapdh and Rpl13a showed stable Ct values 
throughout all CGG length categories, thus proved to be suitable reference genes in this assay. The 
range of Ct values obtained for the different genes were 26 to 28 for Fmr1, 20 to 22 for Gapdh and 19 to 
21 for Rpl13a. Throughout all repeat length categories an approximately two-fold increase of the Fmr1 
mRNA is observed with reference to the age-matched wt, with exception of the single observation of 
the mouse in category >230, which shows a five-fold increase. 
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Figure 3.4  |  Western blot showing Fmrp isoforms (at 70-80kD) of wt (A), 
Fmr1 KO mouse (B) and mice with approximately 230 CGGs (C, D and E). 
Mouse C,D and E show clearly reduced Fmrp levels (75%, 45% and 40% for C, 
D and E respectively). The asterisk marks a background band. Synapthophysin 
(at 38 kD) was used as a loading control.
Protein levels
After finding elevated Fmr1 mRNA levels in a mouse with over 230 CGGs, we were interested in 
Fmr1 protein levels in these mice. We performed Western blotting on whole brain lysates and found 
significantly reduced Fmrp levels (75%, 45% and 40% of wt levels respectively (corrected for input 
material)) in three mice with approximately 230 CGGs, one of which (C), with the longest repeat tract, is 
the mouse that showed five-fold Fmr1 mRNA levels (figure 3.4). 
Figure 3.3  |  Fmr1 mRNA levels are shown relative to 25-week old mice. Bars represent two mice of roughly the same 
repeat length (SEM were 0.9, 0.8 and 0.5 respectively for 170, 190 and >200 CGGs), with exception of >230, which only 
represents one mouse.
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Immunohistochemistry
It was of interest to investigate the decrease in Fmrp expression in vivo, using immunohistochemistry 
on brains of two of the three mice tested by Western blotting. Mice with approximately (CGG)~230 show 
significantly diminished Fmrp expression throughout the brain, although detectable Fmrp remained 
(figure 3.5). Strikingly, the CA2 and CA3 region of the hippocampus showed the highest levels of FMRP 
expression in the ~230 CGG mice. This region, however, is also highly immunoreactive for Fmrp in wt 
mice.
Figure 3.5  |  Mouse brains from wt (A and B), Fmr1 KO (C and D) and the mouse with >230 CGGs (E and F) were stained with antibodies against Fmrp. Photos 
A,C and E show hippocampus and B,D, and F show cortex tissue. DG: dentate gyrus. See page 163 onwards for colour version of this figure.
Methylation status 
The decrease in Fmrp expression led to the question of whether the Fmr1 promoter and (CGG)n are 
methylated in mice carrying ~230 repeats. To obtain a general idea thereof, a methylation sensitive 
digestion was performed, followed by PCR over the promoter region. No PCR products were seen after 
methylation-sensitive digestion of tail DNA of all male mice tested thus far, suggesting that the restriction 
site (BssHII) was not methylated (data not shown). We confirmed the unmethylated status of the Fmr1 
promoter by applying bisulphite conversion followed by sequencing of PCR products of the converted 
DNA. We have successfully applied the bisulphite-conversion method in the past 16,17. Sequencing 
revealed complete bisulphite conversion of cytosines to uracil indicating that no methylated cytosines 
were present in the Fmr1 promoter region of the starting material (data not shown).
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Discussion  |  3.4
We have managed to obtain mice carrying full mutation length (CGG)n in the Fmr1 locus through 
selective breeding of a line of mice that were created by knocking in 98 CGGs. In this study, we have 
characterised these animals for repeat instability during transmission and for expression of the Fmr1 
mRNA and protein. We find that mice carrying large (CGG)n alleles express increased amounts of mRNA, 
but significantly reduced levels of Fmrp. These findings are consistent with the observation that the 
large CGG alleles, which would be considered full mutations in humans, remain unmethylated in male 
mice.
(CGG)n instability
In humans, instability of a PM to a FM occurs exclusively upon maternal transmission 18. Also general 
instability seems to be greater when the repeat allele is of maternal origin. No effect on instability was 
observed for gender of offspring in humans 19. In our mouse model, we find a significant excess of repeat 
expansions over both contractions and stable transmissions, which is consistent with observations of 
human premutations. Statistical analysis revealed no significant differences in magnitude or direction 
of instability for the factors that defined transmissions groups, namely gender of offspring or parental 
allele of origin. 
Different mouse models with random (autosomal) insertion of unstable human PM alleles 
(maximum uninterrupted CGG stretch of 97 repeats) showed a very high incidence of small instabilities 
and occasional large deletions, but no large expansions 20,21. Random integration on an autosome, rather 
than on the X chromosome and the absence of necessary cis-acting factors might explain the different 
findings. Peier and Nelson described the generation of transgenic mice carrying PM-sized (CGG)n on a 
YAC, which enables them to study instability of these sequences within their chromosomal context. 
When looking at different constructs with varying (uninterrupted) (CGG)n lengths, they observed length-
dependent instability. More expansions, however of smaller magnitude, were found than contractions. 
Instability of the (CGG)n was seen in about 17% of transmissions 
22. 
In humans, AGG interruptions in the (CGG)n have a stabilising role. Loss of AGG interruptions 
typically occurs often before a big jump towards the full mutation range, thus reflecting greater 
instability 23. The expanded (CGG)n allele present in the knock-in mouse does not contain AGG 
interruptions 11. Thus, it could be expected that greater instability already occurred right after the 
generation of the mouse model. Our initial report on the instability of an expanded (CGG)n in the Fmr1 
promoter described a much lower frequency of instability than currently seen 11. However, in earlier 
studies a different method was applied to determine (CGG)n length, so no accurate comparison can 
be made with the methodology employed in this study. However, no obvious change in magnitude of 
repeat instability is observed over time. It seems that the risk of becoming unstable upon transmission 
becomes greater as the (CGG)n gets longer, rather than the magnitude of the instability.
Many questions remain unanswered as to how, why and when trinucleotide repeat instability 
occurs. However, some mechanisms have been proposed and some evidence has been given for 
the underlying mechanism of repeat instability. The observation in human fragile X syndrome that 
expansions to a full mutation (FM) only occur upon maternal transmission of a premutation allele, 
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means that repeat expansion must occur during meiosis in the oocyte. Alternatively, it could be due 
to mitotic events in the embryonic development of the germ line 24,25. The mosaic pattern, as often 
seen in Fragile X patients, must result from mitotic contraction or expansion events in the developing 
embryo, leading to the presence of alleles with repeats in both the FM and PM range 11. In male 
Fragile X patients, only PM alleles are present in sperm and testes 26,27, despite the presence of FM in 
peripheral lymphocytes and other tissues 28. In a 13-week old FM foetus, no FMRP expression could be 
demonstrated in primordial germ cells (PGCs), while in a 17-week old FM foetus some primordial germ 
cells expressed FMRP. It was then concluded by the authors that a PM allele must have been present in 
the PGCs to support protein production. This suggests that contraction from FM to PM may occur during 
the maturation of the PGCs, after the initial replication event 25. In both mouse and human zygotes, the 
paternal chromatin undergoes active demethylation soon after fertilisation 29. This process, confined 
to the paternal pronucleus, occurs prior to DNA replication 30,31. In mouse, the demethylation process 
continues up to the morula stage 29. After completion of the first cell cycle passive demethylation 
occurs, due to the absence of a maintenance methylase 32. Soon after implantation, DNA methylation 
is restored and maintained thereafter 33. CpG methylation appears to stabilise the (CGG)n instability 
34. 
Hence, paternally derived alleles can be prone to deletions upon demethylation. Cells in the testis that 
have undergone contraction to PM lengths, thus producing FMRP, might be selectively maintained, as 
FMRP is thought to play a role in gonadal development 35.
Despite the abundance of repetitive DNA in the genome, no general microsatellite instability 
is found in fragile X patients, thus repeat instability as seen in the FMR1 gene is limited to the disease 
locus only. This implies that expansions do not result from aberrant trans-acting factors involved in DNA 
replication, repair and recombination 36.  
Repeat instability is dependent on both the repeat length and the purity of the (CGG)n-tract, 
i.e. the number and locations of AGG interruptions, which in turn determine the likelihood and stability 
of alternate DNA structures such as hairpins 37. Also, the location of transcription start sites has been 
shown to be affected. It was demonstrated that a shift to more upstream transcription initiation sites 
takes place as the (CGG)n expands to the premutation range. This was interpreted as that the (CGG)n 
might act as a downstream enhancer or modulator of transcription. This phenomenon was observed 
both in neuronal and non-neuronal cell lines 38. The expanded (CGG)n mouse model as described here 
might provide insights about repeat instability in vivo, especially with the expanded range of repeat 
lengths now available.
Transcription and translation
Q-PCR analysis on RNA isolated from mouse brains revealed that Fmr1 mRNA levels are two-fold higher 
in 100-week old wt animals, as opposed to 25-week old wt mice, illustrating that Fmr1 mRNA is more 
abundant in old wt mice. On average a two-fold increase of Fmr1 mRNA levels has been reported at 
different ages (1-72 weeks) in expanded (CGG)n mice, when compared with age-matched wt mice 
15. 
Here we report two-fold elevated Fmr1 mRNA levels for mice with 110-200 CGGs, in comparison with 
age-matched wt mice, which is in line with earlier findings in the expanded (CGG)n mouse 
15. So, based 
on the current data, in contrast to observations in humans 5,8,9, in mice Fmr1 mRNA levels do not seem 
to elevate further with added (CGG)n length.  Interestingly, one exception to this observation was seen 
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in the mouse with over 230 (CGG)n, which showed a five-fold increase. More mice with repeats of this 
length should be investigated in the future, in order to be able to assess to what extent mice resemble 
humans with regard to Fmr1 mRNA levels. Also, it should be taken into account that in mice brain mRNA 
was measured, whereas findings in humans represent blood mRNA. Tassone and co-workers have 
shown that Fmr1 mRNA levels, relative to a reference gene, are higher in brain than in blood in humans. 
However, the ratio of Fmr1 mRNA levels in PM carriers is higher in blood (3.8x) than in brain (1.5x) 39. 
Thus our observations of a two-fold elevation of Fmr1 mRNA levels in (CGG)n mice seems to mimic the 
human situation. 
The underlying molecular mechanism of the elevated FMR1 transcript levels has not been 
defined yet. Tassone and colleagues were the first to report elevated FMR1 mRNA levels (at least five-
fold) in leukocytes of carriers of the high PM range (100-200 CGGs), in combination with a reduced 
percentage of FMRP-immunoreactive cells 4. They proposed a model wherein an increase of transcription 
compensates for a diminished translational efficiency that might occur due to an expanded (CGG)n, in 
an attempt to overcome an arising protein deficit. A (linear) correlation between FMR1 mRNA levels 
and repeat size was recently confirmed in a large cohort of both males and females, among whom were 
carriers of common, intermediate and PM alleles 8. Similar correlations between FMR1 transcript levels 
and repeat length were observed in human lymphoblastoid cell lines of PM carriers. Also, an inverse 
correlation was observed in these cell lines between FMRP levels and repeat length 5,9. Primerano and co-
workers found an up to five-fold increase of Fmr1 mRNA in a cell line of a carrier with 195 repeats 9, while 
in the study by Kenneson and colleagues transcription levels did not exceed a three-fold increase when 
repeat length approached 200 units 5. Both authors explained their observations by the occurrence 
of a translational defect that arises as the mRNA carries a longer CGG tract. Primerano et al revealed a 
dramatic change in translational efficiency of Fmr1 mRNA specifically; they demonstrated a reduced 
percentage of Fmr1 mRNA associated with polysomes in cell lines expressing a longer (CGG)n tract. 
However, they showed that a (CGG)n does not impair overall translational activity 
9. 
When comparing our own observations in mice with what has been described for human PM 
carriers, it appears that the positive linear relation between (CGG)n length and Fmr1 transcript levels 
is absent. Furthermore, in humans the increase in FMR1 mRNA levels as compared to controls was 
greater than in mice, although in the study performed by Kenneson and colleagues this increase was 
less pronounced 5. However, the mouse carrying the largest CGG expansion detected in our lab thus far, 
did exhibit a five-fold increase in Fmr1 mRNA levels, when compared to age-matched wild type control 
mice. It must be stressed that this was only observed in a single mouse. This mouse also showed a 
striking difference in protein expression level in brain, as visualised with immunohistochemistry. Brain 
tissue of a second mouse with approximately 230 CGGs showed the same decreased Fmrp expression, 
despite the two-fold increase of Fmr1 mRNA. Throughout the brain a remarkable decrease in Fmrp 
expression could be detected, which was confirmed with Western blot. Interestingly, the CA2 and CA3 
region of the hippocampus showed the strongest Fmrp expression. This is a region with the highest 
Fmrp expression in wt mice. 
It is tempting to regard this particular expanded (CGG)n mouse, with the longest repeat tract 
as yet and the highest Fmr1 mRNA levels, as a parallel to the human situation where at the end of the PM 
80 CHAPTER 3 
range mRNA levels increase significantly and the number of FMRP-immunoreactive lymphocytes drops 
slightly, reflecting a decrease in translation 3,4. However, it is too early to draw conclusions, since, due to 
limited availability of mice with repeat tracts this long; thus far this has only been a single observation. 
Hence, in the near future more mice with repeat lengths over 230 CGGs should be investigated in order 
to be able to distinguish a parallel to the human situation from an outlier. 
To explain the impaired translation, many authors refer to a study performed by Feng et al. 
in 1995, in which they showed that the 40S ribosomal subunit is hampered in scanning for initiation 
codons when the FMR1 mRNA contains over 200 CGGs 40. However, individuals carrying an unmethylated 
full mutation have been reported, who showed normal FMRP expression in their EBV-transformed 
lymphoblasts and show normal cognitive functioning 41. The observation that mice with repeat lengths 
of over 200 trinucleotide units, which in humans would constitute a full mutation, still express Fmrp 
confirms that in murine cells ribosomes are still capable of translating mRNAs carrying (CGG)n of this size.
When considering that a FM in humans is defined as a (CGG)n length greater than 200 CGG 
triplets, and that these alleles are typically hypermethylated 2,42, it can be concluded that a different 
situation occurs in mice carrying Fmr1 (CGG)n of this length. It is as yet unknown whether a mechanism 
similar to that seen in humans might happen at a greater repeat length in mice, or whether a transition 
to a silenced Fmr1 gene might never take place in mice. It is possible that certain methyltransferases that 
are responsible for CpG methylation of the FMR1 promoter and the (CGG)n in humans are not present 
in mice. In embryonic development, differences exist in (de)methylation mechanisms between man 
and mouse. Active demethylation occurs up to a later stage in mouse, as compared with in humans 29. 
After the first cell cycle, passive demethylation occurs, as a result of the absence of a maintenance 
methylase 32. It could be that similar mechanisms play a role in mice with respect to the Fmr1 gene, 
preventing this region from becoming methylated once the CGG tract exceeds 200 CGGs. 
This mouse model provides an excellent tool to investigate whether methylation and silencing 
of the Fmr1 gene takes place in mice. In case a mechanism similar to that in humans does occur, the 
events that trigger methylation, the timing and sequence of methylation and gene silencing events can 
be studied in detail with special emphasis to the gonads. Furthermore, it will be interesting to perform 
behavioural tests in mice with lowered protein expression and possibly in mice with silenced genes to 
investigate learning and memory processes. 
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Abstract  | 
Fragile X-associated tremor/ataxia syndrome (FXTAS) is an adult-onset neurodegenerative disorder that 
is limited almost exclusively to adult carriers of premutation alleles (55 to 200 CGGs) of the FMR1 gene. We 
have discovered that the neurofilament protein isoforms, lamin A/C, are dysregulated in CNS tissue from 
nine patients with FXTAS, generally with dramatic reductions in lamin A/C solubility, compared to CNS 
tissue from three controls. Moreover, there also appears to be a cellular stress response accompanying 
expression of the expanded (CGG)n FMR1 mRNA in neural tissues of six post mortem cases of FXTAS, 
as evidenced by altered expression of the heat shock proteins (Hsp), αB-crystallin, Hsp70, and Hsp27. 
We have also observed remarkably similar features of cellular pathology in cultured skin fibroblasts 
from four patients with FXTAS, including altered nuclear architecture of lamin A/C, abnormal nuclear 
morphology, and an elevated Hsp response. Thus, dysregulation in skin fibroblasts may represent an 
important peripheral manifestation of the pathogenesis of FXTAS. Finally, in mice harboring large 
premutation expansions (~200 CGGs), we observe a corresponding lamin A/C dysregulation in adult as 
well as embryonic fibroblasts; this last observation raises the possibility that, in humans, at least some 
of the neurodevelopmental abnormalities observed in a limited number of children with premutation 
alleles may be due to a similar pathogenic mechanism involving RNA toxicity.
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Introduction  |  4.1
Fragile X-associated tremor/ataxia syndrome (FXTAS) is an adult-onset neurodegenerative disorder that 
is largely restricted to older adult carriers of premutation alleles (55 to 200 CGGs) of the fragile X mental 
retardation 1 (FMR1) gene (OMIM *309550)(recent reviews on FXTAS 2,3-5). The principal features of FXTAS 
include action tremor and gait ataxia; with associated, more variable features that include cognitive 
decline with disinhibition and executive function deficits, mild Parkinsonism, peripheral neuropathy and 
autonomic dysfunction 1,2,6-13. Radiological features of FXTAS include loss of brain volume involving the 
cerebrum, brain stem and cerebellum, and white matter disease in the periventricular and subcortical 
regions, with bilateral high signal lesions in the middle cerebellar peduncles on T2-weighted and FLAIR 
MRI images (MCP sign) observed in approximately 60% of males and 13% of females with FXTAS 7,9,14-16.
Neuropathological studies of post mortem FXTAS brains demonstrate significant white matter 
disease with spongiosis in both the cerebrum and cerebellum and subcortical astroglial activation, 
Purkinje cell loss in the cerebellum, and the presence of eosinophilic, intranuclear inclusions in neurons 
and astrocytes throughout the cortex, subcortical regions, and brainstem (excluding cerebellar Purkinje 
cells) 17,18. Studies of the composition of isolated inclusions have revealed the presence of at least thirty 
proteins, including ubiquitin, lamin A/C isoforms, and the heat shock proteins (Hsps) αB-crystallin, 
Hsp27, and Hsp70 19. Importantly, the inclusions contain the FMR1 mRNA itself 20, in accord with the 
proposed RNA-toxicity model for FXTAS 8,18,21,22, wherein the expanded (CGG)n RNA itself triggers the 
pathogenic process leading to FXTAS.
We have previously reported the presence of lamin A/C protein isoforms (LMNA gene; OMIM 
*150330) within the intranuclear inclusions of neurons and astrocytes from patients with FXTAS, as well 
as disruption of the nuclear lamin A/C architecture in both neural cells from patients with FXTAS and 
in neural cell culture 19,23. Given that specific mutations in the LMNA gene cause a form of peripheral 
neuropathy (Charcot-Marie-Tooth type 2B1; OMIM *605588), and that peripheral neuropathy is a 
prominent clinical feature of FXTAS 24-26, we have proposed that FXTAS may represent, at least in part, 
a functional laminopathy 23. However, to date, the fundamental limitation with the study of FXTAS 
pathogenesis has been that research in patients with FXTAS was limited to studies of either CNS 
neural cells (neurons and astrocytes) from post mortem brain tissue, or to studies of transfected neural 
cells in culture.
We now report that two of the central features of CNS cellular dysfunction in FXTAS, namely, 
disorganisation of the lamin A/C nuclear architecture and a cellular stress response, are recapitulated 
in skin fibroblasts from patients with FXTAS. Therefore, skin fibroblasts may provide a powerful tool to 
study the CNS cellular dysregulation in FXTAS. 
Materials and Methods  |  4.2
Subjects
Post mortem tissue samples were obtained in accordance with University of California, Davis, IRB approved protocols. 
Brain autopsies were performed in a standard fashion as described 17. All subjects contributing skin biopsies were 
participants in a multi-centre study to characterise neurological findings in premutation carriers, after signing 
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informed consent. Institutional Review Boards at RUSH University Medical Centre and the University of California, 
Davis, School of Medicine approved the study. Characteristics of individuals contributing autopsy or biopsy materials 
are listed in Table 1a.
 Post mortem cases were referred to our centre because of FXTAS symptoms including tremor and/or ataxia. 
The clinical and neuropathological features of FXTAS Cases 1, 5 - 9, and 11 have been described previously 17,18, and 
correspond in case number to those presented in Greco et al. 17. Clinical features have also been described for Case 
10 8,27 and Case 12 (Greco et al., unpublished). The following cases were not previously reported.
 Case 2 was characterised by family members as a brilliant professional who had life-long social anxiety, 
with alcoholism and obsessional thinking. At age 60, he had a thalamic stroke, followed by neurological deterioration 
with increasing difficulty swallowing. He had also experienced severe neuropathic pain in both legs for a number 
of years. Ataxia began at 65 yr; intension tremor was evident but sporadic. He developed cognitive decline and 
dementia over several years prior to his death. At autopsy, his brain (left hemisphere) showed multiple, scattered 
cystic infarcts and involving cerebral white matter, basal ganglia, and pons. In addition to vascular hyalinisation, 
confirmation of the remote ischemic nature of the above-described cystic lesions, multiple microinfarcts were 
identified. Rare intranuclear inclusions were identified only in astrocytes of the hippocampal endplate. 
 Case 3 had a long history of ataxia, frequent falling, and deterioration in his handwriting. His MRI 
demonstrated moderate volume loss and severe white matter disease in basal ganglia, anterior capsule, subcortical 
regions; and a prominent MCP sign, which confirmed his clinical diagnosis of FXTAS before his death at age 76. 
Post mortem examination of his brain (right cerebrum) showed moderate frontoparietal atrophy. Histopathological 
evaluation showed pallor and spongiosis of cerebral white matter. Eosinophilic intranuclear inclusions were 
identified in neurons and astrocytes of the hippocampal endplate.
 Case 4 had onset of rest tremor at age 70 and shuffling gait 5 years later, when he was diagnosed as 
having Parkinson disease. Between ages 79 and 80 he developed increasingly severe dysarthria and dysphagia, 
requiring feeding tube placement. He was ambulatory, with very occasional falls until age 80 when he deteriorated 
rapidly, required a walker and, two months after an episode of sepsis, became bedridden and died. There was no 
reported evidence of cognitive impairment. MRI at age 79 revealed moderate brain atrophy and subcortical white 
matter disease with punctate lesions in the pons, typical of neuroimaging findings in FXTAS, although he did not 
have the MCP sign. At autopsy, his brain showed mild, generalised atrophy, and ventriculomegaly. Pigmentation of 
the substantia nigra was diminished. Microscopic evaluation of sections of frontal cortex stained with hematoxylin 
and eosin showed intranuclear inclusions in 1% of astrocytes, although no inclusions were observed in cortical 
neurons. Microscopic studies did confirm the presence of Lewy bodies in the substantia nigra, basal forebrain, and 
parahippocampal cortex. Amyloid cores, indicative of Alzheimer changes, were identified in the temporal cortex. 
 Case (PSP) had onset of falls and occasional choking at age 64. At autopsy, the brain (left hemisphere) 
showed no gross abnormalities. Microscopically, the substantia nigra and locus coeruleus were depleted of 
dopaminergic neurons and showed reactive astrocytes. Neuronal loss, reactive astrocytosis, and grumose 
degeneration were seen in the dentate nucleus. Immunostaining with anti-tau antibody identified positive-staining 
cytoplasmic aggregates in neurons and primarily astrocytes of the basal ganglia, substantia nigra, pons, and dentate 
nucleus. Flame-shaped tangles were also present. Intranuclear inclusions were not seen. This subject was not 
affected with FXTAS. The final neuropathological diagnosis was progressive supranuclear palsy (PSP).
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Cultured human fibroblasts
Full thickness skin biopsies were performed under local anaesthesia with lidocaine. The biopsy was placed in culture 
media and later diced under sterile conditions on a culture plate and then plated in T25 flasks in AmnioMAX™-C100 
Basal Medium (Gibco, Grand Island, NY) containing 15% AmnioMAX™-C100 Supplement (Gibco). After cells grew out, 
longer-term cultures were maintained in RPMI-1640 supplemented with 10% foetal bovine serum and 1X penicillin-
streptomycin (pen-strep) media. Synchronisation of primary fibroblast cultures was achieved by growing the cell 
cultures in RPMI-1640 media without foetal bovine serum, at 37˚ C, 5% CO2, for four days. 
FXTAS Rating Scale
Videotapes from the structured neurological examination, designed to capture the major motor features of FXTAS: 
tremor, cerebellar dysfunction, and parkinsonism, were scored by a movement disorder neurologist, blinded to the 
subject’s premutation status, utilising the FXTAS Rating Scale, Version 1.0 28. 
 Code Gender Age of death CGG repeats
FXTAS clinical 
stagea
CNS neural
inclusions Reference
Controlb
Control 1 946 M 69 30 0 No
Control 2 1206 M 57 28 0 No
Control 3 1578 M 53 21 0 No
FXTAS
Case 1 1 M 70 113 6 Yes Case 1 63,64
Case 2 1006-05 M 72 62 6 Rare
Case 3 1007-05 M 75 78 6 Yes
Case 4 1012-05 M 80 67 6 Rare
Case 5 142-02 M 66 105 5 Yes Case 63,64
Case 6 13-03 M 77 77 6 Yes Case 6 63,64
Case 7 125-02 M 76 88 6 Yes Case 7 63,64
Case 8 58-02 M 75 92 5 Yes Case 8 63,64
Case 9 334-03 M 81 88 5 Yes Case 9 63,64
Case 10 1015-05 M 68 98 5 Yes Case 10 63,64
Case 11 1002-04 M 87 65 4 Yes Case 11 Case 9 63,64
Case 12c 468-05 F 52 30, 75 6 NA Greco et al 2007
unpublished results
Other Neurological Disorders
PSPd 30-03 M 70 42 0 No
Table 4.1a  |  Characteristics of individuals contributing autopsy material.
a FXTAS clinical stages: stages 0/1, uninvolved/equivocal involvement; stage 2, definite tremor or ataxia not interfering with ADLs; stage 3, tremor or ataxia 
interfering with ADLs; stage 4, use of cane or walker; stage 5, use of a wheelchair; stage 6, bedridden 1,  b From Maryland Brain Bank, c FXTAS concurrent with 
multiple sclerosis. Tissue analysed was skin biopsy, d PSP, Progressive Supranuclear Palsy
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FXTAS Clinical Staging Scale
Subjects included in this study were also assigned a rating on a 6-point FXTAS clinical staging scale (Table 1) based 
on the description of the degree of movement and gait problems, as previously described 1,14. 
Molecular Data 
Determination of (CGG)n length – Genomic DNA from peripheral blood lymphocytes or fibroblasts was amplified 
using an enhanced PCR technique as described 29, followed by sizing on polyacrylamide gels 30.
Quantification of mRNA levels - All quantitative analysis of FMR1 mRNA levels utilised quantitative RT-PCR, using 
the 7900 Sequence Detector (Applied Biosystems, Foster City, CA), as described 31. Lamin A/C, αB-crystallin, Hsp27, 
and Hsp70 mRNA levels were determined by quantitative RT-PCR using gene-specific probe/primer sets synthesised 
by (Applied Biosystems, Assays On Demand, Foster City, CA). Quantification of mRNA levels in human fibroblasts, and 
on mouse embryonic fibroblasts (MEF) and adult mouse fibroblasts, was performed on synchronised cell cultures. 
Generation of stable, expanded (CGG)n mouse embryonic fibroblast (MEF) cell lines
The knock-in mice harbouring large expansions (~100-250 CGGs) of the (CGG)n element in the Fmr1 gene have been 
described 32. A timed mating was set up between a male mouse (~220 CGGs) and a female mouse homozygous 
for the expanded (CGG)n (~180 and ~210 CGGs). The pregnant female was sacrificed at day 14-post coitum. Six 
embryos were processed to make six mouse embryonic fibroblast (MEF) lines. The embryonic sacs and placenta 
were removed from each embryo. The embryos were placed in PBS. After removal of PBS, the remainder of the 
embryo was minced. Five ml of trypsin/EDTA (TE) was added per embryo and incubated for 10 minutes at 37˚C while 
Code Age
CGG repeats
(Cultured 
fibroblasts)
CGG repeats
(Blood samples)
FXTAS clinical stage 
a (0-6)
FXTAS Rating Scale b
(0-226)
Control
C1 (1027-07) 57 30 30 0 0
C2 (C170) 75 21 20 0 0
C3 (1028-07) 87 22 NA 0 0
P1 (C082) 70 81 79 0 6
P2 (C124) 75 62 60 0 7
P3 (C146) 64 89 80 2 30
P4 (C154) 63 95 91 3 49
P5 (1025-07) 60 27, 106 98 3 72
P6 (C061) 80 98, 113 107 5 136
Table 4.1b  |  Cultured fibroblasts samples derived from male subjects 
a FXTAS clinical stages: stages 0/1, uninvolved/equivocal involvement; stage 2, definite tremor or ataxia not interfering with ADLs; stage 3, tremor or ataxia 
interfering with ADLs; stage 4, use of cane or walker; stage 5, use of a wheelchair; stage 6, bedridden 1. b FXTAS Rating Scale for major motor features, in 
subjects who underwent videotaping sessions. The ranges for sub domains scored are: Tremor (0-53), ataxia (0-73), and Parkinsonism (0-100) 2. Fibroblasts 
were derived from other subjects than the cases summarised in table 4.1a.
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shaking. The cell-TE suspension was removed and added to DMEM (BioWhittaker) with 10% FCS and 1% pen/strep 
to neutralise the trypsin. After incubation for 30 minutes at 37˚C with shaking, the cells were filtered and spun down, 
resuspended in DMEM with 10% FCS and 1% pen-strep, and plated onto a culture dish for each embryo. Cells were 
split upon reaching confluency.
 Mouse adult skin fibroblast lines were generated by cutting a piece of shaved skin of a mouse harbouring 
a (CGG)n of about 200 CGGs, and a wild type (wt) control, which were sacrificed at 20 weeks of age. The pieces of 
skin were minced and left to proliferate in DMEM with 10% FCS and 1% pen-strep. Cells were split upon reaching 
confluency and cultured until they became established fibroblast lines. MEFs and adult fibroblasts from wt and 
expanded CGG mice were grown on cover slips and further evaluated for the cellular distribution of lamin A/C and 
Hsps.
Immunofluorescence microscopy 
Cultured cells - Primary cultures of dermal human fibroblasts and mouse embryonic and adult skin fibroblasts 
(10000 cells/ cover slip) were grown on individual glass cover slips in RPMI-1640 (Gibco) supplemented with 10% 
fetal bovine serum (JR Scientific, Woodland, CA) and 1X pen-strep (Gibco), and incubated for 48 hours at 37oC and 
5.0% CO2. When cells reached 70% confluency, they were fixed, followed by blocking (Arocena et al., 2005). Blocked 
cover slips were incubated overnight (4oC) with rabbit anti-lamin C (GeneTex Inc., San Antonio, TX; 1:500 dilution) 
and mouse anti-αB-crystallin (Stressgen, Ann Arbor MI; 1:500 dilution) antibodies. The cellular distributions of Hsp27 
and Hsp70, relative to lamin, were studied by incubating fibroblasts with a combination of rabbit anti-lamin C 
(GeneTex Inc.; 1:500) and mouse anti-Hsp27 (Stressgen; 1:500) antibodies, or mouse anti lamin A/C (BD Transduction 
Laboratories, CA; 1: 500) and rabbit anti-Hsp70 (Stressgen; 1:1000) antibodies, respectively. Cover slips were washed 
in PBS-T, and then incubated with secondary antibodies: Alexa 488 goat anti-rabbit (Molecular Probes, Carlsbad, 
CA; 1:500), and Alexa 555 goat anti-mouse (Molecular Probes; 1:1000) for Hsp27; and Alexa 488 goat anti-mouse 
(Molecular Probes; 1:500) and Alexa 555 goat anti-rabbit (Molecular Probes; 1:1000) for Hsp70. All samples were 
counterstained with DAPI (Sigma-Aldrich, St. Louis MO) to define nuclear shape and volume. Slides were examined 
by fluorescence microscopy (Provis Olympus, Center Valley, PA) to characterise lamin organisation (± uniform ring-
like structure) and for presence of Hsp aggregates 23, scoring an average of ~740 cells per subject. Three independent 
staining experiments were performed per cell line. 
 
Whole tissue – Tissues from post mortem brain or skin biopsies were formalin-fixed, and processed for paraffin 
embedding in standard fashion. Antigen retrieval was accomplished by heating of slides for 30 minutes at 95oC in 
0.05 M Tris HCl, pH 9.5 with 0.05% polyoxyethylene (20) sorbitan monolaurate. Slides were allowed to cool to room 
temperature and washed with PBS-T Slides were incubated in blocking solution (5% goat serum in PBS-T); staining 
proceeded as outlined above for cultured cells.
One-dimensional Western blot analysis 
Frozen frontal cortex was powdered in the presence of liquid N2, and homogenised (Dounce) in lysis buffer (20 mM 
Tris-HCl, 137 mM NaCl, 10% glycerol, 0.1% SDS, 0.05% deoxycholate, 1% triton X-100, pH 7.4). Homogenates were 
spun at 16,000 g at 4oC. Protein concentrations of the supernatants and soluble fractions were quantified using a 
protein assay kit (#23225, BCA Protein Assay Kit, Pierce Biotechnology, Rockford, IL). Insoluble fractions (pellets) 
were resuspended in Laemmli sample buffer (62.5 mM Tris-HCl, 2% SDS, 25% glycerol, 0.01% bromophenol blue, 
pH 6.8) and heated at 95oC for 5 minutes. Soluble fractions were diluted in Laemmli sample buffer and heated for 5 
minutes at 95oC. Following electrophoresis on 10.5-14% linear gradient Criterion Tris-HCl gels (BioRad, Hercules, CA), 
proteins were transferred to nitrocellulose membranes. The membranes were subsequently blocked with BLOTTO 
(5% non-fat dry milk in 100 mM Tris-HCl, 0.9% NaCl, 0.1% polyoxyethylene (20) sorbitan monolaurate, pH 7.5) 
followed by overnight incubation with primary antibodies: mouse monoclonal anti-lamin A (MAB3540, Chemicon 
International, Temecula, CA), rabbit polyclonal anti-lamin C (GTX28981, GeneTex, Inc.), rabbit polyclonal anti-Hsp70 
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(SPA-812, Stressgen), mouse monoclonal anti-Hsp27 (SPA-800, Stressgen), mouse monoclonal anti-αB-crystallin 
(SPA-222, Stressgen), or mouse monoclonal anti- glyceradehyde 3-phosphate dehydrogenase (GAPDH) (GTX29484, 
GeneTex, Inc.), diluted in BLOTTO. Following washes with T-TBS (100mM Tris, 150mM NaCl, 0.1% polyoxyethylene 
(20) sorbitan monolaurate), blots were incubated with horseradish peroxidase conjugated secondary antibodies 
(Jackson ImmunoResearch Laboratories). Detection of antibodies was accomplished with SuperSignal West Dura 
Extended Duration Substrate (#34075, Pierce Biotechnology). Autoradiograms were quantified by densitometry 
using ImageJ 33.
Laser scanning cytometry (LSC)
A set of immunofluorescent stained slides, which included fibroblasts (10000 cells per coverslip) derived from 
five premutation carriers, with and without FXTAS symptoms, and three age-matched controls (Table 4.1b), were 
subjected to morphometric analysis of the fibroblast nuclei using an LSC-1 microscope and Wincyte software 
(Compucyte Corp., Cambridge, MA), as described 23. The values for the area of the nuclei were acquired based on the 
contour of DAPI fluorescence. At least 1000 nuclei were acquired and analysed per subject. 
Statistics
The analysis of mRNA levels determined by quantitative RT-PCR was as described in Tassone et al. 31. Independent 
analyses were performed for relative mRNA levels of FMR1, Hsp27, Hsp70, lamin A/C and αB-crystallin. No correction 
for multiple outcomes was applied across independent experiments. A Student’s t-test was used to analyze the pair-
wise differences between phenotypic groups. 
 For the analysis of the numbers of normal lamin C rings in cultured human fibroblasts, an average of ~740 
cells were counted per subject and scored for the presence of a uniform ring-like structure (a complete/closed ring 
of lamin staining the inner nuclear membrane). The percentages of cells with complete lamin rings were grouped 
according to clinical phenotype: FXTAS, stages 3 or greater; asymptomatic carrier; and control. The average percent 
of rings in three independent staining experiments of premutation carriers and controls were graphed and the 
standard deviations indicated by error bars. Pair-wise inter-group comparisons used the Student’s t-test. For LSC 
analysis, we scored at least 1,000 nuclei per subject and performed group-wise comparisons using a chi-squared 
statistical analysis. 
Results  |  4.3
Post mortem  frontal cortex from patients with FXTAS demonstrates both an absolute loss of lamin A/C 
protein and a repartitioning of the protein into a low-solubility fraction upon extraction 
The nuclear intermediate filament protein, lamin A/C was originally identified as a possible participant 
in the pathogenesis of FXTAS by virtue of its presence in the intranuclear inclusions found in the 
post mortem brain tissue of patients with FXTAS 17-19. It was subsequently demonstrated that similar 
inclusions form in cultured neural cells upon expression of reporter mRNAs with expanded (CGG)n in the 
5’UTR region of the message 23. Although inclusions formed in only a small percentage of the cultured 
cells, there was a more pervasive and striking collapse of the normal ring-like nuclear architecture of 
lamin A/C, suggesting that lamin disorganisation and aggregation may participate in the pathogenesis 
of FXTAS.
 To determine whether a relationship exists between the FXTAS phenotype and altered 
structural organisation of lamin A/C, we examined the properties of these lamin isoforms in post mortem 
brain tissue from ten males who had died with FXTAS. Included in this initial study were three male 
controls of comparable ages and a subject who died with an unrelated neurodegenerative disorder, 
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PSP (Table 4.1a). There was a striking difference between FXTAS cases and controls with respect to 
absolute lamin levels and the ratio of soluble/insoluble lamin isoforms in the frontal cortex. Western 
blot analysis of the soluble fraction of protein extracts of post mortem frontal cortex tissue from cases 
with FXTAS and controls (Figure 4.1A) reveals dramatic decreases in the levels of both lamin A and lamin 
C protein isoforms in nine FXTAS cases. The striking exception is a single case of severe FXTAS (Case 10; 
lane 13) where there does not appear to be detectable repartitioning of lamin A/C. This case will be 
considered further below. Interestingly, the PSP case (lane 9), which does not possess the intranuclear 
inclusions, also demonstrates loss of soluble lamin, suggestive of parallel disease processes in these 
two neurodegenerative disorders. A subset of these brain tissue samples, 3 FXTAS, 1 PSP, and 2 controls, 
were analysed further, revealing that at least some of the reduction of lamin A/C observed in patients 
with FXTAS (and the single PSP case) on the initial Western blots was due to repartitioning of lamin 
proteins from the soluble extract to a much less soluble form, one that requires boiling the protein 
extracts in SDS buffer for solubilisation (Figure 4.1B). This redistribution of lamin is consistent with the 
observed aggregation and change in nuclear lamin architecture seen in cultured cells containing the 
expanded (CGG)n 
23.
Figure 4.1  |  Post mortem brain (cerebral cortex) tissue samples from FXTAS patients show reduced levels of soluble lamin A and lamin C, 
and increased levels of Hsp 27. (A) 100 µg of soluble protein from frontal cortex was loaded into each lane. Lamin A and lamin C are detectable in all 
controls (lanes 1-3). Lamin A is detected in only one case (lane 13, Case 10). Two of the FXTAS cases (lanes 4 and 13, Cases 9 and 10) contain detectable lamin 
C. Neither lamin A nor lamin C is detectable in the soluble fraction obtained from a PSP patient (lane 9). (B) Western blot of the insoluble fractions of the 
post mortem  tissue reveals an increase in lamin A in FXTAS (lanes 3, 4,and 6) and PSP (lane 5) patients versus controls (lanes 1 and 2).  (C) 40 µg of soluble 
protein from frontal cortex was loaded into each lane. FXTAS cases (lanes 3-6) show increased levels of Hsp27 compared to controls (lanes 1 and 2); relative 
Hsp27 levels (GAPDH loading standard) are 0.9, 1.1, 7.0, 4.1, 2.6 and 6.6, for lanes 1 – 6, respectively, relative to the average expression of the controls. Post 
mortem intervals for FXTAS/PSP cases were shorter (approximately 12 hours or less) than control cases (all greater than 12 hours).
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To determine whether the reductions in lamin protein were a consequence of reduced transcription 
of the LMNA gene, LMNA mRNA levels from post mortem frontal cortex of six FXTAS cases (including 
Case 10) and two controls were quantified by real 
time (TaqMan) RT-PCR. There was no reduction in 
LMNA mRNA level for any of the FXTAS cases tested, 
ruling out reduced mRNA levels as an explanation 
for the decreased levels of soluble lamin protein. 
In fact, excluding Case 10, we observed an average 
1.7-fold increase (range, 1.2 - 2.5; t-test, p=0.041) in 
LMNA mRNA levels among the cases with FXTAS; 
inclusion of Case 10, which displayed no increase in 
LMNA mRNA reduced the average increase to 1.6-
fold (range, 0.8 - 2.5; p=0.078).
To confirm that the FXTAS samples being 
tested were expressing higher than normal levels of 
FMR1 mRNA, as expected for neural cells expressing 
from premutation alleles, the same tissue samples 
from 6 patients with FXTAS and 2 control subjects 
were analysed for levels of FMR1 mRNA. There 
was an average increase of 2.0-fold compared to 
controls (range, 1.4 - 2.4; p=0.012), including Case 
10, which itself was elevated by 2.1-fold. Thus, the 
absence of a lamin repartitioning in Case 10 was 
not due to lowered FMR1 mRNA expression (Figure 
4.2A). These results are consistent with previous 
findings of increased FMR1 mRNA expression in 
FXTAS brain tissue 20.
FXTAS also involves a cellular stress response with 
induction of heat-shock proteins αB-crystallin, Hsp 
27, and Hsp 70
Like lamin A/C, αB-crystallin is also found within 
the inclusions formed in cultured neural cells upon 
expression of transfected expanded (CGG)n reporter 
RNA 23. To determine whether αB-crystallin is 
induced in FXTAS brain tissue, relative levels of αB-
crystallin mRNA were determined in frontal cerebral 
cortex samples from six FXTAS and two control 
cases. The samples from FXTAS brain tissue express 
higher levels of αB-crystallin mRNA compared to the 
controls: an average 3.5-fold increase (range, 2.1-4.7-
fold; p = 0.0026), including Case 10 (Figure 4.2B).
Figure 4.2  |  Brain tissue from patients affected with FXTAS 
express higher levels of FMR1 mRNA and stress response genes 
compared to the controls in the same age range. (A) FMR1; (B) αB-
crystallin; (C) Hsp70. Cases are displayed according to increasing number 
of CGG repeats (case number).
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The same set of samples was also analysed to quantify the expression levels of Hsp70 and Hsp27 
mRNAs. Our results indicate that mRNA levels of Hsp70 are significantly elevated in FXTAS frontal 
cortex, compared to age-matched controls; an average of 3.2-fold increase (range, 1.4 – 4.7-fold; 
p=0.018), again including Case 10 (Figure 4.2C). There was no significant increase in Hsp27 mRNA level 
for the current samples, due in part to greater variation in Hsp27 mRNA levels within the control group 
(data not shown). However, examination of Hsp27 protein levels in frontal cortex revealed increases in 
several of the FXTAS cases compared to controls (Figure 4.1C). Taken together, the current data provide 
evidence for a stress (heat-shock) response to the expanded (CGG)n FMR1 mRNA, as reflected by either/
both increased Hsp mRNA or protein levels.
Dysregulation of lamin A/C in human skin fibroblasts mirrors the abnormalities found in neural cells
One of the fundamental limitations inherent in characterisation of the FXTAS cellular phenotype is the 
inaccessibility of CNS neural tissue. However, based on the knowledge that a number of laminopathies 
also display altered lamin organisation in dermal fibroblasts, with formation of lamin-containing nuclear 
aggregates 34-39, we explored the possibility that lamin A/C architecture is similarly altered in the skin 
fibroblasts of premutation carriers with FXTAS. Our initial approach was to examine dermal fibroblasts 
in situ from a 52 year old female carrier with alleles of 30 and 75 CGGs (Greco et al., unpublished results) 
who had died with FXTAS and multiple sclerosis, and from a male age-matched control (52 yr) (Figure 
4.3). In the control skin fibroblasts, lamin A/C staining was uniform, with a heavier ring-like pattern at 
the nuclear periphery. By contrast, in the FXTAS case, the normal ring-like distribution of lamin A/C was 
frequently disrupted or distorted. Interestingly, some nuclei in the patient with FXTAS appear to have 
essentially normal morphology, presumably representing those cells where the normal allele ((CGG)30) 
is active. The immunofluorescent patterns, using antibodies directed to either lamin A/C, lamin A or 
lamin C, gave the same results. These observations strongly indicate that expression of the expanded 
(CGG)n FMR1 mRNA leads to cellular dysregulation in human dermal fibroblasts. 
 To extend these results obtained with post 
mortem skin cells to living cells, fibroblasts were 
cultured from four affected male carriers (FXTAS 
ratings of 30, 49, 72, and 136; clinical stages of 2, 3, 3, 
and 5, respectively), two premutation males with no 
clinical signs of FXTAS, and three male controls with 
normal alleles (Table 4.1b). The (CGG)n numbers 
present in the cultured fibroblasts are approximately 
the same as the alleles observed in blood samples 
from the same subjects; with the exception of 
subject P5, who displays allele-size mosaicism (27 
and 106 CGGs) in cultured fibroblasts. The levels 
of FMR1 mRNA were quantified for each fibroblast 
culture, demonstrating that FMR1 expression is 
upregulated by an average of 1.7-fold (p=0.025) in 
fibroblasts derived from the premutation carriers 
Figure 4.3 |  Post mortem skin biopsy in a case (468-05) with FXTAS 
displays frequently distorted nuclear ring-like distribution of 
lamin A/C (lower panel) compared to an age-matched control (upper 
panel). Green, lamin A/C; blue, DAPI staining of nuclei. See page 163 
onwards for colour version of this figure. 
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(n= 6) with and without FXTAS, relative to normal controls, in agreement with previous observations in 
both neural and non-neural cells 20,31. 
 Immunocytochemical staining with lamin C antibodies revealed a striking disruption of the 
normal nuclear shape and the normal ring-like pattern in fibroblasts from three cases with moderate to 
severe FXTAS (P3-P6 with clinical stage 3 or greater) (Figure 4.4). For these three cases, we observed the 
ring-like lamin architecture in an average of only 26 (± 7)% of 2,667 cells scored, relative to an average 
of 74 (± 13)% of 2,008 cells from controls (t-test; p=0.0095). This result mirrors our earlier observation 
of lamin disruption in cultured neural cells transfected with expanded (CGG)n 
23. Remarkably, we see 
an average decrease in lamin rings for 
the two asymptomatic carriers (P1 and 
P2) and the mildly affected case (P3; 
stage 2) relative to the normal controls 
(number of lamin ring nuclei/total 
nuclei: 1466/2008, controls; 825/1975, 
non- and mildly-affected premutation 
carriers; Fisher’s exact test; p <0.0001); 
a comparison of the means leads to 
the same conclusion (student’s t-test, 
p = 0.011). These preliminary results 
suggest that skin fibroblasts may report 
early states of the cellular dysfunction 
that eventually leads to FXTAS. Given the 
small number of asymptomatic carriers 
examined thus far, it would be premature 
to draw conclusions regarding incipient pathology or the likelihood of progression; however, our 
observations with asymptomatic carriers provide motivation for additional molecular-clinical and 
longitudinal studies.
 A second morphological abnormality previously associated with expression of the expanded 
(CGG)n in cultured neural cells is increased nuclear volume 
23. We therefore examined the cultured 
fibroblasts from cases with FXTAS for corresponding changes. For the three cases with FXTAS with 
moderate to severe FXTAS (stage 3-5), we find an average increase in area of 1.4 (± 0.2) fold (p=0.005). 
A comparison of fibroblasts derived from a clinical stage 5 FXTAS case (P6; 80 yr) and a normal control 
(C3; 87 yr) is presented in figure 4.5. 
The cellular phenotype of dermal fibroblasts also parallels CNS neural cell dysregulation in FXTAS with 
respect to a stress response involving over-expression of Hsp27 mRNA
The induction of a cellular stress response in the CNS of FXTAS cases raises the possibility of a 
corresponding stress response in dermal fibroblasts, since these peripheral cells also over-express 
the expanded (CGG)n FMR1 mRNA. In all fibroblast cultures from patients with FXTAS (n=4; FXTAS 
clinical stage ≥ 2), the level of Hsp27 mRNA is also elevated by an average 2.7-fold (range 1.7 – 4.1-
fold; p=0.037). These results demonstrate that the response to expression of the expanded (CGG)n in 
Figure 4.4 |  Reduction of normal lamin rings in cultured fibroblasts derived 
from FXTAS patients (Table 1b). Open bars, controls; light grey bars, premutation 
carriers with no symptoms of FXTAS (P1, P2) or mild features (clinical stage 2; P3); dark 
grey bars, individuals with moderate to severe FXTAS (P4-P6).
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fibroblasts involves both morphologic changes that parallel those in neural cells, and corresponding 
biochemical changes involving a stress response. 
Figure 4.5 |  Increased nuclear area in human fibroblasts from a patient with FXTAS.  Morphometric values of individual 
human skin fibroblasts contoured on the basis of DAPI fluorescence. (A) Distribution of the nuclear areas of 2013 fibroblasts derived from 
an 87-year old normal control (C3). (B) The nuclear areas of 2009 fibroblasts derived from an 80-year old patient with severe FXTAS (P6) 
exhibit a broader distribution of nuclear areas, with an average 1.3-fold increase, compared to the age-matched control (overlay tracing 
of the distribution in part A). See page 163 onwards for colour version of this figure. 
Mouse embryonic fibroblasts harbouring large premutation expansions (~200 CGGs) also display an 
abnormal cellular phenotype involving nuclear lamin A/C dysregulation 
Studies of the cellular phenotypes induced by the expanded (CGG)n FMR1 mRNA have thus far been 
largely restricted to tissue samples obtained from adult carriers and controls. However, cellular 
phenotypes can be induced in a much shorter time-frame in neural cell culture 23, raising the possibility 
of an early-onset cellular phenotype. As an initial approach to address this possibility, we utilised mouse 
embryonic fibroblasts (MEFs) derived from knock-in mice with expanded (~200 CGGs), unmethylated 
Fmr1 alleles 32. These animals show elevated Fmr1 mRNA levels and mildly reduced FMRP levels 
characteristic of large premutation alleles in humans 31,32. 
We quantified the levels of Fmr1 mRNA in cultured mouse fibroblasts, derived from embryos 
and adult mice with expanded (CGG)n, relative to wt control fibroblasts. MEFs derived from expanded 
(CGG)n mice express a four-fold elevation (p< 0.001) in Fmr1 mRNA levels, compared to MEFs derived 
from wt controls. Moreover, premutation MEFs express 4.6-fold (p< 0.01) more Fmr1 mRNA than 
premutation adult mouse fibroblasts, indicating that Fmr1 expression is very high in fibroblasts during 
early development and decreases in adulthood. Interestingly, we observed no significant difference in 
Fmr1 mRNA levels in adult cultured mouse fibroblasts between expanded-repeat and wt mice. 
Remarkably, the MEFs from premutation mice already display evidence of lamin dysregulation, 
with a 4.7 fold decrease in the number of complete lamin rings (p < 0.001, Fisher’s exact test) relative to 
cells derived from wildtype MEFs.  Fibroblasts derived from adult expanded repeat mice also display a 
significant, albeit less pronounced lamin C dysregulation than their MEF counterparts (50% vs 18% of 
complete lamin rings; p < 0.001, Fisher’s exact test). This result suggests that the fundamental processes 
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leading to lamin dysregulation may be at least in part reversible, since the adult mice developing from 
such embryos do not display the degree of abnormality exhibited by the MEFs. 
In addition, we have observed a greater degree of perinuclear αB-crystallin aggregation in the MEFs 
(Figure 4.6) relative to adults with the same range of expanded repeats. Indeed, although the number 
of MEFs from expanded repeat mice displaying both lamin C and αB-crystallin aggregates is a small 
percentage of the total cells examined, the reduced number found in adult cells is highly significant 
(47/380, MEFs; 4/398 adult mice; Fisher exact test, p <0.0001). 
Discussion  |  4.4 
To determine whether there is a broader lamin A/C abnormality than simply its presence in intranuclear 
inclusions 19, which are present in a minority of neural cells, we determined the expression pattern 
of this protein in frontal cortex from patients with FXTAS and normal controls. Patients with FXTAS 
clearly express increased levels of LMNA mRNA; however, levels of soluble lamin A/C were dramatically 
reduced, consistent with its aggregation in FXTAS cells. Thus, altered expression of lamin A/C is clearly a 
component of the CNS cellular response to expression of the expanded-repeat FMR1 mRNA. 
 We also demonstrate that the clinical presentation of FXTAS is associated with a cellular 
stress response that involves at least three Hsps, αB-crystallin, Hsp27 and Hsp70. In frontal cortex from 
patients with FXTAS and age-matched controls, the transcription levels of αB-crystallin and Hsp70 are 
significantly elevated (Figure 4.2) though the overall levels of protein seem to be unchanged, perhaps 
due to altered post-translational regulatory events. By contrast, Hsp27 protein levels are clearly 
elevated in the frontal cortex from patients with FXTAS (Figure 4.1C). It has long been known that the 
Hsps function as chaperones in mitigating protein misfolding and aggregation 40-42. More recently, Hsps 
have been shown to interact with elements of the cytoskeleton that are adversely affected by several 
Figure 4.6 |  Immunocytochemical localisation of lamin C and αB-crystallin in mouse embryonic fibroblasts. Lower panel: mouse fibroblasts 
harbouring the expanded-CGG-repeat display irregular nuclear morphology (nuclei counterstained with DAPI, blue), marked lamin C disruption and 
aggregation with loss of the normal ring-like architecture (green), and an increased number of perinuclear aggregates containing αB-crystallin (red). See 
page 163 onwards for colour version of this figure. 
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types of cellular stress (43-46, reviewed in 47,48). Our observations suggest that neurons and astrocytes 
in patients with FXTAS are responding to a form of stress that is triggered by elevated levels of FMR1 
mRNA, and which also leads to altered cytoskeletal structure. 
Whereas Case 1 possesses the highest levels of Hsp and lamin A/C mRNAs, and the 
highest numbers of inclusions in both neurons and astrocytes 17, this patient displayed the mildest 
neuropathological findings of the five cases 17. By contrast, Case 6, which has the lowest levels Hsp 
mRNAs and lamin A/C, displays the most extensive brain abnormalities, involving severe white matter 
spongiosis with axonal and myelin loss, and extensive cerebellar Purkinje cell dropout. Although 
there appears to be a similar trend in Cases 5, 7, 9, and 10, the significance of this trend has not been 
quantified. Such a trend, if established in a larger series, would be in accord with the recently described 
neuroprotective action of αB-crystallin, Hsp27, and Hsp70 49-51. 
 Overexpression of Hsp27 and Hsp70 has been shown to prevent neuronal death in some 
studies in animal models of neurodegenerative diseases reviewed by 22,49. However, therapies targeting 
FXTAS progression (and reversal) will likely need to do more than simply boosting the heat shock 
response, as recently exemplified in a mouse model for multiple sclerosis 52. Efforts should be made 
to target earlier events in FXTAS pathogenesis, including the reduction of excess FMR1 mRNA in 
susceptible cells. In view of the significant fraction of FXTAS cases that have peripheral neuropathy 24-26, 
it is interesting to note that one form of Charcot-Marie-Tooth disease (CMT2F) is due to a missense 
mutation in the gene encoding Hsp27; the mutant form of the gene appeared to disrupt neurofilament 
(intermediate filament) assembly 53.
Willemsen et al. 54 have demonstrated that mice with expanded repeats (~100 CGGs) 
developed neuronal intranuclear inclusions in broad distribution throughout the brain. In the current 
work, we demonstrate that mouse embryonic fibroblasts (MEFs) with expanded (CGG)n already display 
dramatic evidence of early lamin dysregulation, although there is no evidence of any upregulation of 
αB-crystallin mRNA levels. 
By analogy to the mouse model demonstrating altered lamin A/C architecture, we propose 
that, in humans, the impaired cytoskeletal network induced by overexpression of the expanded (CGG)n 
FMR1 RNA will likely have an adverse impact on neural development and differentiation, during which 
extensive neurofilament rearrangement takes place 43. Cytoskeletal components have been shown 
to play a major role in the elaboration of axons and dendrites, and in the proper maintenance of 
neuronal connectivity and dynamics through adulthood 55. Many of the clinically affected children who 
carry a premutation allele have autism spectrum disorders (ASD) 56. An important neuropathological 
mechanism leading to ASD involves connectivity deficits, which have been studied by several authors 57,58. 
Impaired functional connectivity has been demonstrated on fMRI studies of the amygdala response to 
fearful stimuli in young adult males with the premutation who do not have neurological symptoms 59. 
Therefore, by analogy with our current observations with MEFs, the lamin A/C dysregulation in human 
embryonic and/or fetal cells may impact the subsequent development of connectivity in the brain of 
premutation carriers 56,60,61.
In addition to the proposed effects in early development, impaired organisation of the 
cytoplasmic cytoskeleton impedes axonal transport of organelles and nutrients, eventually leading to 
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neuronal death 62.  This phenomenon could explain the formation of pathological axonal torpedoes in 
FXTAS 17,18.
Finally, our observation of parallel cellular phenotypes in CNS and dermal fibroblasts (e.g. 
lamin disorganisation/aggregation, heat-shock response) indicates that the latter cell type provides 
an accessible (peripheral) cellular marker of the FMR1 mRNA-induced cellular pathology that underlies 
FXTAS. In particular, the cellular status of dermal fibroblasts in premutation carriers may be linked to 
eventual clinical progression, and may also report efficacy of therapeutic intervention. These possibilities 
clearly require further investigation.
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Abstract  | 
The human FMR1 gene contains an unstable CGG-repeat ((CGG)n) in its 5’ untranslated region. The repeat 
length in the normal population is polymorphic (5-54 CGGs). Individuals carrying lengths beyond 200 
CGGs (i.e. the full mutation) show hypermethylation and as a consequence gene silencing of the FMR1 
gene. The absence of the gene product FMRP causes the fragile X syndrome, the most common inherited 
form of mental retardation. Elderly carriers of the premutation (PM), which is defined as a repeat length 
between 55-200 CGGs, can develop a progressive neurodegenerative syndrome: fragile X-associated 
tremor/ataxia syndrome (FXTAS). The high FMR1 mRNA levels observed in cells from PM carriers 
have led to the hypothesis that FXTAS is caused by a pathogenic RNA gain-of-function mechanism. 
Apart from tremor/ataxia, specific psychiatric symptoms have been described in PM carriers with or 
without FXTAS. Since these symptoms could arise from elevated stress hormone levels, we investigated 
hypothalamo-pituitary-adrenal (HPA) axis regulation using a knock-in mouse model with an expanded 
(CGG)n in the PM range (>98 repeats) in the Fmr1 gene, which shows repeat instability, and displays 
biochemical, phenotypic and neuropathological characteristics of FXTAS. We show elevated levels of 
corticosterone in serum and ubiquitin-positive inclusions in both the pituitary and adrenal gland of 
100-week old animals. In addition, we demonstrate ubiquitin-positive inclusions in the amygdala from 
aged expanded (CGG)n mice. We hypothesise that altered regulation of the HPA axis and the amygdala 
and higher stress hormone levels in the mouse model for FXTAS may explain associated psychological 
symptoms in humans.
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 Introduction  |  5.1 
The fragile X mental retardation gene 1 (FMR1), located on the X chromosome, harbours a (CGG)n in 
its 5’ untranslated region (5’UTR). This repeat may become unstable upon transmission to the next 
generation. Different clinical outcomes occur depending on the length of this trinucleotide repeat. 
Normal individuals carry a repeat of up to 44 CGG units, which remains stable on transmission 1. Alleles 
with between 45 and 54 repeats are considered intermediate size alleles, which are associated with 
some degree of instability. Individuals with over 200 CGGs have the full mutation, which usually leads 
to methylation of both the promoter region and the (CGG)n, and consequent transcriptional silencing 
of the gene. The absence of the gene product fragile X mental retardation protein (FMRP) is the cause of 
the mental retardation seen in fragile X patients 2. Individuals with the premutation (PM) have between 
55 and 200 CGGs. Female carriers of the PM are at increased risk of developing premature ovarian failure 
(POF) 3. PM carriers also are at risk for fragile X-associated tremor/ataxia syndrome (FXTAS), which has 
been observed in elderly men over age 50, and less often in female PM carriers 4-6. 
FXTAS is a progressive neurodegenerative disorder, believed to be the result of a pathogenic 
RNA gain-of-function mechanism, as PM carriers produce 2-8 fold elevated levels of FMR1 mRNA in 
their lymphocytes. While transcription is increased, translation is hampered, resulting in slightly lower 
FMRP levels in individuals with high (CGG)n alleles within the PM range 
7-10. Patients with FXTAS usually 
present with tremor and ataxia, but may develop other neurological symptoms such as Parkinsonism, 
autonomic dysfunction and peripheral neuropathy and may suffer from cognitive decline including 
formal dementia. Post mortem studies of brains from patients with FXTAS reveal intranuclear inclusions 
in neurons and astrocytes in multiple brain areas 11. These inclusions contain several proteins, 
including ubiquitin, heat shock proteins including αB-crystallin, the RNA binding proteins hnRNP-A2 
(heterogeneous nuclear ribonucleoprotein A2) and MBNL1 (muscle blind-like protein 1)  and a number 
of neurofilaments, among which are lamin A/C 12 and FMR1 mRNA 13. Very recently, Pur α has been 
identified as a component of the ubiquitin-positive inclusions in FXTAS brain 14. Proteins that are 
sequestered into the inclusions may be prevented from exerting their normal function, thus resulting 
in cellular dysfunction, ultimately leading to neurodegeneration 14-16.
Recent studies have documented that the abnormal elevation of FMR1 mRNA is associated 
with increased psychological symptoms, such as anxiety, depression, and irritability in adult PM carriers, 
with or without symptoms of FXTAS, especially males 17-20. These psychological symptoms could arise 
from elevated stress hormone levels, thus aberrant regulation of the hypothalamo-pituitary-adrenal 
gland (HPA) axis. More evidence suggestive of altered regulation of the HPA axis by the PM comes 
from the observation that ubiquitin-positive intranuclear inclusions are also present in the anterior and 
posterior lobes of the pituitary gland of patients with FXTAS 21,22. A link has been suggested between 
pituitary inclusions and dysregulated neuroendocrine function in patients with FXTAS. Increased 
Follicle Stimulating Hormone (FSH) 22-24 and decreased inhibin A and B levels in female PM carriers 
were reported even in those who are cycling normally, suggestive of early ovarian aging and ovarian 
compromise 25. Elevated levels of FSH have been found to reflect decreasing ovarian reserve 26, which 
can be correlated to the risk of developing POF seen in female PM carriers. Interestingly, intranuclear 
inclusions have been reported in the testicles of two men with FXTAS; inclusions were present in the 
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anterior and posterior pituitary gland of one of these for whom the pituitary gland was available 22. 
Finally, a reduced amygdala response has been reported in PM male carriers which may explain the 
aetiology of psychological symptoms involving emotion and social cognition as well 27.
An expanded (CGG)n knock-in ((CGG)n) mouse model has been generated 
28,29, by substituting 
the endogenous mouse (CGG)8 with a human (CGG)98. The (CGG)n in the mouse model shows instability 
upon transmission to the next generation 30, similar to humans. Also, the (CGG)n mice show elevated 
Fmr1 mRNA levels 30, as well as ubiquitin-positive neuronal inclusions throughout the brain 28,29. 
Aberrant behaviour in mice was described by Van Dam and colleagues, including mild learning deficits 
and increased anxiety 31.
We explored HPA axis physiology in expanded (CGG)n mice for two reasons: 1) increased 
anxiety has been observed in our mouse model 31 and PM carriers, especially those with elevated FMR1 
mRNA experience more psychological distress 19, 2) ubiquitin-positive inclusions have been found in 
the pituitary gland of male patients with FXTAS 22. Here we further characterise the expanded (CGG)n 
mouse model for FXTAS and more specifically we demonstrate the presence of inclusions in several 
endocrine organs of the (CGG)n mice and in the amygdala. The amygdala plays an important role in the 
regulation of the secretion of HPA axis-related hormones in the hypothalamus 32. We also report elevated 
corticosterone levels in response to a mild stressor. Thus we present evidence that HPA axis physiology 
is disturbed in (CGG)n mice, which might explain molecular mechanisms underlying psychopathology 
in PM carriers and/or patients with FXTAS.
Materials and methods | 5.2 
Mice
Both the expanded (CGG)n knock-in ((CGG)n) mice and the wild type (wt, with an endogenous (CGG)8-repeat) mice 
were housed under standard conditions. All experiments were carried out with permission of the local ethical 
committee. (CGG)n lengths were determined for the whole colony, but only male mice were used for experiments. 
All mice had a mixed C57/BL6 and FVB/n genetic background. 
Genotyping of the mice
DNA was extracted from mouse tails as described previously 30. Determination of the (CGG)n length was performed 
by means of PCR using the Expand High Fidelity Plus PCR System (Roche Diagnostics), with forward primer 
5’- CGGAGGCGCCGCTGCCAGG-3’ and 5’-TGCGGGCGCTCGAGGCCCAG-3’ as reverse. PCR products were visualised 
on a 6% polyacrylamide gel. As these primers are specific to the knock-in allele, a separate PCR is performed 
for the wt allele. The wt allele was detected using TaKaRa LA Taq polymerase (using GC buffer II), according to 
manufacturer’s instructions (Takara Bio Inc), with 5’-GCTCAGCTCCGTTTCGGTTTCACTTCCGGT-3’ as forward primer 
and 5’-AGCCCCGCACTTCCACCACCAGCTCCTCCA-3’ as reverse primer (detailed description in 30). The 100-week old 
mice used in this study had (CGG)n lengths between 100 to 160 CGGs, while 25-week old mice had 160-200 CGGs. 
Western blotting
Half brains (sagittal) were homogenised in HEPES buffer. We loaded 100 µg of protein onto an 8% SDS-PAGE gel, 
which was then electroblotted onto a nitrocellulose membrane. The membrane was incubated overnight at 4°C with 
the monoclonal 2F5-1 antibody specific for Fmrp 33 and a monoclonal antibody against Gapdh (Chemicon), which 
served as a loading control. The next day the membrane was incubated with a horseradish peroxidase conjugated 
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rabbit-anti-mouse antibody (DAKO), allowing visualisation by chemilluminescence using an ECL kit (Amersham) (for 
details, see 30). Quantification of protein bands was performed using TotalLab software (Nonlinear Dynamics Ltd). 
All three Fmrp isoforms were taken into account in the calculations. Multiple comparable series of increasing repeat 
lengths were performed, both for young and old mice. One series, representative of many repeated experiments, is 
shown.
Blood collection and hormone levels 
In the morning, mice were transported from the animal facility to the laboratory in their home cage, which can 
be considered a mild stressor. After arrival in the laboratory they were left to acclimate for at least 30 minutes. The 
order of sacrifice was random with respect to genotype. After sacrifice by cervical dislocation, blood was collected 
immediately from the thoracic cavity by perforating the right cardiac atrium and collecting the resulting blood flow. 
Blood was kept at 4°C overnight and centrifuged the next day at 4°C for 15 minutes. The supernatant was stored at 
-20°C until analysis. Serum corticosterone levels were estimated using radio immunoassays or enzyme immunoassays 
for the determination of corticosterone in serum provided by Diagnostic Systems Laboratories (Webster, TX). Both 
assays use the same antiserum and yielded identical results for the internal quality control sera. Intra-assay and inter-
assay variation coefficients were below 7 and 13%, respectively. Thus, all data were analyzed together.
Measured serum corticosterone levels did not follow a normal distribution (positively skewed: standard 
deviation > ½ * mean). Therefore measured corticosterone levels were subjected to logarithmic transformation. 
The lognormal plot showed a strongly improved distribution, hence the log-transformed data were used for further 
analysis. Back-transformation of the means of the values by calculating 10mean gives the geometrical mean (GM). 
Analysis of variance (ANOVA) was performed on log-transformed corticosterone levels to test the difference between 
wt and (CGG)n mice, at 25 and 100 weeks of age. Since significance was revealed, posthoc pair wise comparisons 
were performed with Bonferroni correction for multiple comparisons. Geometrical mean differences (GMD) are 
presented with their respective corrected p-value. GMDs were calculated by subtracting back-transformed mean 
log-transformed corticosterone levels. The correlation between corticosterone levels and repeat length was also 
examined. The statistical software package SPSS (version 11) was used for all analyses. The level of statistical 
significance was set at p<0.05.
Immunohistochemistry
After mice were sacrificed brains were dissected, followed by the pituitary gland and adrenal gland and fixed 
overnight in 3% paraformaldehyde. Tissues were embedded in paraffin according to standard protocols. Sections (7 
µM) were deparaffinised followed by antigen retrieval using microwave treatment in 0.01 M sodium citrate solution. 
Endogenous peroxidase activity blocking and immunoincubation were performed as described before 34, using 
a polyclonal rabbit antibody against ubiquitin (Dako, ZO458), a monoclonal antibody against FMRP (1C3)34 and 
a polyclonal antibody against glucocorticoid receptor (GR: Affinity BioReagents PA1-511A). Ubiquitin-positive 
intranuclear inclusion counts in amygdala, pituitary and adrenal gland were determined by counting the number 
of inclusion-bearing cells in a field of 100 neurons counted. Per area of interest three fields of 100 neurons were 
counted. Mean counts and the range are given.
RNA isolation, RT and Q-PCR
RNA of pituitary glands of 100-week old animals was extracted using a RNeasy Mini Kit, according to 
manufacturer’s instructions (Qiagen). RNA concentration and purity were determined using a NanoDrop ND-1000 
Spectrophotometer (NanoDrop Technologies). Reverse transcriptase was performed on 1 µg RNA using iScript cDNA 
Synthesis Kit (BioRad) according to manufacturer’s instructions. Detailed description of RNA isolation and RT can be 
found in Brouwer et al (2007). Q-PCR was performed on 0.1 µl of RT product. Primers used for Q-PCR were as follows: 
Fmr1 (transition exon 7/8: forward: 5’- TCTGCGCACCAAGTTGTCTC -3’, reverse: 5’-CAGAGAAGGCACCAACTGCC-3’), 
Gapdh (forward: 5’-AAATCTTGAGGCAAGCTGCC-3’, reverse: 5’-GGATAGGGCCTCTCTTGCTCA-3’), GR (nuclear receptor 
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subfamily 3, group C, member 1: Nr3c1: transition exon 4/5: forward: 5’-CAAAGGCGATACCAGGATTCA-3’, reverse: 
5’- GGGTCATTTGGTCATCCAGGT-3’), Corticotrophin releasing hormone receptor type 1 (Crhr1: transition exon 2/3: 
forward: 5’-TCTGACAATGGCTACCGGG-3’, reverse: 5’-AATAATTCACACGGGCTGCC-3’), Arginine vasopressin receptor 1b 
(Avpr1b: transition exon 1/2: forward: 5’-GGACGAGAATGCCCCTAATGA-3’, reverse: 5’-TCGAGATGGTGAAAGCCACAT-3’) 
and Proopiomelanocortin (Pomc: transition exon 2/3: forward: 5’-AACCTGCTGGCTTGCATCC-3’, reverse: 
5’-TGACCCATGACGTACTTCCG-3’). Efficiencies of the different primer sets were checked and found to be comparable. 
Ct values of the reference gene were subtracted from the Ct value of the target gene for each sample, which gives 
the ∆Ct. ∆Ct of wt was then subtracted from ∆Ct of (CGG)n mice, which is designated as the ∆∆Ct. 2
-∆∆Ct then gives 
fold change.
Results  | 5.3 
All knock-in mice have a (CGG)n length in the PM range, and they all show Fmrp expression as illustrated 
by Western blot analysis (figure 5.1). Analysis of different (CGG)n animals shows that Fmrp levels 
decrease mildly with increasing repeat length and a transition to reduced levels seems to occur around 
170 CGGs. Western blot was performed on multiple series of brain lysates of mice with increased repeat 
lengths. All experiments showed the same 
pattern, both when brains from old (72- 
or 100-weeks old) and young (25-weeks 
old) were used. Figure 5.1 shows a series 
representative of what was seen in all 
experiments. For the samples used in 
figure 5.1, quantification of the amount of 
Fmrp in each sample relative to wt brain 
revealed 100% for 112 and 129 CGGs 
and 80% and 70% for 174 and 185 CGGs 
respectively.
Corticosterone levels in (CGG)n mice
To study the regulation of the HPA axis in our mouse model, we first investigated the endpoint of this 
axis, namely corticosteroid levels. The predominant corticosteroid in mice is corticosterone. Moving the 
mice from the animal facility to the laboratory where they were sacrificed is a mild stressor. We waited at 
least 30 minutes before mice were sacrificed and since corticosterone response to stress occurs within 
approximately 30 minutes, we measured corticosterone levels in response to this mild stressor 35-37. 
Mean corticosterone levels as measured in (CGG)n and wt mice at 25 and 100 weeks of age are depicted 
in figure 5.2. One-way ANOVA on log transformed corticosterone levels revealed that the four groups, 
based on genotype and age, were significantly different (Fdf=3=10.675, p<0.001). Bonferroni corrected 
post hoc pair wise comparison revealed a statistically significant geometrical mean difference (GMD) 
between (CGG)n and wt mice at 100 weeks (GMD=285.4, p=0.002) and between (CGG)n mice at 100 
weeks and (CGG)n mice at 25 weeks (GMD=338.4, p<0.001). No statistically significant differences 
were seen between (CGG)n and wt mice at 25 weeks (GMD=-102.1, p=0.44) or between wt mice at 25 
weeks and wt mice at 100 weeks (GMD=-49.1, p=1). Scatter plots with repeat length plotted against 
corticosterone levels for each age did not reveal statistically significant correlations (data not shown). 
Wt 112 129 174 185
- 75
CGG
- 40
Fmr1 KO
Figure 5.1 |  Fmrp levels at different CGG-repeat lengths in 100-week old whole mouse 
brain lysates. An antibody against Gapdh was used as loading control. Fmrp levels 
decrease mildly as CGG-repeat length increases. Quantification of the amount of Fmrp 
in each sample relative to wt brain revealed 100% for 112 and 129 CGG-repeats and 80% 
and 70% for 174 and 185 CGGs respectively.
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Ubiquitin-positive inclusions in HPA axis related organs
Immunohistochemistry on paraffin sections of the pituitary gland of 100-week old expanded (CGG)n 
mice showed intranuclear inclusions using an antibody directed against ubiquitin (figure 5.3). Highest 
numbers were present in the pars intermedia (table 5.1 and figure 5.3A and 5.3B), while inclusions were seen 
to a lesser extent in the pars anterior (table 5.1 and figure 5.3A). Inclusions were virtually absent in the pars 
posterior (table 5.1 and figure 5.3A). Immunolabelling for Fmrp expression in the pituitary gland correlated 
with the presence of the number of inclusions, that is, high Fmrp expression in the pars intermedia (figure 
5.3C and 5.3D) and very low expression in both pars anterior and pars posterior (figure 5.3C). 
Immunohistochemistry was also performed on pituitary gland sections of 25-week old 
(CGG)n mice. Ubiquitin-positive intranuclear inclusions could be detected, although in a much lower 
percentage of cells (table 5.1) compared to 100-week old animals. Also they were smaller and less 
consistently spherical (data not shown). Wild-type animals did not show inclusions at either age. 
Cellular localisation of glucocorticoid receptors (GRs) in pituitary glands of 100-week old mice 
was not different between (CGG)n mice and wt mice (data not shown).
Next, immunostainings for ubiquitin in sections of 100-week old adrenal glands were 
performed, which showed significant numbers of inclusions in the parenchymal cells of the medulla 
(figure 5.4A) and parenchymal cells of the zona fasciculata (figure 5.4B and 5.C) of the adrenal cortex.
Parenchymal cells of the zona reticularis and the zona glomerulosa were virtually devoid of 
inclusions. The percentage of ubiquitin-positive intranuclear inclusions in the different layers of the 
adrenal gland was substantially less compared to the percentage in the pars intermedia of the pituitary 
gland (table 5.2).
Figure 5.2  |  Mean corticosterone levels as measured in CGG and wt mice at 25 and 100 weeks of age. Error bars represent 95% confidence intervals (mean 
± 1.96 * st.dev). One-way ANOVA on logtransformed corticosterone levels revealed that the four groups, based on genotype and age, were significantly 
different (F
df=3
=10.675, p<0.001). Bonferroni corrected post hoc pair wise comparison revealed a statistically significant geometrical mean difference (GMD) 
between CGG and wt mice at 100 weeks (GMD=285.4 nmol/L, p=0.002) and between CGG mice at 100 weeks and CGG mice at 25 weeks (GMD=338.4 nmol/L, 
p<0.001). 
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Note that the intranuclear inclusions in the parenchymal cells of the zona fasciculata are more irregularly 
shaped, more elongated compared to the circular intranuclear inclusions found thus far in brain, 
pituitary gland and other layers of the adrenal gland. Also, in the zona fasciculata frequently small, round 
cytoplasmic inclusions were seen, occasionally more than one per cell (figure 5.4D). In adrenal gland of 
25-week old (CGG)n animals, few inclusions were observed (table 5.2).
Neurons and astrocytes in the human FXTAS amygdala bear intranuclear inclusions and 
showed aberrant brain activation in a functional MRI study 27. The amygdala helps control arginine 
vasopressin (AVP) and corticotrophin releasing hormone (CRH) secretion in the hypothalamus 32. 
We observed the presence of intranuclear ubiquitin-positive inclusions throughout the amygdala of 
100-week old (CGG)n mice. High percentages were seen in the posteromedial amygdalohippocampal 
nucleus (figure 5.5, 59% of neurons counted), the posteromedial cortical amygdaloid nucleus (57%) 
Pituitary gland
Pars anterior Pars intermedia Pars posterior
25
 
wk
s Wt 0 0 0
CGG 2 (1-3) 34 (25-45) 0
10
0 
wk
s Wt 0 0 0
CGG 18 (4-38) 58 (44-75) 1 (0-2)
Adrenal gland
Zona glomerulosa Zona fasciculata Medulla
25
 
wk
s Wt 0 0 0
CGG 1 (0-2) 2 (0-4) 6 (5-6)
10
0 
wk
s Wt 0 0 0
CGG 1 (0-4) 4 (1-6) 16 (9-27)
Table 5.2  |  Mean percentages (range) of adrenal cells with ubiquitin-
positive intranuclear inclusions in 25- and 100-week old wt and (CGG)n mice.
Table 5.1  |  Mean percentages (range) of pituitary cells with ubiquitin-
positive intranuclear inclusions in 25- and 100-week old wt and (CGG)n mice.
Figure 5.3  |  Immunohistochemistry with antibodies against ubiquitin and Fmrp in pituitary gland of 100-week old CGG mice. A: Many intranuclear ubiquitin-
positive inclusions (arrows) are seen in the pars intermedia, while hardly any were observed in the pars posterior. B: Ubiquitin-positive inclusions in the pars 
intermedia. C: Highest levels of Fmrp are observed in the pars intermedia. D: Fmrp expression in the pars intermedia. PA: pars anterior, PI: pars intermedia, PP: 
pars posterior. See page 163 onwards for colour version of this figure. 
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and the anterior amygdaloid area (58%). Other regions of the amygdala only showed inclusions in up 
to 5% of neurons. In (CGG)n mice of 25 weeks of age, intranuclear inclusions were counted in on average 
6% of neurons in the three regions specified for old mice.
Transcript levels in the pituitary gland 
Fmr1 transcript levels were found to be 3.4-fold higher (SD=0.6) in pituitary glands of (CGG)n mice, as 
compared with wt mice, at 72 weeks of age.
Several feedback mechanisms exist for the HPA axis to prevent lasting high levels of 
corticosteroids. We analysed effects of corticosterone binding to its receptor, the GR, namely transcription 
levels of the glucocorticoid, Crh and vasopressin receptors and of the ACTH precursor molecule Pomc. 
Quantitative PCR revealed no statistically significant difference for any of the receptors tested, neither 
for Pomc, in (CGG)n mouse pituitary gland when compared with wt pituitary gland (data not shown). 
Discussion  |  5.4
Recently, observations have accumulated that PM carriers, both with and without FXTAS are more often 
affected by psychiatric problems than controls 17-20. Although a link between the presence of inclusions 
in the hippocampus and the frequent occurrence of anxiety and depression in patients with FXTAS has 
been suggested 17, little is known about the origin of the psychopathology.
Figure 5.4  |  Immunohistochemistry with an antibody against ubiquitin show ubiquitin-positive inclusions in adrenal gland of 100-week old CGG mice. A: 
Ubiquitin-positive intranuclear inclusions (arrows) in chromaffin cells of the adrenal gland. B+C: Elongated, irregularly shaped ubiquitin-positive intranuclear 
inclusions in the zona fasciculata of the adrenal gland. D: Cytoplasmic inclusions (arrow heads) in the zona fasciculata of the adrenal gland. See page 163 
onwards for colour version of this figure. 
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In the (CGG)n mouse model, which shows genetic, 
biochemical, behavioural and neuropathological 
parallels to the human situation in FXTAS, we investigated 
whether altered HPA axis regulation could play a role in 
the development of these symptoms. The presence of 
ubiquitin-positive intranuclear inclusions in the pituitary 
and adrenal glands and the elevated corticosterone levels 
in 100-week old (CGG)n mice point towards disturbed HPA 
axis physiology. At 25 weeks of age (CGG)n mice did have 
ubiquitin-positive inclusions in pituitary gland, although 
these were smaller in size and number, and less spherical 
than in the 100-week old animals. In 25-week old (CGG)
n mice also inclusions in the amygdala were observed. 
Interestingly, no inclusions have been observed in other 
brain regions at this age, including amygdala 29. It seems 
that inclusions start to develop around this time point, 
with the pituitary gland and amygdala being the first 
sites of inclusion development followed by other regions 
in the brain at 40-50 weeks of age 29. At 25 weeks of age 
corticosterone levels are not yet elevated in (CGG)n mice. 
Fmr1 mRNA levels are elevated at all ages 30, including in pituitary gland. If inclusions in the amygdala 
play a role in the dysregulation of the HPA axis, then apparently a threshold exists for the amount of 
inclusions that can cause an effect. Intranuclear inclusions in the pituitary gland could impair cellular 
function, although they may be just a marker for the degree of protein dysregulation that is occurring 
in the cell. 
The presence of inclusions in the pars intermedia is puzzling since this area contains one major 
endocrine cell type in mammals, the melanotrophs. These cells process the precursor molecule POMC 
and release b-endorphin and α-melanocyte stimulating hormone. This POMC processing is different 
from that in the pars anterior, where predominantly ACTH and b-endorphin are released. Also, in adult 
humans the pars intermedia has undergone involution 38. Negative feedback of corticosteroids occurs via 
GRs in the hypothalamic paraventricular nucleus and the pituitary gland. Rapid feedback effects of 
glucocorticoids prepare an organism for a stressful situation 32,35. Slower gene transcription-mediated 
systems come into action when corticosteroids bind to the cytoplasmic GR, present as a complex with 
other proteins among which hsp90 and hsp70. Ligand-binding disassembles the complex, upon which 
the GR can translocate to the nucleus. There it binds to negative glucocorticoid responsive elements, 
downregulating factors involved in corticosteroid synthesis 39-41. Hence GR function would be worth 
investigating. However, since mice were mildly stressed before sacrifice, likely causing GR translocation, 
no localisation differences were observed. 
We did not detect differences in pituitary gland receptor mRNA levels, involved in HPA axis 
negative feedback. The hypothalamus secretes AVP and CRH under the control of the hippocampus and 
Figure 5.5 | Ubiquitin-positive intranuclear inclusions in the 
amygdala of a 100-week old CGG mouse. A en B show the 
posteromedial amygdalohippocampal nucleus, where B is a 
higher magnification of what is seen in A. See page 163 onwards 
for colour version of this figure. 
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the amygdala 32. CRH provides the predominant stimulus to the anterior pituitary gland to synthesise 
and secrete ACTH, whereas AVP strengthens the effect of CRH to secrete ACTH. Changes in hormone and 
receptor levels of the HPA axis are very specifically dependent on the type and duration of stressors 42. 
GR is known to repress its own synthesis in a hormone-dependent manner 40. Negative feedback at the 
level of the pituitary gland to block synthesis and secretion of ACTH by the corticotroph cells occurs 
by directly inhibiting synthesis of Pomc mRNA 35. No such effect was found in pituitary glands of (CGG)n 
mice in this study. Not finding any transcriptional differences between (CGG)n and wt mice could be 
because mice were sacrificed before a change at the transcription level could have taken place, or the 
stressor could have been too mild.
In the adrenal gland, we found ubiquitin-positive inclusions not only in the chromaffin cells of 
the medulla, which are the main source of catecholamines, but also in the zona glomerulosa and zona fasciculata 
of the adrenal cortex. The zona glomerulosa is the site where mineralocorticoids are produced, while the 
zona fasciculata produces glucocorticoids 43. It is as yet unclear how inclusions might affect the functioning 
of the adrenal gland. It is striking that the inclusions seen in the zona fasciculata were differently shaped 
from those seen thus far in brain, pituitary gland and the other cell layers of the adrenal gland. This 
might indicate that inclusions in the zona fasciculate develop in a different way and from different 
components compared to the ones studied previously. 
A review summarising observations in a large group of patients with the premutation reported 
anxiety and depression in over 30% of patients with FXTAS and anxiety in almost 40% and depression in 
9% of non-FXTAS PM carriers 19. The authors suggested a relationship with the inclusions present in the 
hippocampus, which is the area with the highest inclusion density in the human FXTAS brain 17. Another 
study described more psychopathology, including phobic anxiety and obsessive-compulsive symptoms 
in patients with FXTAS compared to published norms 19. Interestingly, PM carriers without signs of 
FXTAS also showed more obsessive-compulsive symptoms. Moreover, there was a stronger correlation 
between psychopathology and FMR1 mRNA levels in PM carriers who had not developed FXTAS, than 
in patients with FXTAS. It is not yet understood whether psychological symptoms are associated with 
the PM from a developmental perspective or whether they reflect prodromal symptoms of later onset 
FXTAS 19. Although patients with FXTAS show higher scores of psychopathology on a neuropsychiatric 
inventory than controls 18, anxiety has also been observed in young PM carriers, who were free of FXTAS 
symptoms. Anxiety along with shyness and social deficits are common among young boys with the 
premutation compared to brothers who do not have the premutation 44. This suggests that there is 
a developmental effect of the premutation that can lead to this type of psychopathology. As FXTAS 
develops these symptoms can be aggravated by the neuropsychological deficits that set in 18. Another 
report described that seven out of fifteen male patients with FXTAS suffered from mood and/or anxiety 
disorders, and twelve out of fifteen were found to have neuropsychological problems 20. Increased 
irritability, agitation/aggression and anxiety might suggest further HPA axis dysregulation.
Naturally, it will be of interest to measure cortisol levels in PM carriers with and without FXTAS. 
In humans, it is as yet unknown whether only symptomatic PM carriers develop inclusions or whether 
the PM itself leads to inclusion formation with another factor in turn causing clinical manifestations. 
All mice carrying the PM develop inclusions, so the mouse model cannot be used to show whether 
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individuals without inclusions will suffer from a similarly altered HPA axis regulation and associated 
psychopathology. 
Given the broad range of cognitive and emotional disturbances seen in PM carriers or patients 
with FXTAS, it cannot be excluded that altered HPA physiology is secondary to impaired coping strategies 
in stressful situations. For example, the amygdala was suggested to be a potential site of dysfunction 
underlying social deficits, when PM carriers showed diminished brain activation in the amygdala and 
other brain areas that mediate social cognition while viewing fearful faces in a functional MRI study. In 
the same study, sympathetic activation as measured by skin conductance upon a mild social stressor, 
was also lower in PM carriers than in controls. Sympathetic outflow is normally conducted by the 
amygdala 27. Interestingly, intranuclear inclusions are also present in neurons and astrocytes in the 
amygdala in humans 21. Dysfunction of the amygdala through elevated FMR1 mRNA levels and inclusion 
formation might play a role in the aetiology of psychological symptoms involving emotion and social 
cognition as well. The presence of inclusions had not been investigated in our previous studies, but 
now we demonstrate significant numbers of intranuclear neuronal inclusions in amygdala of (CGG)n 
mice of 100 weeks of age (figure 5.5). It is unclear why amygdala response is reduced in humans while 
corticosterone levels are elevated in (CGG)n mice. For human brain, it is as yet unknown when inclusions 
first develop, since no post mortem material has been available of relatively young patients. It should 
be noted that the mean age of subjects tested in the study by Hessl and co-workers 27 was lower (~43 
years) than the age at which inclusions have been seen thus far 45. Around 40 years of age in a human life 
might be comparable to about 25 weeks of age in mice, thus it could be that reduced limbic response 
and elevation of corticosteroid levels are different stages of the same syndrome. 
Fragile X individuals 46,47, as well as Fmr1 KO mice 48, have also been shown to have an 
exaggerated stress response. Children with the fragile X full mutation have elevated cortisol levels which 
are associated with severity of behavioural problems 46,47. Both fragile X patients and Fmr1 KO mice have 
a delayed return to baseline glucocorticoid levels, which was explained by the normal binding of GR 
mRNA to FMRP 49. Fragile X individuals and Fmr1 KO mice do not express FMRP, thus in the absence of 
FMRP inappropriate transport or translation of GR could lead to altered HPA responsiveness 48. Mice 
with (CGG)n shorter than 170 trinucleotides have close to normal Fmrp levels (figure 5.1). In our study, 
corticosterone levels did not correlate with repeat length in the range tested (100-170 CGGs). Also, the 
25-week old mice tested had higher (CGG)n lengths (170-200 CGGs) and lower Fmrp levels, but they did 
not have elevated corticosterone levels, indicating that lower Fmrp levels did not lead to inappropriate 
GR expression. Thus elevated stress responses develop differently in fragile X individuals and Fmr1 KO 
mice as compared to (CGG)n mice. Although representing different molecular genetic mechanisms, 
these prior studies document the impact of FMR1 gene mutation on the HPA axis. It should be noted 
that the decreased levels of Fmrp in animals with >170 CGGs do not represent a uniform decrease in 
cellular Fmrp throughout the brain. We have previously shown that some brain areas had very low Fmrp 
expression, while in other areas Fmrp levels were closer to normal 30.
Since we measured corticosterone levels only at one time point after a mild stressor, we cannot 
draw conclusions on the course of the corticosterone response over time. It is not yet known whether 
corticosterone levels in (CGG)n mice return to baseline levels in a normal or delayed fashion, or whether 
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peak stress levels are higher than in controls. Our future study will therefore focus on investigating 
corticosterone levels at different time points after a mild stressor.
It is intriguing that in different organs in the HPA axis ubiquitin-positive inclusions are 
observed, despite their different cell types. Within these organs, specific cells appear to be particularly 
prone to inclusion formation, for instance the chromaffin cells in the adrenal medulla. This, however, 
gives no clue as to why corticosterone levels are elevated in (CGG)n mice. The observation that there are 
much fewer and smaller intranuclear inclusions at 25 weeks than at 100 weeks of age and no difference 
in corticosterone levels at 25 weeks suggests that inclusions have a role in the origin of elevated 
corticosterone levels. Dysregulation of the HPA axis might arise at any of the organs involved. Although 
based on our current observations we cannot unravel the mechanism underlying the aberrant HPA 
axis physiology and its relation to the inclusions observed in (CGG)n mice, we do believe that this is 
an important observation in view of the emerging evidence of psychiatric symptoms in PM carriers. A 
combination of clinical and animal research is likely to lead to answering questions on the origin of the 
psychopathology observed in PM carriers, which may ultimately lead to novel therapeutic strategies. 
A first step into this direction is to determine basal salivary cortisol and cortisol stress response in PM 
carriers with and without FXTAS. 
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Abstract  | 
The 5’UTR of the FMR1 gene contains approximately 30 CGG-repeats ((CGG)n) in the normal population, 
with a range of 5-55. This trinucleotide repeat is polymorphic and unstable upon transmission to 
the next generation. When repeat length exceeds 200 (full mutation), the FMR1 gene generally 
undergoes methylation-mediated transcriptional silencing. The subsequent absence of the gene 
product FMRP results in mental retardation seen in fragile X patients. A repeat length of between 55 
and 200 trinucleotides has been termed the premutation (PM). In particularly male elderly carriers of 
the PM are at risk of developing a progressive neurodegenerative disorder, called fragile X-associated 
tremor/ataxia syndrome (FXTAS). All PM carriers have elevated FMR1 mRNA levels, in spite of slightly 
decreased FMRP levels. The presence of intranuclear ubiquitin-positive inclusions in many brain regions 
is a neuropathological hallmark of FXTAS. Efforts have been made to correlate clinical outcomes with 
molecular measures, although this has mostly been limited to (CGG)n length. However, such studies 
in humans are difficult due to the limited availability of tissue. Therefore, we have used the expanded 
(CGG)n knock-in mouse model of FXTAS to examine the relationship between the molecular and 
neuropathological parameters in brain, the central organ involved in the pathogenesis of FXTAS. 
In the present study Fmr1 mRNA and Fmrp levels and the presence of intranuclear inclusions, the 
neuropathological hallmark of FXTAS, are described for different repeat lengths. In addition, our results 
suggest that in aged KI mice the presence of intranuclear inclusions may not depend on elevated 
Fmr1 transcript levels.
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Introduction  |  6.1
The CGG-repeat ((CGG)n) in the 5’UTR of the Fragile X mental retardation 1 (FMR1) gene  is polymorphic. 
Normal individuals have alleles that are within the range of 5 to 44 CGGs 1. Repeat lengths between 
45 to 54 are considered intermediate alleles, which can show minor instability when transmitted to 
the next generation 2,3. Over 200 CGGs has been named the full mutation (FM), since this usually leads 
to CpG methylation of the FMR1 promoter and the (CGG)n, which results in transcriptional silencing 
of the gene 4-6. The consequent absence of the gene product FMRP is the cause of mental retardation 
in fragile X patients 7,8. Unmethylated expansions of 55 to 200 CGGs are considered premutation (PM) 
alleles. Initially, it was thought that the only risk associated with the PM was expansion to an FM when 
a mother transmits the allele to her child. However, it was later recognised that carriers of the PM are 
at risk of developing a progressive neurodegenerative disorder called fragile X-associated tremor/
ataxia syndrome (FXTAS) 9-11. About 30% of male PM carriers over 50 years of age will develop FXTAS, 
although penetrance increases with age 12. Few cases of female PM carriers presenting with FXTAS have 
been described 13,14. Females are less severely affected, which can be explained by the presence of a 
second, normal allele. The process of X-inactivation determines how many PM alleles are on the active X 
chromosome, thereby influencing the clinical outcome 13,15. About 20% of female carriers are at further 
risk of developing premature ovarian failure 16,17.
In FXTAS, patients usually present with progressive intention tremor and/or ataxia. As the 
disease progresses, symptoms worsen and a wider range of clinical involvement develops, including 
cognitive decline with impaired memory and executive function, autonomous dysfunction and 
peripheral neuropathy 11,18. 
PM carriers have elevated FMR1 mRNA levels in spite of normal or slightly reduced FMRP levels. 
The increase of FMR1 mRNA levels seems to be correlated to the length of the (CGG)n 
19-21. Expanded 
(CGG)n tracts negatively influence translation of the FMR1 mRNA, such that FMRP gradually decreases 
with increasing repeat length, despite increased levels of FMR1 mRNA 19,20,22. 
Since FXTAS is restricted to the PM range, as no aged FM carriers have been observed with 
signs of FXTAS, FMRP deficiency is unlikely the cause of the disease. This combined with the fact that 
FMR1 mRNA levels are increased in PM carriers, led to the proposal that an RNA toxic gain-of-function 
mechanism underlies the symptoms seen in FXTAS patients 10,23. In analogy to the well-described 
pathogenic RNA gain-of-function model for myotonic dystrophy (DM) (reviewed in 24), this hypothesis 
predicts that certain proteins are sequestered to the expanded (CGG)n-containing RNA, away from their 
normal function. Loss of the normal function of these (CGG)n-binding proteins (BPs) could then lead to 
cellular toxicity or ultimately cell death 10,23.
Neurohistological studies on post mortem brains of PM carriers with FXTAS have revealed the 
presence of ubiquitin-positive intranuclear inclusions in neuronal and astrocytic cell types throughout 
the brain. Furthermore, Purkinje cell dropout and Bergmann gliosis were observed. Purkinje cells did 
not show intranuclear inclusions 25. FMR1 mRNA has also been detected in the intranuclear inclusions, 
further strengthening its involvement in the pathogenesis of FXTAS 26. 
A mouse model originally developed in our group 27 to study instability of the FMR1 
(CGG)n is also an adequate model for FXTAS 
28-30. In this animal model, the endogenous mouse (CGG)8 was 
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exchanged with a human (CGG)98, which is in the PM range in humans. These expanded (CGG)n ‘knock-
in’ ((CGG)n) mice show moderate repeat instability upon both maternal and paternal transmission 
27,28. 
Neurohistological studies performed on (CGG)n mouse brains revealed ubiquitin-positive intranuclear 
inclusions in neurons. Number and size of inclusions increase with time, paralleling the progressive 
nature of the disease in human patients. Furthermore, the presence of inclusions in distinct brain 
regions and organs associated with the hypothalamo-pituitary-adrenal axis in (CGG)n mice can be 
linked to clinical features of FXTAS patients 29,30. The mouse model also mimics human FXTAS in that 
Fmr1 transcript levels are elevated 28,30. 
Efforts have been made to correlate clinical outcomes to molecular measures, although this 
has mostly been limited to (CGG)n length 
31-33. Human studies using brain tissue are limited due to the 
availability of material. Therefore, this study is designed to use (CGG)n mice to establish the relationship 
between the molecular and neuropathological parameters in brain, the central organ involved in the 
pathogenesis of FXTAS. In the present study Fmr1 mRNA and Fmrp levels and the presence of intranuclear 
inclusions, the neuropathological hallmark of FXTAS, are described for different repeat length categories. 
Our results in aged (CGG)n mice suggest that the sole presence of expanded (CGG)n Fmr1 mRNA rather 
than elevation of Fmr1 transcript levels is important for the neuropathology in FXTAS.
Methods and Materials  |  6.2
Mice
The expanded (CGG)n mice used in this study have been described before 
27-30. Although this mouse model was 
created by exchanging the murine endogenous (CGG)8 with a human (CGG)98 
27, we now also report data on mice 
carrying (CGG)70. These alleles arose in our colony through a contraction of the longer (CGG)n. Both the expanded 
(CGG)n knock-in (CGG)n mice and the wild type (wt) mice with an endogenous (CGG)8 were housed under standard 
conditions. All experiments were carried out with permission of the local ethics committee. (CGG)n lengths were 
determined for the whole colony, but only male mice were used for experiments. All mice had a mixed C57/BL6 
and FVB/n genetic background. All mice used in this study were between 55 and 58 weeks old, unless specified 
otherwise.  
Genotyping of the mice
DNA was extracted from mouse tail snips as previously described 28. Determination of the (CGG)n length was 
performed by means of PCR using the Expand High Fidelity Plus PCR System (Roche Diagnostics), with forward 
primer 5’-CGGAGGCGCCGCTGCCAGG-3’ and reverse primer 5’-TGCGGGCGCTCGAGGCCCAG-3. PCR products 
were visualised on a 6% polyacrylamide gel. As these primers are specific to the knock-in allele, a separate PCR 
is performed for the wt allele. The wt allele was detected using TaKaRa LA Taq polymerase (using GC buffer II), 
according to manufacturer’s instructions (Takara Bio Inc), with 5’-GCTCAGCTCCGTTTCGGTTTCACTTCCGGT-3’ as 
forward primer and 5’-AGCCCCGCACTTCCACCACCAGCTCCTCCA-3’ as reverse primer (detailed description in 28). 
Based on their repeat length, mice were grouped into one of 5 repeat length categories, namely wt, 70CGG, 100-
150CGG, 151-200CGG and >200CGG.
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Immunohistochemistry
Half (sagittal) brains were fixed overnight in 3% paraformaldehyde. Tissues were embedded in paraffin according to 
standard protocols. Sections (7 μM) were deparaffinised followed by antigen retrieval using microwave treatment in 
0.01 M sodium citrate solution. Endogenous peroxidase activity blocking and immunoincubation were performed 
as described before 34, using a polyclonal rabbit antibody against ubiquitin (Dako, ZO458) or a monoclonal 2F5-1 
antibody specific for Fmrp 35. Ubiquitin-positive intranuclear inclusion counts in colliculus inferior and dentate gyrus 
were quantified by counting the number of inclusion-bearing cells in a field of ~200 (colliculus inferior) or ~400 
(dentate gyrus) neurons. At least four such fields were counted for each field of interest. Average inclusion counts 
and standard deviations were calculated for mice in each of the 5 repeat length categories.
Preparation of protein, RNA and DNA extracts
Half brains (sagittal) were homogenised in 500 µl HEPES-buffer (10 mM HEPES, 300 mM KCl, 3 mM MgCl2, 100 µM 
CaCl2, 0.45% Triton X-100 and 0.05% Tween-20, pH 7.6), with Complete protease inhibitor cocktail (Roche Diagnostics), 
3 mM DTT (Invitrogen) and 20U RNAsin (Promega). After incubating the homogenates on ice for 30 minutes, 100 µl 
was taken for RNA isolation, using 1 ml of RNAbee (Tel-Test). 200 µl chloroform was then added and the mixture 
was centrifuged for 15 minutes at 13000 rpm at 4°C for phase separation. One volume of isopropanol was added 
to the aqueous phase to precipitate the RNA. The pellet was washed with 80% ethanol and dissolved in DEPC-
treated MilliQ-H2O. RNA concentration and purity was determined using a NanoDrop ND-1000 Spectrophotometer 
(NanoDrop Technologies). 
The remainder of the brain homogenates was centrifuged for 15 minutes at 13000 rpm at 4°C. Protein 
concentration of the supernatant was determined before use in SDS-PAGE. The pellet was used for DNA extraction, 
following the same protocol as described for the mouse tail snips. 
Quantitative RT-PCR
Reverse transcriptase was performed on 1 μg RNA using iScript cDNA Synthesis Kit (BioRad) according to manufacturer’s 
instructions. Q-PCR was performed on 0.1 μl of RT product. Primers used for Q-PCR were as follows: Fmr1 transition 
exon 16/17 (5’-CCGAACAGATAATCGTCCACG-3’ as forward primer and 5’-ACGCTGTCTGGCTTTTCCTTC-3’ as reverse), 
Fmr1 transition exon 7/8 (forward: 5’- TCTGCGCACCAAGTTGTCTC -3’, reverse: 5’-CAGAGAAGGCACCAACTGCC-3’), 
Gapdh (internal reference) (forward: 5’-AAATCTTGAGGCAAGCTGCC-3’, reverse: 5’-GGATAGGGCCTCTCTTGCTCA-3’). 
Efficiencies of the different primer sets were checked and found to be comparable. Ct values for Gapdh mRNA were 
subtracted from the Ct value of Fmr1 mRNA for each sample, which gives the ΔCt. Average ΔCt of wt mice was then 
subtracted from ΔCt of CGG mice, which is designated as the ΔΔCt. The value 2-ΔΔCt then gives the fold change. 
Average Fmr1 mRNA levels for each of the repeat length categories were calculated. Differences between the repeat 
length categories were investigated with one-way ANOVA with fold change Fmr1 mRNA as dependent variable and 
repeat length category as the grouping factor. Dunnett’s post hoc test was performed to compare all expanded 
repeat categories against the wt animals and to test for significantly elevated Fmr1 mRNA levels. 
In addition, the existence of a correlation between (CGG)n length and Fmr1 mRNA levels was investigated 
by calculation of the Spearman’s rho, both for all repeat lengths taken together, and for each repeat category 
separately. 
Western blotting
We loaded 150 μg of protein onto an 8% SDS-PAGE gel, which was then electroblotted onto a nitrocellulose 
membrane. The membrane was incubated overnight at 4°C with the monoclonal 2F5-1 antibody specific for 
Fmrp 35 and a monoclonal antibody against Gapdh (Chemicon), which served as a loading control. The next day the 
membrane was incubated with a goat-anti-mouse secondary antibody with 800 nm conjugate. After washing, the 
blot was scanned using the Odyssey™ Infrared Imager. Quantification of integrated intensities of the fluorescent 
signals was performed using the Odyssey™ 2.1 software. All three Fmrp isoforms were included in the calculations. 
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The relative Fmrp levels in the (CGG)n animals were calculated using the average of the Fmrp levels measured in wt 
animals as a reference. One-way ANOVA was performed with relative Fmrp levels as the dependent variable and 
repeat length category as the grouping factor. Dunnett’s post hoc test was performed to compare all expanded 
repeat categories against the wt animals and to test for significantly decreased Fmrp levels. 
Spearman’s rho was calculated to reveal the existence of a correlation between (CGG)n length and 
Fmrp levels. 
Methylation status
Shortly after birth, tail DNA was checked for the presence of methylated CpGs in the Fmr1 promoter region. 
We subjected 1 µg of DNA to bisulphite conversion, using the Qiagen Epitect kit, according to manufacturer’s 
instructions. 1.5 µl of converted DNA was then used for two PCR reactions, where one reaction detects methylated 
alleles and the other PCR detects unmethylated alleles. For the methylated allele, we used the forward primer 
5’- GTTTAAATAGGTTTTACGTTAGTGTC-3’, and the reverse primer 5’-CGTCCGTTTACTTCACTACCCG-3’, followed 
by a semi-nested PCR on 3 µl of PCR product using forward primer 5’- GAAGAGGTTTTTAGTTTTCGCGGC-3’ and 
reverse primer 5’-CTCAAACGCGACCCCTCACCG-3’. The unmethylated primer was amplified with forward primer 5’- 
GTTTAAATAGGTTTTATGTTAGTGTT-3’ and reverse primer 5’-CATCCATTTACTTCACTACCCA-3’, followed by a semi-
nested PCR on 3 µl of PCR product using forward primer 5’-GAAGAGGTTTTTAGTTTTTGTGGT-3’ and reverse primer 
5’-CTCAAACACAACCCCTCACCA-3’. The PCR mixtures contained 10x PCR buffer, W-1, 4% DMSO, 0.5 µM of both the 
forward and reverse primer, 1 unit Taq Polymerase (all Invitrogen) and 2 mM MgCl2 for the methylated allele and 1.5 
mM MgCl2 for the unmethylated allele. The PCR program was as follows: 5 minutes denaturation at 95°C, 35 cycles of 
10 seconds at 93°C, 20 seconds annealing at 55°C and 30 seconds at 72°C, followed by a final elongation step of 10 
minutes at 72°C. PCR products were visualised on a 2% agarose gel. The same methylation analysis was performed 
on DNA isolated from brain.
Results  |  6.3
A threshold for (CGG)n length exist for inclusion formation
When some mice in our colony showed a contraction to about (CGG)70, we examined how this shorter 
repeat length affected inclusion formation. Immunohistochemistry for ubiquitin in 72-week old animals 
with (CGG)70 and (CGG)~100 shows that inclusions were present neither in the colliculus inferior (figure 
6.1), nor in other brain areas (data not shown) of (CGG)70 animals. In contrast, the colliculus inferior of 
animals with (CGG)~100 showed many inclusions (figure 6.1 and figure 6.3).  Thus, a threshold (CGG)n 
length exists for the development of inclusions. Fmrp levels were comparable between (CGG)70 and wt 
animals (figure 6.1 and figure 6.5).
Elevated Fmr1 mRNA levels are only seen in lower range PM alleles
With the availability of a range of repeat lengths we extended our findings about the Fmr1 mRNA levels 
to a broader range of repeat lengths using more mice 28,30. Figure 6.2 shows average fold changes of 
Fmr1 mRNA from brain in the different repeat categories with error bars indicating standard deviations. 
In these experiments, 13 Wt, 4 (CGG)70, 15 (CGG)100-150, 8 (CGG)151-200 and 14 (CGG)>200 animals were 
124 CHAPTER 6 
used. One-way ANOVA revealed a statistically significant overall difference between the categories 
(F=6.47, df=4, p<0.001). To determine which individual categories differed, Dunnett’s post hoc test 
was performed. This revealed that only animals with 100-150 CGGs differ significantly from wt animals 
(fold change mean difference= 1.60, SE=0.36, p<0.001, statistical parameters of other categories not 
shown).
No statistically significant correlation was found between (CGG)n length and Fmr1 mRNA 
levels when all categories were taken together (Spearman’s rho=0.22, p=0.11), neither when repeat 
categories were analysed separately (data not shown).No statistically significant correlation was found 
between (CGG)n length and Fmr1 mRNA levels when all categories were taken together (Spearman’s 
rho=0.22, p=0.11), neither when repeat categories were analysed separately (data not shown).
Figure 6.1 | No ubiquitin-positive inclusions are seen in the 
colliculus inferior of 72-week old mice with (CGG)70 (A), while 
mice with (CGG)106 do show ubiquitin-positive inclusions (B) brown, 
round intranuclear staining). Immunohistochemistry for Fmrp in 
cortex of (CGG)70 (C) and wt (D) animals gives a similar staining 
pattern. See page 163 onwards for colour version of this figure. 
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Figure 6.2 | Average fold change of Fmr1 mRNA 
levels in the different (CGG)n length categories. Only 
(CGG)100-150 animals had statistically significantly elevated 
levels (mean difference=1.60, SE=0.36, p<0.001), as 
compared with wt. 
Not all (CGG)n animals have inclusions in the dentate gyrus
In our previous studies in which we looked for the presence of inclusions in our expanded (CGG)n animals, 
we did not see inclusions in the dentate gyrus at 55 and 72 weeks of age (106 CGGs) 30. When examining 
mice with a wider range of (CGG)n lengths, we now see that some mice have many inclusions, while 
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others do not have inclusions in this brain region (figure 6.3). The presence or absence of inclusions 
does not appear to be dependent on (CGG)n length (data not shown), indicating that the dentate gyrus 
may be less consistent in forming inclusions than other brain regions such as the colliculus inferior.
A threshold for (CGG)n length exists above which few inclusions are present
FXTAS is proposed to be the result of an RNA gain-of-function mechanism 10, and inclusions are 
associated with the development of the disease 25. Therefore, we were curious to see the proportion of 
inclusion-bearing cells in our mice, which do ((CGG)100-150) or do not ((CGG)>150) have significantly elevated 
Fmr1 mRNA levels.  Percentages of neurons with inclusions in the colliculus inferior and the dentate 
gyrus are shown in figure 6.3 (7 (CGG)100-150, 4 (CGG)151-200 and 6 (CGG)>200 animals were used). Mice with 
repeat lengths exceeding 200 CGGs showed very little inclusion formation (figure 6.3 and 6.4). One-
way ANOVA revealed a statistically significant difference between the three inclusion-bearing repeat 
length categories in both the colliculus inferior (F=8.16, df=2, p<0.01) and the dentate gyrus (F=6.13, 
df=2, p=0.02). Bonferroni-corrected post hoc pair-wise comparisons revealed that inclusion counts 
did not differ statistically significantly 
between (CGG)100-150 and (CGG)151-200 in the 
colliculus inferior (mean difference=0.10, 
SE=0.15, p=1) and the dentate gyrus 
(mean difference=0.08, SE=0.12, 
p=0.12). However, inclusion formation 
in the (CGG)>200 mice differed statistically 
significantly from (CGG)100-150 in the 
colliculus inferior (mean difference=-0.42, 
SE=0.11, p<0.01) and the dentate gyrus 
(mean difference=-0.30, SE=0.09, p=0.02), 
but not from (CGG)151-200 (colliculus inferior: 
mean difference=-0.33, SE=0.15, p=0.15, 
dentate gyrus: mean difference=-0.22, 
SE=0.12, p=0.31). Not surprisingly, 
Spearman’s rho revealed a statistically 
significant correlation for (CGG)n repeat 
length and the proportion of inclusion-
bearing neurons in the colliculus inferior 
(rho=-0.90, p<0.001) and the dentate gyrus 
(rho=-0.78, p=0.001).
p<0.001) and8, p=0.001). 
Although percentages vary in different regions, an abundance of inclusions is seen in (CGG)n mice with 
100 to 200 CGGs repeats in most brain regions. The observation that only few inclusions can be seen 
in the brain areas described here (colliculus inferior and the dentate gyrus) in mice with >200 CGGs is 
representative for all other brain areas examined (data not shown). 
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Figure 6.3 | A: Average percentages of inclusion-bearing cells in the colliculus 
inferior and dentate gyrus in the different (CGG)n length categories. Error bars show 
standard deviations. B: Dentate gyrus of an animal with (CGG)106 that does not show 
intranuclear inclusions, while a mouse with (CGG)130 (C) does. See page 163 onwards 
for colour version of this figure.
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Fmrp levels are reduced in the upper PM range 
Measurement of Fmrp levels by SDS-PAGE followed by Western blotting revealed decreased Fmrp levels 
in expanded (CGG)n mice. A total of 3 Wt, 1 (CGG) 70, 10 (CGG)100-150, 5 (CGG)151-200 and 9 (CGG)>200 animals 
were used for these studies. Since only 1 brain of an animal with (CGG)70 was available for protein 
measurement, this sample was not included in the statistical analyses. One-way ANOVA revealed that 
there was a statistically significant difference between (CGG)n categories (F=7.02, df=3, p<0.01). A 
Dunnett’s post hoc test was performed to compare Fmrp levels between mice in each repeat category 
with wt animals. Animals with (CGG)100-150 did not show significantly altered Fmrp levels compared to 
wt mice (%Frmp mean difference= -0.19, SE=0.11, p=0.11). Mice with expanded alleles of (CGG)151-200 
(%Frmp mean difference= -0.40, SE=0.13, p<0.01) or (CGG)>200 (%Frmp mean difference= -0.44, SE=0.12, 
p<0.01) did have statistically significantly lower Fmrp levels than wt mice.
A significant correlation between CGG repeat length and Fmrp level was also found (Spearman’s rho= 
-0.58, p<0.01). 
As shown before 28 and confirmed by immunohistochemistry in the present study (data not 
shown) this decrease in Fmrp is not found in all cells of the brain. For example, while most brain areas 
showed greatly reduced levels, levels of Fmrp in other regions such as the hippocampal CA2 and CA3 
region were relatively unchanged from wt. 
Correlations of other parameters
All data (without indication of the variability of the data) are summarised in figure 6.6. Spearman’s 
two-tailed bivariate correlations between all possible combinations of Fmr1 mRNA, Fmrp and inclusion 
counts in both regions quantified (i.e., colliculus inferior and dentate gyrus) only revealed a statistically 
Figure 6.4 | Ubiquitin-positive inclusions are present in colliculus inferior (A-C) and dentate gyrus (D-F) of mice with (CGG)130 and (CGG)180, but not 
in mice with (CGG)>200. See page 163 onwards for colour version of this figure. 
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significant correlation coefficient (rho=0.61, p=0.03) for the relation between Fmrp levels and the 
proportion of inclusion-bearing cells in the colliculus inferior (other correlation analyses not shown).
 No methylation is seen in the Fmr1 promoter region 
No methylation was detected in any of the DNA samples isolated from tail DNA shortly after birth 
(data not shown). Nor was methylation seen in DNA isolated from brain at the time of sacrifice at 
approximataely 55-58 weeks of age (data not shown). 
Figure 6.5 | Fmrp levels in mouse brain of the different (CGG)n length categories. A shows an example of a Western Blot, visualised with the 2F5 
antibody against Fmrp, Gapdh was used as a loading control. Approximate (CGG)n lengths are indicated. B shows average Fmrp levels relative to the average wt 
level. Error bars represent standard deviations. Note that (CGG)70 has no error bar, as this bar represents one sample. Animals with (CGG)>150 have statistically 
significantly lowered Fmrp levels. See text for details on statistical analyses. See page 163 onwards for colour version of this figure.
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Repeat length analysis in DNA extracted from total brain lysate only showed a single PCR product. Thus, 
no heterogeneity for repeat length was apparent in the brains of (CGG) n mice, although we cannot 
exclude the possibility that with more sensitive methods of visualisation some heterogeneity might 
be detectable. In addition, comparison with repeat length in tail DNA obtained at 10 days postnatal 
Figure 6.6  |  Summary of the molecular correlates. Fold change Fmr1 mRNA (left y-axis), % Fmrp and % of inclusion-bearing neurons in colliculus 
inferior and dentate gyrus  (right y-axis) are given. Please refer to the individual graphs for an indication of the variability of the observed data. See page 163 
onwards for colour version of this figure. 
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revealed very minor repeat length differences (data not shown). Thus, we did not find evidence that 
somatic instability occurs over the course of life in our mouse model.
Discussion  |  6.4
This study was designed to establish the relationships between molecular and neuropathological 
parameters in an expanded (CGG)n knock-in mouse model. The results show a high percentage of 
neurons with intranuclear inclusions in mice with 100 to 200 CGGs, while mice with greater than 200 
CGGs show few such inclusions.  In addition, only mice with (CGG)100-150 have significantly elevated Fmr1 
mRNA levels, and Fmrp levels are significantly reduced when (CGG)n length exceeds 150. Our studies 
furthermore indicate that a lower (CGG)n length threshold exists, below which no inclusions are formed, 
as well as a higher threshold, above which few inclusions are seen. 
It is striking that mice with 151-200 CGGs have many inclusions, in spite of relatively normal 
Fmr1 mRNA levels. This might imply that it is the presence of mutant (CGG)n RNA that determines the 
occurrence of cellular toxicity (i.e., inclusions), rather than the precise level of (CGG)n mRNA. Since there 
is slightly more Fmrp expressed in mice with 151-200 CGGs as compared with >200 CGGs, it could also 
be that a minimal amount of Fmrp is necessary for inclusion formation, which is still present in mice with 
(CGG)151-200. In mice with over 200 CGGs, Fmrp levels might have dropped just below this level, thereby 
preventing inclusion formation. However, the possibility can not yet be excluded that repeat tracts 
with over 200 CGGs adopt different tertiary structures than do shorter repeats, thereby influencing the 
binding of CGG binding proteins (CGG-BPs) and possibly preventing the formation of inclusions. 
While  Fmrp may be important for inclusion formation, it is noteworthy that Fmrp has not yet 
been detected in inclusions in mice 30 and in humans 36. Furthermore, inclusions could be induced in a 
human neuronal cell model expressing a (CGG)n fused to a Gfp reporter 
37, showing that inclusions can be 
formed, without the need for the (CGG) n to be in the context of Fmr1. These cells did express endogenous 
Fmrp levels 37. In order to investigate the role of Fmrp in the formation of inclusions, breedings of female 
mice homozygous for (CGG)>200 with male Fmr1 KO mice heterozygous for a yeast artificial chromosome 
(YAC) containing the entire human FMR1 gene and some flanking sequences 38,39 will be set up. This will 
allow comparison of inclusion formation in the (CGG)>200 offspring in the presence (YAC +/-) or absence 
(YAC -/-) of FMRP expression. 
It is possible that a minimal abundance of CGG triplets is needed, either due to elevated 
transcript levels or the length of the repeat tract, or a combination thereof, to cause cellular pathology. 
Such an effect of ‘CGG molarity’ in the development of cellular toxicity in FXTAS has been hypothesised 
in the toxic RNA gain-of-function model 23. In light of the toxic RNA gain-of-function model, it could be 
that a longer repeat tract provides more binding sites for (CGG)n-BPs, such that it exerts toxicity similar 
to higher levels of a shorter repeat. With regard to the protein sequestration model for DM, it has been 
found that Muscleblind-like protein 1 (MBNL1) binding is proportional to (CUG)n length 
40. Sequestration 
of (CUG)n-BPs away from their normal cellular functions, including splice regulation, has been proposed 
to be the mechanism underlying DM 40-42. Interestingly, MBNL1 has also been found in intranuclear 
inclusions in human FXTAS brain 36, suggesting that a similar pathogenic mechanism may occur in 
FXTAS. However, no downstream splicing defects have thus far been revealed in FXTAS. In addition, we 
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have not detected Mbnl1 in the inclusions present in our (CGG)n mouse model (unpublished results).
Our studies in animals carrying a (CGG)70 allele may provide insight on the observation that 
shorter PM alleles (<70 CGGs) may pose a lower risk of developing FXTAS for the carrier than do longer 
repeats 43. Although some cases with repeat lengths below 70 CGGs have been described 44,45, clinical 
presentation was atypical and thus these findings may be coincidental 43. It is therefore interesting 
that mice with (CGG)70 neither show inclusions, nor elevated Fmr1 mRNA, suggesting that there is a 
minimum repeat length necessary for the development of disease in mice. 
Some correlations between molecular and clinical measures in FXTAS patients have been 
described. For instance, (CGG)n length strongly correlates with age of death 
31. (CGG)n length has also 
been reported to correlate negatively with age of onset of action tremor and ataxia. Age of onset of 
these motor symptoms was not correlated to FMR1 mRNA or FMRP levels in blood. For FMRP levels, 
this is not surprising, as they are close to normal in FXTAS patients. The lack of correlation with FMR1 
transcript levels might be explained by the fact that mRNA levels are measured in blood, whereas clinical 
symptoms derive from brain pathology 32. Furthermore, (CGG)n has been correlated with increased 
cognitive and functional impairment 33. In addition, (CGG)n length in humans has been found to be 
highly correlated to the number of intranuclear inclusions in both neurons and astrocytes, suggesting 
that it might serve as a powerful predictor of neuropathological involvement 31. 
The presence of inclusions is associated with disease 31. The size and number of inclusions in 
murine brain increase with time, reflective of the progressive nature of the disease. In addition, functions 
of some inclusion-bearing brain regions in expanded (CGG)n mice can be linked to clinical symptoms in 
patients with FXTAS. Both findings are suggestive of a role for inclusions in the disease process 30. It is, 
however, as yet unknown how inclusions cause cellular dysfunction, and eventually neurodegeneration 
and clinical pathophysiology. Their immunoreactivity to antibodies against ubiquitin and components of 
the proteasome, Hsp70 and αB-crystallin suggests involvement of the proteasomal protein degradation 
pathway 25,30. In mouse brain, an antibody directed against only poly-ubiquitinated proteins, as well as 
against mono- and polyubiquitinated proteins, detected inclusions 30. However, in isolated inclusions 
from human FXTAS brain, there was little evidence that the proteins present in the inclusions are poly-
ubiquitinated, which is normally the signal that causes a protein to be degraded by the proteasome. 
Thus, impaired proteasomal degradation does not seem to play a central role in the formation of the 
inclusions 36. It appears more likely that expanded (CGG)n FMR1 mRNA acts as a nucleation centre for 
other proteins, similar to the nuclear RNA foci seen in DM 23. 
In a previous study we reported elevated Fmr1 mRNA levels in mice with over 150 CGGs 28, 
which is in contrast with our current findings. At the time of that study, availability of mice with such long 
repeat tracts was limited, so few animals could be investigated. Therefore, along with considering the 
large variability seen for all repeat categories as well as for the wt animals, we believe that our previous 
findings likely represented a coincidental, biased selection of animals for study. Our conclusion still 
stands that in mouse brain there is no linear relationship between (CGG)n length and Fmr1 mRNA levels, 
unlike what has been reported in the blood of human PM carriers. In humans, there is no evidence for 
a drop in FMR1 mRNA levels above a certain unmethylated (CGG)n length 
16,19,20. In another expanded 
(CGG)n mouse model developed by Entezam and colleagues, a linear increase in Fmr1 mRNA with 
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increasing (CGG)n length was reported 
46. However, the number of animals that was used per repeat 
length was not reported. It is therefore unclear whether those findings were also influenced by high 
inter-animal variation. Also, t-tests were performed to compare the different repeat lengths, without 
the mention of correction for multiple comparisons. 
The Fmrp levels measured in this study are consistent with those reported in our previous 
study 28, such that decreased levels were only seen when (CGG)n exceeded 150. Again, variability was 
large. In the other mouse model for FXTAS Fmrp levels had already decreased at (CGG)130, but again the 
number of mice used in that study was not reported 46.
The high variability found in Fmr1 transcript levels in KI mouse brain, might explain the fact 
that not all PM carriers develop FXTAS. Most studies on FMR1 expression have been done in blood of 
PM carriers with or without FXTAS, and both show elevated levels on average.  However, increases of 
differing magnitude in FMR1 mRNA have been described 19,20,22. The generally higher fold change of 
FMR1 mRNA in human PM carriers versus normal controls, in comparison with lower 2-3 fold changes 
measured in our mice can be explained by the fact that we isolate RNA from whole brain lysate, whereas 
RNA in human studies is extracted from blood. Thus far, brain FMR1 mRNA levels have been quantified 
in one FXTAS patient. Absolute FMR1 mRNA levels were found to be higher in brain than in peripheral 
blood leukocytes, although fold increases as compared to normal controls were more pronounced in 
RNA isolated from blood. Furthermore, differential FMR1 expression was seen in different brain regions, 
despite the fact that neurons in each region showed the same repeat length 47.  Thus our results in 
(CGG)n mice might represent an average of higher and lower regional expression levels throughout the 
brain. It would be interesting to measure Fmr1 mRNA and Fmrp levels in different mouse brain areas 
and relate this to the proportion of inclusion-bearing neurons. However, it would be very challenging 
to reliably dissect the small mouse brain. 
In postmitotic neurons in a mouse model for Huntington’s disease, higher (CAG)n instability 
was observed in brain regions that show high expression of the mutant allele 48. Thus, if Fmr1 mRNA 
expression varies among different brain regions in our (CGG)n mice, it would be interesting to investigate 
somatic instability in those specific regions. However, to date there is no evidence that (CGG)n length 
heterogeneity exists in human FXTAS brain 47. In the present study very minor (CGG)n instability was 
seen when comparing brain DNA obtained at death with DNA obtained from tail shortly after birth. 
Naturally, this comparison cannot be made in patients with FXTAS. No evidence for a broader pattern 
of (CGG)n lengths was seen in brain DNA as compared with tail DNA, thus repeat length heterogeneity 
does not seem to be a major occurrence.
The elevated FMR1 mRNA levels have been attributed to increased transcription, rather than 
to increased stability of the FMR1 transcripts 49,50. The cause of increased transcription is unknown, 
although it could be that the expanded (CGG)n causes the chromatin to adopt a more open conformation, 
which could facilitate transcription. In addition, the (CGG)n length has been shown to influence which 
transcription start site is used, with the use of more upstream start sites corresponding to increased 
FMR1 transcription 51. It has been proposed that a feedback system might exist such that lower FMRP 
levels cause increased FMR1 transcription 20,52. However, cellular studies show increased expression of 
reporter constructs containing the FMR1 5’UTR containing various (CGG)n lengths, in the absence of 
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FMRP. This suggests that an intrinsic quality of the FMR1 5’UTR and/or the (CGG)n might be the cause of 
the elevated transcription. In addition, since the FMR1 5’UTR was driven by the CMV immediate early 
promoter in these experiments, the increased transcription must be independent of the FMR1 promoter. 
Thus, although it should be noted that this study was performed under conditions of overexpression of 
the construct, at least part of the elevated transcript levels seen in PM carriers may be a direct cis-acting 
effect of the (CGG)n, rather than a compensatory response to reduced FMRP levels 
53. This possibility 
might be reflected by the lack of correlation between Fmr1 transcript levels and Fmrp levels in this study. 
Current evidence suggests that FMR1 transcripts are not retained in the nucleus, making this 
an unlikely reason for reduced translation 50. The (CGG)n has been found to impede the 40s ribosomal 
unit, leading to suppression of translation 54. Indeed, FMRP levels are mostly reduced in the upper PM 
range in humans 19,50, as well as in mice. 
In humans, CGG expansions above 200 generally lead to methylation of the repeat and 
silencing of the gene 4-6. This has not been observed in expanded (CGG)n mouse models 
28,46. In general, 
it has been proposed that mouse models for trinucleotide repeat disorders need longer repeats in order 
to see major instability than do human repeats 55. The same might be true for methylation of the gene 
and/or phenotypes associated with the repeats. 
The finding that some animals show inclusions in the dentate gyrus, while others do not, 
irrespective of (CGG)n length, implies that modifying factors play a role in the formation of inclusions. We 
cannot exclude that the same effect occurs in other brain regions, as we have not investigated all brain 
areas extensively. As our breedings are mostly set up to obtain certain repeat lengths, animals have a 
mixed genetic background. As it is known that genetic background has an influence on behavioural 
phenotype in different strains of Fmr1 KO mice 56, a similar influence of the genetic background on 
inclusion formation in specific regions could have taken place in our mice. 
In summary, this study indicates that there is both a lower repeat length threshold, below 
which no inclusions form, and an upper threshold above which hardly any inclusions develop. There 
does not appear to be a linear correlation between (CGG)n and Fmr1 mRNA levels in brain or the presence 
of inclusions. Fmrp levels do decrease with increasing repeat length, specifically after the (CGG)n 
exceeds 150. Thus, if inclusions are responsible for the clinical outcome, the current results suggest 
that merely the presence of expanded (CGG)n Fmr1 mRNA, rather than the precise level of expression, 
possibly in combination with a minimal level of remaining Fmrp, determines the occurrence of inclusion 
neuropathology. Behavioural studies in mice of differing (CGG)n repeat lengths will be necessary to 
establish whether an aberrant phenotype is primarily related to the length of the (CGG)n expansion or 
to Fmr1 expression levels.
Acknowledgements  |
We are grateful to Tom de Vries Lentsch for graphical support. We also like to thank Asma Asmani and Marit de Haan for help 
with the immunohistochemical studies. This study was financially supported by the Prinses Beatrix Fonds (J.R.B: MAR03-0208) 
and by the National Institutes of Health (RL1 NS062411, UL1 RR024922) (R.W. and R.F.B.) and (ROI HD38038) (B.A.O)
132 CHAPTER 6 
References  |
1. Fu YH, Kuhl DP, Pizzuti A, Pieretti M, Sutcliffe JS et al. 1991. Variation of the CGG repeat at the fragile X site results in genetic 
instability: resolution of the Sherman paradox. Cell 67:1047-1058.
2. Zhong N, Ju WN, Pietrofesa J, Wang DW, Dobkin C et al. 1996. Fragile X ‘’gray zone’’ alleles: AGG patterns, expansion risks, and 
associated haplotypes. Am J Med Genet 64:261-265.
3. Nolin SL, Lewis FA, Ye LL, Houck GE, Glicksman AE et al. 1996. Familial transmission of the FMR1 CGG repeat. Am J Hum Genet 
59:1252-1261.
4. Oberlé I, Rousseau F, Heitz D, Kretz C, Devys D et al. 1991. Instability of a 550-base pair DNA segment and abnormal methylation in 
fragile X syndrome. Science 252:1097-1102.
5. Sutcliffe JS, Nelson DL, Zhang F, Pieretti M, Caskey CT et al. 1992. DNA methylation represses FMR-1 transcription in fragile X 
syndrome. Hum Mol Genet 1:397-400.
6. Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP et al. 1991. Identification of a gene (FMR-1) containing a CGG repeat coincident 
with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65:905-914.
7. Pieretti M, Zhang FP, Fu YH, Warren ST, Oostra BA et al. 1991. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 
66:817-822.
8. Verheij C, Bakker CE, de Graaff E, Keulemans J, Willemsen R et al. 1993. Characterization and localization of the FMR-1 gene product 
associated with fragile X syndrome. Nature 363:722-724.
9. Hagerman RJ, Hagerman PJ. 2002. The fragile X premutation: into the phenotypic fold. Curr Opin Genet Dev 12:278-283.
10. Hagerman RJ, Leehey M, Heinrichs W, Tassone F, Wilson R et al. 2001. Intention tremor, parkinsonism, and generalized brain 
atrophy in male carriers of fragile X. Neurology 57:127-130.
11. Jacquemont S, Hagerman RJ, Leehey M, Grigsby J, Zhang L et al. 2003. Fragile X Premutation Tremor/Ataxia Syndrome: Molecular, 
Clinical, and Neuroimaging Correlates. Am J Hum Genet 72:869-878.
12. Jacquemont S, Hagerman RJ, Leehey MA, Hall DA, Levine RA et al. 2004. Penetrance of the fragile x-associated tremor/ataxia 
syndrome in a premutation carrier population. JAMA 291:460-469.
13. Hagerman RJ, Leavitt BR, Farzin F, Jacquemont S, Greco CM et al. 2004. Fragile-X-Associated Tremor/Ataxia Syndrome (FXTAS) in 
Females with the FMR1 Premutation. Am J Hum Genet 74:1051-1056.
14. Zuhlke C, Budnik A, Gehlken U, Dalski A, Purmann S et al. 2004. FMR1 premutation as a rare cause of late onset ataxia. Evidence for 
FXTAS in female carriers. J Neurol 251:1418-1419.
15. Berry-Kravis E, Potanos K, Weinberg D, Zhou L, Goetz CG. 2004. Fragile X-associated tremor/ataxia syndrome in sisters related to 
X-inactivation. Ann Neurol 57:144-147.
16. Allen EG, He W, Yadav-Shah M, Sherman SL. 2004. A study of the distributional characteristics of FMR1 transcript levels in 238 
individuals. Hum Genet 114:439-447.
17. Sherman SL. 2000. Premature ovarian failure in the fragile X syndrome. Am J Med Genet 97:189-194.
18. Berry-Kravis E, Abrams L, Coffey SM, Hall DA, Greco C et al. 2007. Fragile X-associated tremor/ataxia syndrome: Clinical features, 
genetics, and testing guidelines. Mov Disord 14:2014-2030.
19. Kenneson A, Zhang F, Hagedorn CH, Warren ST. 2001. Reduced FMRP and increased FMR1 transcription is proportionally associated 
with CGG repeat number in intermediate-length and premutation carriers. Hum Mol Genet 10:1449-1454.
20. Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE et al. 2000. Elevated levels of FMR1 mRNA in carrier males: A new 
mechanism of involvement in the Fragile-X syndrome. Am J Hum Genet 66:6-15.
21. Tassone F, Hagerman RJ, Taylor AK, Mills JB, Harris SW et al. 2000. Clinical involvement and protein expression in individuals with 
the FMR1 premutation. Am J Med Genet 91:144-152.
22. Primerano B, Tassone F, Hagerman RJ, Hagerman P, Amaldi F et al. 2002. Reduced FMR1 mRNA translation efficiency in Fragile X 
patients with premutations. RNA 8:1-7.
23. Hagerman PJ, Hagerman RJ. 2004. The Fragile-X Premutation: A Maturing Perspective. Am J Hum Genet 74:805-816.
24. Ranum LP, Day JW. 2004. Pathogenic RNA repeats: an expanding role in genetic disease. Trends Genet 20:506-512.
25. Greco CM, Hagerman RJ, Tassone F, Chudley AE, Del Bigio MR et al. 2002. Neuronal intranuclear inclusions in a new cerebellar 
tremor/ataxia syndrome among fragile X carriers. Brain 125:1760-1771.
26. Tassone F, Iwahashi C, Hagerman PJ. 2004. FMR1 RNA withinthe intranuclear inclusions of fragile X-associated Tremor/Ataxia 
syndrome (FXTAS). RNA biology 1:103-105.
27. Bontekoe CJ, Bakker CE, Nieuwenhuizen IM, van Der Linde H, Lans H et al. 2001. Instability of a (CGG)(98) repeat in the Fmr1 
promoter. Hum Mol Genet 10:1693-1699.
Correlation between (CGG)n length and phenotype in FXTAS 133
28. Brouwer JR, Mientjes EJ, Bakker CE, Nieuwenhuizen IM, Severijnen LA et al. 2007. Elevated Fmr1 mRNA levels and reduced protein 
expression in a mouse model with an unmethylated Fragile X full mutation. Exp Cell Res 313:244-253.
29. Brouwer JR, Severijnen E, de Jong FH, Hessl D, Hagerman RJ et al. 2008. Altered hypothalamus-pituitary-adrenal gland axis regulation 
in the expanded CGG-repeat mouse model for fragile X-associated tremor/ataxia syndrome. Psychoneuroendocrinology.
30. Willemsen R, Hoogeveen-Westerveld M, Reis S, Holstege J, Severijnen L et al. 2003. The FMR1 CGG repeat mouse displays ubiquitin-
positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome. Hum Mol Genet 12:949-959.
31. Greco CM, Berman RF, Martin RM, Tassone F, Schwartz PH et al. 2006. Neuropathology of fragile X-associated tremor/ataxia 
syndrome (FXTAS). Brain 129:243-255.
32. Tassone F, Adams J, Berry-Kravis EM, Cohen SS, Brusco A et al. 2007. CGG repeat length correlates with age of onset of motor signs 
of the fragile X-associated tremor/ataxia syndrome (FXTAS). Am J Med Genet B Neuropsychiatr Genet 144B:566-569.
33. Grigsby J, Brega AG, Jacquemont S, Loesch DZ, Leehey MA et al. 2006. Impairment in the cognitive functioning of men with fragile 
X-associated tremor/ataxia syndrome (FXTAS). J Neurol Sci 248:227-233.
34. Bakker CE, de Diego Otero Y, Bontekoe C, Raghoe P, Luteijn T et al. 2000. Immunocytochemical and biochemical characterization of 
FMRP, FXR1P, and FXR2P in the mouse. Exp Cell Res 258:162-170.
35. Gabel LA, Won S, Kawai H, McKinney M, Tartakoff AM et al. 2004. Visual Experience Regulates Transient Expression and Dendritic 
Localization of Fragile X Mental Retardation Protein. J Neurosci 24:10579-10583.
36. Iwahashi CK, Yasui DH, An HJ, Greco CM, Tassone F et al. 2006. Protein composition of the intranuclear inclusions of FXTAS. Brain 
129:256-271.
37. Arocena DG, Iwahashi CK, Won N, Beilina A, Ludwig AL et al. 2005. Induction of inclusion formation and disruption of lamin A/C 
structure by premutation CGG-repeat RNA in human cultured neural cells. Hum Mol Genet 14:3661-3671.
38. Peier AM, McIlwain KL, Kenneson A, Warren ST, Paylor R et al. 2000. (Over)correction of FMR1 deficiency with YAC transgenics: 
behavioral and physical features. Hum Mol Genet 9:1145-1159.
39. Musumeci SA, Calabrese G, Bonaccorso CM, D’Antoni S, Brouwer JR et al. 2007. Audiogenic seizure susceptibility is reduced in 
fragile X knockout mice after introduction of FMR1 transgenes. Exp Neurol 203:233-240.
40. Timchenko LT, Miller JW, Timchenko NA, DeVore DR, Datar KV et al. 1996. Identification of a (CUG)n triplet repeat RNA-binding 
protein and its expression in myotonic dystrophy. Nucleic Acids Res 24:4407-4414.
41. Miller JW, Urbinati CR, Teng-Umnuay P, Stenberg MG, Byrne BJ et al. 2000. Recruitment of human muscleblind proteins to (CUG)(n) 
expansions associated with myotonic dystrophy. Embo J 19:4439-4448.
42. Fardaei M, Larkin K, Brook JD, Hamshere MG. 2001. In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts. 
Nucleic Acids Res 29:2766-2771.
43. Jacquemont S, Leehey MA, Hagerman RJ, Beckett LA, Hagerman PJ. 2006. Size bias of fragile X premutation alleles in late-onset 
movement disorders. J Med Genet 43:804-809.
44. Kamm C, Healy DG, Quinn NP, Wullner U, Moller JC et al. 2005. The fragile X tremor ataxia syndrome in the differential diagnosis of 
multiple system atrophy: data from the EMSA Study Group. Brain 128:1855-1860.
45. Macpherson J, Waghorn A, Hammans S, Jacobs P. 2003. Observation of an excess of fragile-X premutations in a population of males 
referred with spinocerebellar ataxia. Hum Genet 112:619-620.
46. Entezam A, Biacsi R, Orrison B, Saha T, Hoffman GE et al. 2007. Regional FMRP deficits and large repeat expansions into the full 
mutation range in a new Fragile X premutation mouse model. Gene 395:125-134.
47. Tassone F, Hagerman RJ, Garcia-Arocena D, Khandjian EW, Greco CM et al. 2004. Intranuclear inclusions in neural cells with 
premutation alleles in fragile X associated tremor/ataxia syndrome. J Med Genet 41:E43.
48. Gonitel R, Moffitt H, Sathasivam K, Woodman B, Detloff PJ et al. 2008. DNA instability in postmitotic neurons. Proc Natl Acad Sci U 
S A 105:3467-3472.
49. Tassone F, Hagerman RJ, Chamberlain WD, Hagerman PJ. 2000. Transcription of the FMR1 gene in individuals with fragile X 
syndrome. Am J Med Genet 97:195-203.
50. Tassone F, Beilina A, Carosi C, Albertosi S, Bagni C et al. 2007. Elevated FMR1 mRNA in premutation carriers is due to increased 
transcription. RNA 13:555-562.
51. Beilina A, Tassone F, Schwartz PH, Sahota P, Hagerman PJ. 2004. Redistribution of transcription start sites within the FMR1 
promoter region with expansion of the downstream CGG-repeat element. Hum Mol Genet 13:543-549.
52. Oostra BA, Willemsen R. 2003. A fragile balance: FMR1 expression levels. Hum Mol Genet 12 Suppl 2:R249-257.
53. Chen LS, Tassone F, Sahota P, Hagerman PJ. 2003. The (CGG)n repeat element within the 5’untranslated region of the FMR1 message 
provides both positive and negative cis effects on in vivo translation of a downstream reporter. Hum Mol Genet 12:3067-3074.
134 CHAPTER 6 
54. Feng Y, Zhang FP, Lokey LK, Chastain JL, Lakkis L et al. 1995. Translational suppression by trinucleotide repeat expansion at FMR1. 
Science 268:731-734.
55. Gourdon G, Radvanyi F, Lia AS, Duros C, Blanche M et al. 1997. Moderate intergenerational and somatic instability of a 55-CTG 
repeat in transgenic mice. Nature Genet 15:190-192.
56. Spencer CM, Serysheva E, Yuva-Paylor LA, Oostra BA, Nelson DL et al. 2006. Exaggerated behavioral phenotypes in Fmr1/Fxr2 
double knockout mice reveal a functional genetic interaction between Fragile X-related proteins. Hum Mol Genet 15:1884-1894.
CHAPTER 7
General discussion 
 135

General discussion 137
Although the clinical consequences for carriers of FMR1 FM alleles had long been established 1-3, only 
few reports were initially published on mild clinical involvement in carriers of the PM, predominantly 
in females (reviewed in 4). Intelligence was normal 5,6, but emotional problems such as attention deficit 
hyperactivity disorder and anxiety were observed 7,8. Premature menopause and a higher rate of 
twinning had been recognised among female PM carriers 9,10. Male PM carriers were also characterised; 
a subgroup was found to have cognitive impairment 11,12. These findings prompted Tassone and 
colleagues to look into the consequences of premutations at a molecular level. They found that PM 
carriers have elevated FMR1 mRNA levels 13. 
The authors hypothesised that elevated transcript levels, in combination with slightly 
decreased FMRP levels, represented a defective translational efficiency, which might be responsible 
for the clinical involvement in the PM range 13. Soon after the recognition of the molecular phenotype, 
a new neurodegenerative syndrome was appreciated in a subgroup of elderly men with the FMR1 
premutation 14-17, which was designated fragile X-associated tremor/ataxia syndrome (FXTAS) 18. This 
syndrome was postulated to result from a toxic RNA gain-of-function mechanism 4,14,15,18-20, similar to the 
pathogenesis model described for myotonic dystrophy 21. 
The toxic RNA gain-of-function pathogenesis model for FXTAS  |  7.1
The combination of several observations has lead to the hypothesis that FXTAS is the result of a toxic 
RNA gain-of-function mechanism. First, PM carriers have elevated FMR1 mRNA levels, while FMRP levels 
are only mildly reduced 13,22. No signs of FXTAS have been observed among elderly FM carriers, thus, 
the slight protein deficiency in PM carriers is not likely the cause of FXTAS 14,18,19. Also the presence 
of FMR1 transcripts in intranuclear inclusions suggests a role for the mRNA in the pathogenesis 
(23, summarised in 4).
In support of the toxic RNA pathogenesis model for FXTAS, long, transcribed but untranslated 
(CGG)n  were found to be toxic to human cells. The repeat-containing transcripts alter the expression of 
a wide variety of genes, suggestive of an effect on a variety of biological processes 24. In a neural cell 
model, expression of the FMR1 5’UTR containing the expanded (CGG)n, fused to a reporter gene, as 
RNA, was capable of inducing inclusion formation 25, showing that inclusion formation was possible 
without FMRP synthesis. A neurodegenerative eye phenotype could be induced upon expression of 
(CGG)n-containing constructs in a Drosophila model. Higher expression levels of (CGG)60-containing 
RNA were necessary than of (CGG)90 RNA to induce a similar neurodegenerative phenotype 
26. This 
indicates that both (CGG)n length and expression level determine RNA toxicity in the Drosophila model 
for FXTAS. 
(CGG)n-binding proteins  |  7.1.1 
The capacity of some (CGG)n-binding proteins ((CGG)n-BPs: Pur α, hnRNP A2/B1, (CUG)-BP1), as well as 
co-expression of the FMR2 (GCC)n to rescue the neurodegenerative phenotype in Drosophila further 
underscores the central role of the expanded (CGG)n RNA in the pathogenesis of FXTAS 
27-29.
Some of these (CGG)n-BPs have also been identified in inclusions in human FXTAS brain, such 
as hnRNP A2/B1 30 and Pur α 27. Also MBNL1, known to bind (CUG)n-containing transcripts and to play a 
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central role in the pathogenesis of myotonic dystrophy, was present in the inclusions in human FXTAS 
brain 30. In myotonic dystrophy, it is now well established that sequestering these (CUG)n-BPs away from 
their normal function leads to dysregulated splicing, of which the effects can sometimes directly be 
linked to the clinical outcome (summarised in 31). In FXTAS, no downstream effects of the sequestering 
of certain proteins into the inclusions, such as altered splicing regulation, have been described to 
date. 
It has been speculated that hnRNP A2 is involved in the development of FXTAS, as it was 
present in intranuclear inclusions and found to bind directly to the 5’UTR of FMR1 mRNA. hnRNP A2 
mediates transport of mRNAs, including Myelin Basic Protein (MBP) mRNA in oligodendroglial cells. 
MBP is a major component of the myelin sheath, and was also found to be present in neuronal and glial 
inclusions. hnRNP A2 function might be affected in FXTAS. Interestingly, white matter disease, with loss 
of axons and myelin, is a central neuropathological feature in FXTAS. Partial sequestration of hnRNP A2 
might thus affect MBP mRNA transport and could adversely affect axon myelination in FXTAS 30. 
We made an attempt at visualising cellular localisation of Fmr1 mRNA in mouse brain, by 
means of in situ hybridisation. Naturally, we were interested to see whether Fmr1 mRNA is also present in 
inclusions in mouse brain. Unfortunately this failed due to the low abundance of these transcripts and/
or the inability to design good probes for this gene. Immunohistochemistry using antibodies against 
possible (CGG)n-binding proteins on brain sections of (CGG)n and wt mice could reveal altered cellular 
localisation. This might shed light on proteins that are sequestered to the (CGG)n RNA and drawn away 
from their normal function, possibly into the intranuclear inclusions. Another approach to answer the 
question which proteins interact with the (CGG)n RNA is to cross-link proteins to RNA in (CGG)n mouse 
brain cell suspensions and then to specifically pull down the Fmr1 mRNA. The (CGG)n RNA-interacting 
proteins can then for example be investigated using immunogenic visualisation by SDS-PAGE followed 
by Western blotting for likely targets or protein identification by mass spectrometry to find new binding 
partners.
hnRNP A2/B1 showed a much more prominent interaction with (CGG)n RNA in the cytoplasmic 
fraction than in the nuclear fraction of mouse cerebellar lysates 29. Thus, cytoplasmic interaction of 
(CGG)n-BP with (CGG)n RNA should also be considered, although no model has been proposed which 
could link cytoplasmic protein-RNA interactions with presence of this protein in the intranuclear 
inclusions. 
Inclusion formation in the brain  |  7.1.2
It is currently unknown how mutant RNA leads to inclusion formation. Chapter 6 describes that Fmr1 
levels are elevated in mice with 100 to 150 CGGs, but return to normal when (CGG)n exceeds 150. 
Inclusions are ubiquitous in animals with up to 200 CGGs. Fmrp levels are significantly reduced in mice 
with over 150 CGGs. Thus, in light of the toxic RNA gain-of-function hypothesis, it is interesting to note 
that mice with 151-200 CGGs do have many inclusions, despite normal Fmr1 mRNA levels. Based on these 
findings it could be hypothesised that not necessarily the precise amount of Fmr1 mRNA determines 
cellular toxicity, but that the mere presence of mutant RNA might be responsible for the formation of 
inclusions. Willemsen and colleagues already proposed before that the Fmr1 gene is likely to play a direct 
role in the development of inclusions, either by (CGG)n expansion itself or elevated transcript levels 
32. 
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It can, however, not be excluded that a minimal amount of Fmrp is needed for formation of inclusions, 
which is still present in mice with (CGG)151-200. Above 200 CGGs, the Fmrp level might drop below this 
threshold, protecting the mice from inclusion formation. Nevertheless, this role for Fmrp is difficult 
to explain considering that no Fmrp has been detected in inclusions in mice 32 or men 30. In order to 
determine whether Fmrp is necessary for inclusion formation, breedings of female mice homozygous 
for (CGG)>200 with male Fmr1 KO mice heterozygous for a yeast artificial chromosome (YAC) containing 
the entire human FMR1 gene and some flanking sequences 33,34 will be set up. Since the YAC transgene 
introduces FMRP expression, this will allow comparison of inclusion formation in the (CGG)>200 offspring 
in the presence (YAC +/-) or absence (YAC -/-) of FMRP expression. Alternatively, (CGG)>200 might adopt 
different secondary structures, such that CGG-BPs cannot bind the repeat, possibly thereby preventing 
inclusion formation.
Chapter 4 discusses cellular pathology in fibroblast lines derived from embryonic and adult 
(CGG)>200 mice. Fmr1 mRNA levels are elevated as compared with wt mice in (CGG)n embryonic fibroblasts, 
but not in adult fibroblasts. Although more pronounced in the embryonic fibroblasts, both (CGG)n cell 
lines show signs of cellular stress. This also suggests that the presence of expanded (CGG)n, although 
not at high levels, is sufficient to cause cellular toxicity. Intranuclear inclusions were not observed, likely 
due to the high proliferation rate of fibroblast lines.
It is unclear what this means for carriers of repeat lengths in the high PM range. Few PM 
individuals with (CGG)151-200 have been described, but all had elevated FMR1 mRNA levels in blood 
22,35-37. 
It is interesting to note that to date no patients with FXTAS have been seen in carriers of repeats longer 
than 150 CGGs (R. Hagerman, personal communication). This could mean that carriers with PM alleles 
in this range hardly exist, because shorter PM alleles almost always expand directly into the FM range. 
Alternatively, they might exist, but they might not develop any clinical signs, and therefore do not 
consult clinicians. They would, however, likely be discovered in screening efforts in fragile X families. 
Interestingly, although prevalence of POF increases in female PM carriers with (CGG)n with up to 100 
CGGs, it is noteworthy that above this length, the risk for ovarian dysfunction remains stable or perhaps 
decreases 38. Very recently, also the risk of getting lifetime major depressive disorder (MDD) was found 
to exhibit a non-linear relationship with (CGG)n length in PM mothers with at least one child with fragile 
X. Although preliminary, this study suggests that PM females with longer (CGG)n are at lower risk of 
developing MDD than are carriers of mid-range (CGG)n 
39.
It remains to be solved whether inclusions are a by-product of cellular toxicity, or the origin 
of the cellular dysfunction. It has been proposed that (CGG)n mRNA may act as a nucleation centre for 
other proteins 4. Indeed, FMR1 mRNA is present in inclusions 23. Over 20 proteins have been identified in 
isolated inclusions. There is no dominant protein species present; all proteins represent less than 10% 
of the total protein content of the isolated inclusions 30. A role for intermediate filaments (IFs) and αB-
crystallin, both present in the inclusions 30, has been suggested in the formation of inclusions. Increased 
αB-crystallin immunoreactivity is seen in several neurodegenerative disorders. αB-crystallin is a small 
heat shock protein, thought to be involved in normal dynamics of cytoskeletal proteins, as well as in 
prevention of protein aggregation during cellular stress 40. Also IFs are seen in inclusions in FXTAS and 
aggregates of other neurodegenerative diseases. Thus, aggregate formation may reflect a failed attempt 
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of αB-crystallin to repair the stress-induced disrupted IF cytoskeletal architecture. In FXTAS, in particular 
lamin A/C appears be involved 25,30.  In expanded (CGG)n mice this heat shock protein reactivity and 
disrupted lamin A/C architecture have not been detected.
It is unclear whether the components are trapped into the inclusions via a specific process, 
or whether this may be the result of a somewhat random process. It could be that not all inclusions 
have the same composition. Most of the proteins in the inclusions have been identified by tandem 
mass spectrometry analysis 30. Although a sensitive method, it does not give information about the 
composition of individual inclusions. More immunocytochemical experiments with antibodies against 
the identified proteins might answer the question whether all inclusions contain the same constituents. 
This in turn could give an indication whether inclusion formation is a determined or a random process, 
after an initial nucleation event.
We have investigated the presence of proteins in inclusions in murine brain 32 and compared 
with those that have been identified in inclusions in human FXTAS brain. We did not find Pur-α, hnRNP 
A2/B1, αB-crystallin or lamin A/C in inclusions in the expanded (CGG)n mice. Neither was a prominent 
difference in distribution or immunoreactivity in expanded (CGG)n mice observed in comparison with 
wt mice. The differences in protein composition of the inclusions between human and mice could 
derive from fundamental differences in the disease progress between the two species, or they could 
reflect the possible random trapping of proteins in the inclusions.
Intranuclear inclusion formation is not limited to disease development in FXTAS. For instance, 
all polyglutamine diseases caused by an expanded (CAG)n in a coding sequence, are associated with 
neuronal intranuclear aggregates 41-43. Mouse models suggest that the inclusions are clearly related 
to disease pathology 44. However, it is unclear whether the formation of inclusions is a prerequisite 
for toxicity 45. Interestingly, evidence from a neuronal model for Huntington’s disease suggests that 
inclusions may represent a protective mechanisms against cytotoxicity, by sequestering away soluble, 
more toxic forms of a protein 46-48. It should, however, be noted that polyglutamine-induced diseases, 
including Huntington, result from the presence of a mutant protein, the effects of which might differ 
greatly from mutant RNA.
Knowing how inclusions are formed and what they are composed of will hopefully shed light 
on the origin of cellular toxicity, as well as how this leads to neurodegeneration. Future studies should 
and will furthermore continue to focus on (CGG)n RNA-binding proteins, to find downstream effects, 
which may explain the pathogenic mechanisms underlying the symptoms seen in FXTAS. Although two 
different expanded (CGG)n knock-in mouse lines are available that exhibit at least most of the symptoms 
observed in humans with FXTAS, they do not model human FXTAS in all aspects, including absence of 
inclusions in mouse astrocytes and absence of a significant degenerative neuropathology. Therefore 
new transgenic mouse models need to be developed with conditional and inducible (CGG)n expression 
in neurons and/or astrocytes, which will allow testing for sufficiency and necessity (which cell types) 
and timing of reversibility of neuropathology when stopping expanded (CGG)n expression (critical 
period). These new transgenic mice probably will result in earlier onset and increased severity of the 
FXTAS phenotype in mice and model FXTAS more accurately.
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Inclusions in organs other than the brain   |  7.1.3
When considering the presence of inclusions in organs other than the brain, their role in relation to 
disease possibly becomes even more puzzling. Chapter 5 describes altered hypothalamo-pituitary 
-adrenal (HPA) axis regulation in aged expanded (CGG)n mice, with elevated corticosterone levels as 
the most prominent finding. Furthermore, inclusions were detected in the pituitary and adrenal gland. 
Although these organs are directly linked to the HPA axis, the precise cell types in which inclusions are 
found are puzzling in relation to HPA axis physiology. In mice, inclusions in the pituitary gland were 
mostly seen in the pars intermedia. The pars anterior, however, is the region where the corticotrophs 
secrete adrenocorticotrophin hormone (ACTH). The pars intermedia has undergone involution in adult 
humans, so it is unclear what this observation in mice means for the human situation. Similarly, in the 
adrenal gland, inclusions are also seen in tissue layers that are not responsible for the production of 
corticosterone. 
In human FXTAS tissue, inclusions were found in the anterior and posterior lobes of the pituitary 
gland 49,50. Although some publications suggests that PM carriers suffer from more psychopathological 
symptoms than do controls 39,51-55, of which the origin might lie in elevated stress hormone levels, it is 
unclear how inclusions might affect cell function and thereby HPA axis physiology. 
An attempt has been made to study the HPA axis negative feedback loop, which should keep 
corticosterone levels within the physiological range, or cause it return to normal levels after a stress-
induced elevation. We wanted to know whether corticosterone levels in aged (CGG)n mice had a slower 
return to pre-stressor levels, or whether they might react inappropriately to a mild stressor, as this 
might hint at which level in the HPA axis the altered physiology originates. We analysed corticosterone 
levels in serum obtained at different time points after moving the animals from the animal facility to 
the lab, which can be considered a mild stressor. Measuring corticosterone levels at 0, 15, 30 or 90 
minutes after the stressor in both (CGG)n and wt mice (on average 6 per genotype per time point) 
did not allow us to draw a conclusion on the HPA feedback system. Individual variation was too large, 
despite standardising the experimental set up as much as possible. Adrenal weight was also measured, 
as prolonged exposure to ACTH stimulation causes adrenal hypertrophy. No significant difference was 
seen between (CGG)n and wt mice, likely due to large variation.
The pituitary gland is of particular interest, as this is also a central organ in the hypothalamo-
pituitary-gonadal (HPG) axis. Female PM carriers have elevated follicle stimulating hormone (FSH) levels 
49,56,57, which is indicative of decreasing ovarian reserve. This can be linked to the risk of developing 
premature ovarian insufficiency in female PM carriers. Testosterone measurements have been conducted 
in three FXTAS patients, revealing lowered levels or complete deficiency. Testes of two other men have 
been studied, and showed non-specific atrophic changes and inclusions in Leydig cells, the testosterone 
producing cells and in myoid cells of the tubular walls. These testicular inclusions had an appearance 
identical to those reported in brain 49. Immunohistochemical studies in murine testis and ovary did not 
reveal this. It could be that the pituitary gland is dysfunctional at a more general neuroendocrine level, 
which has an effect on both the HPA and the HPG axes. The basis for this phenomenon remains to be 
established. 
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It is furthermore interesting that inclusions were detectable in mouse amygdala and pituitary gland at 
25 weeks of age, before they appeared in brain. The amygdala projects to and helps to control secretion 
of HPA-related hormones in the hypothalamus (chapter 4, 58). FSH levels are increased in PM women 
before ages at which inclusions have been seen in human FXTAS brain 19. Also, young adult male PM 
carriers were shown to have amygdala dysfunction in a functional MRI study 59. Thus, altered pituitary 
gland physiology, or possibly broader changes involving brain regions that project to the HPA axis, 
might be responsible for symptoms seen in male and female carriers, before the possible onset of 
FXTAS.
Non-mammalian models for FXTAS  |  7.2 
In the process of gaining more insight into the pathogenic mechanisms underlying FXTAS, studying 
human material is of limited use. Molecular measures can be quantified in blood, but the most 
interesting organ in this disease, the brain, is only available after the patient has passed away, thus, at 
the final stage of the disease. Attempts are made to find alternatives, such as skin fibroblast cell lines, 
which mimic cellular changes seen in post mortem brain material, which could serve as a marker for the 
disease progress (described in chapter 4). 
Cellular models   |  7.2.1
Cell lines could also be valuable in unravelling aspects of the mechanisms underlying cellular toxicity, 
as they are easier to manipulate than complex organisms such as mouse models. Although fibroblasts 
have the advantage that they can directly be taken from patients or mice, a neural cell type might be 
more informative, as it has more resemblance to cells in the brain. 
We have made attempts to develop a cellular model by stably expressing an expanded (CGG)n 
(30CGG or 100CGG) fused to a GFP reporter gene in rat pheochromocytoma (PC12) cells, which can adapt 
a neuron-like phenotype upon differentiation with neuronal growth factor. This cell line was established 
to study factors that might play a role in the formation of inclusions. Unfortunately, although inclusions 
did form in a minority of cells, cells did not remain healthy and attached to the cell culture dish long 
enough, for it to be a workable model. Hence, we are limited to the mouse model. Naturally, working 
with a mouse model cannot be seen as a limitation, as mice are very important in approaching the 
complexity of human disease. In addition, the fact that FXTAS only manifests itself in aged individuals 
underscores the advantage of using mice as a model organism. We did, however, generate adult skin 
and embryonic fibroblast lines from mice that carry (CGG)>200, as described in chapter 4.
Drosophila melanogaster model    |  7.2.2 
Jin and colleagues developed a Drosophila model in which they can induce ectopic expression of 
different (CGG)n lengths at various expression levels 
26. Moderate expression of a tract of 60 CGGs 
hardly causes any phenotype in the eye, whereas 90 CGGs lead to rough eye, loss of pigmentation and 
disturbed architecture. Strong expression of either repeat length caused a more severe phenotype, 
with an even stronger effect for the (CGG)90, including major cell death. The neurodegenerative eye 
phenotype worsened with age. It was a late onset phenomenon rather than a developmental defect. 
Inclusions have been found in retina, both in nuclei and cytoplasm, positive for ubiquitin, hsp70 and 
proteasome. 
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By using this model to investigate the effects of overexpression of several proteins, including heat 
shock proteins and (CGG)n-BPs, a proof-of-principle was provided that the RNA-induced phenotype can 
be rescued 26. For instance, overexpression of Hsp70 26, CUGBP1, hnRNP A2/B1 29, Pur α 27 was found to 
be capable of suppressing the CGG RNA-induced degeneration. 
The expanded (CGG)n mouse model for FXTAS  |  7.3 
Although the expanded (CGG)n knock-in mouse was originally generated to study mechanisms of  (CGG)n 
instability 60, it turned out to be a suitable model to study FXTAS as well 32. Not only elevated Fmr1 mRNA 
levels, decreased Fmrp levels and instability of the (CGG)n upon transmission to the next generation 
mimic the situation in humans. Also the presence of intranuclear inclusions, the neuropathological 
hallmark of FXTAS, greatly adds to the value of this mouse model. Inclusions increase in size and 
number with age, paralleling the progressive nature of FXTAS (chapter 3 and 6, 32,61). In addition, 
behavioural studies revealed mild learning disabilities and motor problems in aged (CGG)n mice 
62. Thus, 
the expanded (CGG)n knock-in mouse model is a valuable tool to study the  molecular mechanisms 
underlying FXTAS, as well as the onset and progression of the disease.
However, some differences exist between the human and murine situation. As described in 
chapter 3, the (CGG)n in our mice has expanded to over 200 trinucleotides, which is in the full mutation 
range in humans. In humans this generally leads to methylation-mediated silencing of FMR1, but in our 
knock-in mice this has not occurred yet. Another Fmr1 expanded (CGG)n knock-in mouse model also 
yielded mice carrying alleles with over 200 CGGs that remained unmethylated 63. It has been proposed 
that the threshold for large increases in trinucleotide repeat length is higher in transgenic mice 64. Thus, 
as gene silencing in humans is preceded by a large ‘jump’ in repeat length, and since this kind of large 
expansions have not been seen frequently in our mice, the threshold for expansion-induced gene 
silencing might also be higher. 
It is interesting to note that the phenotype in the expanded (CGG)n mice is much less severe 
than it is in humans. A recent study that compared documented phenotypes of null mutations in 
humans and mice, showed that over 20% of mutations that in humans cause death before puberty 
(‘gene essentiality’), showed ‘nonessentiality’ for the mouse orthologue, meaning that mice survived up 
to reproductive age and were fertile 65. 
Aged (CGG)n mice only showed mild learning and motor impairment in comparison with age-
matched wt mice 62. Neuropathologically, human FXTAS brain shows more signs of neurodegeneration, 
as well as significant astrocytic involvement. Unlike in humans 19,66, mice do not have astrocytic 
inclusions. This could be due to the much lower expression or total absence of Fmr1 mRNA in mouse 
astrocytes 32. These differences might mean that astrocyte disease is important in the development of 
human disease, as has been suggested before 66. 
Studies in a transgenic mouse model for SCA7 showed dramatic Purkinje cell degeneration, even 
though the expanded (CAG)n-Ataxin7 construct was not expressed in Purkinje cells. This was interpreted 
as that polyglutamine-induced dysfunction in neighbouring cells contributes to neurodegeneration 
in Purkinje cells 67. As the cell bodies of Bergmann glia radial fibers surround Purkinje neurons and 
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the dendritic processes, these cells were investigated for having a role in Purkinje degeneration. 
A transgenic mouse model that expresses an expanded (CAG)n-SCA7 in Bergmann glia developed 
motor coordination problems, as well as Purkinje cell pathology. Bergmann glia are responsible for the 
removal of glutamate from Purkinje cell synaptic regions. GLAST is a glutamate transporter that is only 
expressed in Bergmann glia. GLAST expression, as well as glutamate uptake, was markedly reduced 
in presymptomatic expanded (CAG)n-SCA7 mice. These findings showed that expression of expanded 
(CAG)n-Ataxin7 in Bergmann glia is sufficient to cause Purkinje cell degeneration, through interfering with 
Bergmann glia-mediated glutamate uptake. Prolonged glutamatergic stimulation leads to glutamate 
excitotoxicity 68. Evidence is slowly accumulating that altered glutamate uptake may also contribute 
to other cerebellar disorders, such as SCA1, SCA5 and Huntington. Different glutamate transporters 
might disturb glutamate transport similarly, thereby causing different cerebellar and polyglutamine 
degenerative disorders 69-71. Similar glutamate excitotoxicity might underlie Purkinje cell degeneration 
in FXTAS. It would be interesting to see whether driving expanded (CGG)n expression in Bergmann 
glia aggravates the neurodegenerative phenotype in mice. Thus, also studying differences of disease 
development between mice and humans can provide important insight into disease mechanisms. 
 Individual variation in the manifestation of FXTAS  |  7.4
The core features of FXTAS are action tremor and cerebellar gait ataxia, but it can be accompanied by 
a wide range of other symptoms. Inter-individual variability of clinical involvement, as well as severity 
of the syndrome is large 72,73. All PM carriers have elevated FMR1 mRNA levels in blood, irrespective of 
whether they have FXTAS 13,22. It will be important to unravel factors that determine whether somebody 
will develop FXTAS or not, in addition to factors that influence the onset and severity of the clinical 
picture. It cannot be excluded that every PM carrier would develop FXTAS, if only he (or she) would 
become old enough. An MRI study showed subtle volumetric differences between PM carriers without 
FXTAS and controls, which might be early indicators of developing FXTAS at a later stage, which is 
associated with more prominent brain atrophy 74. However, PM carriers older than 80 years have been 
known that were devoid of any signs of FXTAS 75.  
The effect of genotype differences for the serotonin transporter polymorphism has been 
described to affect aggressive and stereotypic behaviour in boys with fragile X 76. Thus, although FXTAS, 
like fragile X syndrome, is commonly considered to be a single gene disorder, it might similarly be 
affected by the influence of modifying genes. Also the effect of aging or environmental factors on the 
severity of the phenotype cannot be excluded.
It is also still unknown whether inclusions form a direct link to the disease; the presence 
of inclusions is associated with FXTAS 19,66, but it remains to be elucidated whether inclusions are a 
prerequisite for the symptoms to manifest themselves, or alternatively, whether FXTAS can develop 
without inclusion formation. Thus, a clear causal relationship as found for the role of nuclear foci in 
myotonic dystrophy 31,77 remains to be established. Furthermore, it is interesting to know whether PM 
carriers that did not show signs of FXTAS also have inclusions. Over time, more brains of PM carriers with 
or without FXTAS will become available for research. This might reveal a basis for individual variation 
in the severity of the clinical outcome in patients with FXTAS. Presence of inclusions in certain brain 
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regions could play a role, but also size and quantity, or specific composition of the inclusions might 
affect individual clinical outcome. Also, studying more brains might shed light on to what extent 
inclusions can explain other symptoms associated with the PM. Several studies have reported clinical 
involvement in PM carriers, other than FXTAS. For instance, emotional problems, such as anxiety and 
depression, as well as mild cognitive impairment and autism spectrum disorder have been described 
(4,39,54,78,79). It is still unknown whether these symptoms reflect prodromal symptoms, or a milder form of 
RNA pathogenesis or a consequence of mildly reduced FMRP levels. 
Most alleles in the general population are interspersed with an AGG, about every (CGG)9 
80-82. The 
expansion process of the (CGG)n is believed to begin with loss of the most 3’ AGG interruption 
80,83. Most 
PM alleles only have one AGG at the 5’ end of the (CGG)n, or none at all 
80,82,84. Interruptions determine 
the likelihood of the repeat to fold into hairpins, as well as the stability of these hairpins. This can lead 
to instability of the repeat, as hairpins may cause slippage of the replication fork 80,85. It may also affect 
binding of (CGG)n-BPs, thereby possibly affecting the extent to which cellular dysfunction develops. 
Napierala and colleagues postulated that interruption-dependent structure variants of the FMR1 mRNA 
affect the phenotype in PM carriers. Indeed they found that AGG interruptions shorten the effective 
length of a pure (CGG)n hairpin, and hypothesised that this may protect the PM carrier from developing 
FXTAS. Their proposal that AGG interruption status can influence the correlation between repeat length 
and clinical outcome may, however, particularly be important for short PM alleles 86. Thus, it will be 
interesting to check AGG interruption patterns in a large cohort of PM carriers, with or without FXTAS, 
to reveal whether a correlation exist with clinical outcome.
Interestingly, the expanded (CGG)n in our knock-in mouse model does not have any 
AGG interruptions. If the above is true, one would expect less individual variation in the clinical or 
neuropathological outcome. Indeed, all mice develop inclusions. However, it cannot be ruled out that 
also PM carriers who do not develop FXTAS have inclusions.
(CGG)n instability  |  7.5
All known trinucleotide repeat disorders result from (CNG)n expansions, where N can be any nucleotide. 
Although the different repeats share some aspects of repeat instability (described in chapter 2), there 
might also be some fundamental differences. The specific sequence determines the propensity to form 
secondary structures such as hairpins and the stability thereof 87-89. The hairpin-like structures formed 
by single stranded (CNG)n consist of both Watson-Crick and mismatched base pairs. The stability of 
these imperfect hairpins is dependent on the sequence, due to the free energy contribution of the 
mismatched base pairs. Hairpins made of (CGG)n are most stable, (CTG)n is a bit less stable, followed by 
(CAG)n and (CCG)n with similar stability 
87. 
Although 64 (43) triplet compositions are possible, large expansions have only been observed 
in two trinucleotide groups, namely (CAG)·(CTG) and (CGG)·(CCG), which are the repeats responsible 
for the majority of trinucleotide repeat disorders. This sequence selectivity cannot solely be explained 
by GC-content or the frequency of occurrence in the genome. (CAG)·(CTG) and (CGG)·(CCG) both 
contain purine and pyrimidine bases. (CCA)·(TGG), another GC-rich group that is overrepresented in 
the genome, is similar in that respect, but to date no disease has been found to be associated with 
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this repeat 90. Both a correct sequence and a correct repeat length need to be present in order to form 
hairpins of the threshold energy needed for the large expansions associated with human disease. These 
criteria are only met for (CAG)·(CTG) and (CGG)·(CCG) 87.
Analysis of (CGG)n with or without AGG interruptions showed that the presence of an interruption 
greatly affects the free energy of a hairpin. Alleles with AGG interruptions form hairpins with energies 
below the threshold for expansion. Loss of an interruption by a single point mutation causes formation 
of a hairpin with an energy much greater than the threshold for expansion, allowing expansion of the 
repeat. This is another clear indication that the exact sequence determines the energy of a hairpin and 
thereby its stability 87. However, a more recent melting study showed that an AGG interruption did 
not have a significantly different thermodynamic stability at near physiological MG2+ concentrations. 
However, this study found evidence for the presence of a G·G non-Watson-Crick base pair in a (CGG)n 
duplex RNA, that increases the free energy of the hairpin 91.
Another aspect that might cause the (CGG)n to behave differently from other trinucleotide 
repeats, is its X-chromosomal location. Although some instability was seen upon transgenically 
expressing a YAC carrying the FMR1 with a PM-sized (CGG)n with a substantial amount of flanking 
region 92, only large (CGG)n instability was seen after expanded (CGG)n knock-in mouse models were 
generated (chapter 3, 61,63). This suggests that factors causing repeat instability exist, related to the 
X-chromosome, that could not be mimicked when the YAC carrying the (CGG)n with flanking regions 
was randomly integrated and thus autosomally expressed. It is unknown whether meiosis plays a 
role herein. 
Furthermore, the (CGG) n is different from some other (CNG)n in that it does not show 
substantial somatic instability. It is as yet unknown whether this is the result of the same mechanism as 
which causes intergenerational instability. In addition, timing of instability could vary among different 
trinucleotide repeats. For instance, although most evidence points at a prezygotic origin of the FMR1 
(CGG)n instability (outlined in chapter 2), in DM1, intergenerational instability appears to result not only 
from (CTG)n instability in the germ line of the transmitting father, but another instability event occurring 
shortly after fertilisation also appears to take place 93.
These factors likely contribute to the observation that, despite similarities, different 
trinucleotide repeats do behave differently (discussed in more detail in chapter 2). One should keep 
this in mind when wanting to extrapolate observations on repeat behaviour of other trinucleotides to 
(CGG)n instability.
(CGG)n  transmission and gene silencing in the mouse model  |  7.6
Both humans and (CGG)n mice show a bias towards (CGG)n expansions, when transmitting PM alleles 
to the next generation. While in humans, risk of expansion appears to be greater when the expanded 
(CGG)n allele is of maternal origin and large increases into the FM range are exclusively seen when 
the repeat allele is maternally transmitted 94, no difference in direction or magnitude of the instability 
between maternal or paternal transmission was seen in mice (chapter 3, 61). Gender of offspring has no 
effect on the risk of expansion to an FM in humans 95, neither on direction or magnitude of instability in 
(CGG)n mice (chapter 3, 
61). It should be noted, that in mice, only occasional large expansions have been 
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observed. The resulting (CGG)n lengths would be considered FMs in humans, however, thus far they 
remain unmethylated in mice (chapter 3, 61,63). Thus, as yet, the expanded (CGG)n knock-in mice are not 
an appropriate model to study gene silencing. 
Although the current hypothesis is that expansions to an FM occur prezygotically, followed by selection 
for PM alleles in sperm, the fact that expansion to an FM only occurs upon maternal transmission might 
also suggest that men lack specific factors that allow this expansion event, or it may mean that men 
possess other factors that prevent this expansion from taking place. Both scenarios could also be true 
for our mouse model.
Only time will tell whether methylation-mediated silencing of the Fmr1 gene will happen in 
mice. It is possible that mice are not equipped with the same methylases and histone deacetylases that 
are responsible for the silencing of FMR1 in humans. It is clear that, if inactivation of Fmr1 will happen 
in mice, it will do so at a higher threshold (CGG)n length than in humans. It has indeed been proposed 
before that the threshold for large expansions is higher in mice than in men 64. Such large jumps in 
repeat length with major phenotypic consequences have been observed in a transgenic mouse model 
for DM1 96, but this is no guarantee that the same could happen with (CGG)n  in Fmr1. In case our mice 
will undergo a transition to the FM situation, such that Fmr1 gets inactivated, the order of events in 
this transition will be the focus of our attention. Studying the gonads of the transmitting parents as 
well as early embryos will shed light on the timing of expansion and the accompanying gene silencing 
events. It will be interesting to elucidate whether the same methyl binding proteins recognise the 
methylated CpGs and subsequently recruit proteins that deacetylate and affect methylation status of 
certain histone tails, as in humans (outlined in more detail in chapter 1). Ultimately, this might provide 
a model in which ways to modify Fmr1 gene activity can be tested. Also without gene silencing taking 
place, studies in our mice might also provide information on the moment of expansion, by looking at 
germ cells and the early embryo. This, however, is currently highly challenging, given the small repeat 
length changes that we see between different generations. 
Up till now, we have only checked for methylation of the Fmr1 promoter region as a screening 
method to reveal gene silencing. A recent study in human embryonic stem cells carrying an FM 
suggests that chromatin changes precede methylation of the promoter region and that methylation 
might contribute to maintenance rather than to the induction of the transcriptionally inactive state. 
Reduction of H3 tail acetylation and H3K9 becoming methylated, both associated with reduced gene 
activity, were observed in combination with a hypomethylated FMR1 5’UTR 97. Until our mice have 
proven to be an appropriate model to study epigenetic changes in the Fmr1 silencing process, these 
embryonic stem cells might provide a good alternative. However, the teratomas generated by inducing 
differentiation of the stem cells have a limited life span, so they cannot provide as much information as 
a living, complex organism would. 
To our knowledge, these histone modifications or chromatin changes have not been studied 
in carriers with high end PM alleles, thus it is not known whether some of these changes might already 
occur before FMR1 gets fully inactivated. It could be proposed that the lack of elevated Fmr1 mRNA 
levels in (CGG)n mice with >150 CGGs represent a transition phase in which histone tail modifications 
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lead to partial chromatin condensation, without inducing methylation of the Fmr1 promoter region. 
It might therefore be informative to investigate histone tail modifications in mice with (CGG)151-200 and 
(CGG)>200. 
Two brothers, grandfathers of boys with fragile X, who carry an unmethylated FM allele and do not show 
the fragile X phenotype 98, might also represent such a transition state, as they escaped methylation, 
despite having a (CGG)n in the FM range. Although these brothers are mosaic for a PM in blood leukocytes, 
analysis of a cell line derived from one of these high functioning males, revealed a (CGG)~400, which 
was unmethylated. This cell line has deacetylated histones and methylated lysine 9 of histone 3, as is 
normally found in fragile X cell lines, while also showing high levels of methylated lysine 4 of histone 
3, which is correlated with active transcription in normal controls. Indeed FMR1 mRNA is detected 
at normal levels in this cell line. FMRP is also detected, although at about 20-30% compared with a 
normal cell line. Thus, the FM length (CGG)n reduces translational  efficiency 
99. Molecular epigenetic 
characterisation of cell lines of two newly identified individuals without an apparent phenotype but 
with unmethylated full mutations, revealed similar characteristics as the cell line with an unmethylated 
(CGG)~400 described above. It was concluded that DNA methylation is the critical step in the silencing of 
FMR1. The suggestion that a common mechanism exists for these rare unmethylated FM alleles, might 
be important in view of therapeutic strategies. It would be worthwhile to investigate options to convert 
methylated into unmethylated alleles, to restore FMR1 expression 100.
A combination of research in these cells with unmethylated FM alleles, the FM human 
embryonic stem cell line and hopefully in due time the mouse model that shows (CGG)n expansion-
induced Fmr1 silencing will likely complete the puzzle of epigenetic events involved in inactivation of 
FMR1. 
Concluding remarks and future directions  |  7.7
The work in this thesis has attempted to unravel part of the mechanisms underlying FXTAS, by using 
the expanded (CGG)n knock-in mouse model. Transmission of the (CGG)n in mice has been studied 
and molecular changes accompanying (CGG)n expansion have been characterised. Studies in (CGG)n 
mice suggest that inclusions are indeed related to the expanded (CGG)n RNA and links to the clinical 
outcome in humans can be drawn. Preliminary findings of cellular stress in human FXTAS brain and 
cell lines might shed light on the nature of the cellular dysfunction induced by the (CGG)n RNA. The 
main question remains however; namely how the (CGG)n RNA leads to formation of inclusions and 
how cellular dysfunction originates, ultimately leading to neurodegeneration and clinical problems. 
Future studies should focus on the identity and role of (CGG)n-BP, and the cellular consequences of their 
binding. If these proteins are indeed sequestered away from their normal function, as the toxic RNA 
gain-of-function model predicts, their function might provide important links between the mutant 
RNA and clinical symptoms. 
The mouse model will remain valuable since the onset as well as the course of disease can be 
studied. Not only symptoms associated with FXTAS, but also prodromal symptoms should be the focus 
of attention, although the latter might be challenging to study in mice, due to their subtle nature. Since 
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the fibroblast cell lines derived from patients and expanded (CGG)n mice mimic signs of cellular stress 
seen in FXTAS brain, further characterisation of these cells might also proof valuable in recognising 
early signs of cellular dysfunction. 
The (CGG)n mice will furthermore be valuable in attempts at reversing the neurodegenerative phenotype. 
Conditional transgenic mice can provide important information, when Fmr1 expanded (CGG)n transgene 
expression can be directed to certain tissues or turned off or on in certain time windows. Therapeutic 
strategies will likely focus on diminishing (CGG)n mRNA levels. The studies conducted in Drosophila are 
promising in this light, as reversing the negative effect of the expanded (CGG)n RNA by co-expressing 
an anti-sense repeat or by overexpressing the proteins sequestered to the repeat RNA, rescued the 
neurodegenerative phenotype. Hence, strategies involving the siRNA pathway might prove beneficial 
in the future. In addition, when more (CGG)n-BPs will be identified, this might provide new therapeutic 
targets.
This thesis has not focused on the effect of the expanded (CGG)n in female mice, in relation to 
the risk of developing premature ovarian insufficiency. Preliminary data suggest that female (CGG)n mice 
indeed have lower AMH levels, representing a smaller follicle pool. Additional studies will likely confirm 
that expanded (CGG)n mice are also a valuable model for premature ovarian insufficiency seen in female 
PM carriers. This research might also shed light on the link between the presence of inclusions in brain 
or other organs and clinical consequences. 
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Samenvatting  |
Het FMR1 gen, gelegen op het X chromosoom, heeft een aaneenschakeling van CGG trinucleotiden in 
een DNA regio die wel als RNA wordt afgeschreven, maar niet naar eiwit wordt vertaald. In 1991 werd 
ontdekt dat deze CGG herhaling ((CGG)n) in lengte kan variëren, doordat hij instabiel is bij overerving. 
Een lengte van meer dan 200 CGGs bleek verantwoordelijk voor het fragiele X syndroom, dat zich met 
name uit in mentale retardatie. Deze (CGG)n is een van de eerste instabiele, verlengde trinucleotide-
herhalingen die geïdentificeerd zijn als genetische oorzaak van een neurologische aandoening. In 
de normale populatie is de (CGG)n in het FMR1 gen tussen de 5 en 55 CGGs lang. Wanneer de (CGG)n 
langer is dan 200 trinucleotiden (volledige mutatie: FM), wordt deze doorgaans gemethyleerd, evenals 
de promoter regio van het FMR1 gen. Dit resulteert in een inactivatie van het gen, waardoor het eiwit 
FMRP niet wordt gemaakt. In uitlopers van neuronen reguleert FMRP het transport en de vertaling van 
bepaalde mRNA moleculen naar eiwitten. FMRP beïnvloedt in deze dendrieten de plasticiteit van de 
synaps: de ruimte tussen twee neuronen waar de signaaloverdracht plaatsvindt. Hierdoor speelt het 
een belangrijke rol bij leerprocessen en geheugen. De afwezigheid van FMRP in neuronen resulteert in 
de verstandelijke handicap bij fragiele X patiënten. 
Lang werd gedacht dat mensen met een (CGG)n lengte van tussen de 55 en 200 (premutatie: 
PM) geen risico op klinische problemen lopen, behalve de mogelijkheid dat bij vrouwen de (CGG)n 
lengte bij overdracht naar de volgende generatie kan verlengen tot een FM, waardoor het fragiele X 
syndroom optreedt bij het nageslacht. In 2001 werden echter de eerste PM dragers beschreven die op 
latere leeftijd een neurologisch syndroom hadden ontwikkeld. Dit progressieve, neurodegeneratieve 
syndroom werd fragiele X-geassocieerd tremor/ataxie syndroom (FXTAS) genoemd, naar de twee 
belangrijkste symptomen waarin het syndroom zich uit. Inmiddels zijn veel meer patiënten met deze 
aandoening beschreven. Het blijkt dat het syndroom een zeer grote individuele variabiliteit kent wat 
betreft ernst, verloop en verscheidenheid aan symptomen. FXTAS patiënten kunnen naast eerder 
genoemde symptomen ook onder meer Parkinsonisme ontwikkelen, alsmede problemen bij het 
uitvoeren van dagelijkse handelingen en op termijn ook cognitieve achteruitgang. 
Alle PM dragers hebben verhoogde FMR1 mRNA niveaus. Omdat zij ongeveer normale 
hoeveelheden eiwit hebben én omdat in oudere FM dragers geen symptomen van FXTAS zijn gezien, 
is het niet aannemelijk dat een gebrek aan FMRP de oorzaak is van het ontwikkelen van FXTAS. De 
hypothese is daarom dat de aanwezigheid van teveel FMR1 mRNA, dat een verlengde (CGG)n bevat, 
voor problemen zorgt in cellen in het brein, hetgeen uiteindelijk voor de klinische symptomen zorgt. 
Een indicatie hiervoor is onder andere de detectie van FMR1 mRNA in de eiwitinsluitsels (‘inclusies’) die 
in celkernen gezien worden in diverse regios van de hersenen van overleden FXTAS patiënten. 
Er is nog veel onduidelijk over de ontstaanswijze van de klinische symptomen bij FXTAS 
patiënten. Tevens is onbekend waarom sommige dragers van de PM wel FXTAS ontwikkelen en anderen 
niet. Onderzoek naar het onderliggende mechanisme van dit syndroom is in mensen beperkt tot post 
mortem hersenmateriaal, dus in het eindstadium van de ziekte. Om het ontstaan en het verloop van 
de ziekte te kunnen bestuderen, kan een muismodel een waardevol hulpmiddel zijn. In ons lab is een 
genetisch gemodificeerde muis ontwikkeld, die als model dient voor FXTAS. De (CGG)8 die een normale 
muis in zijn Fmr1 gen heeft, is vervangen door een humane (CGG) 98. Dit muismodel werd ontwikkeld 
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om de instabiliteit van de (CGG)n te kunnen bestuderen. Toen FXTAS voor het eerst beschreven werd, 
bleek de verlengde (CGG)n muis ook een geschikt model te zijn voor dit syndroom, aangezien het naast 
de (CGG)n instabiliteit, ook de verhoogde Fmr1 mRNA niveaus en de vorming van inclusies nabootst. 
Het doel van dit onderzoek was middels dit muismodel meer inzicht te verkrijgen over het 
ontstaansmechanisme van FXTAS. 
Hoofdstuk 1 van dit proefschrift geeft een algemene inleiding op de eigenschappen van 
het FMR1 gen, FMRP en de verschillende syndromen die daaraan gerelateerd zijn. De bevindingen en 
hypotheses over de onderliggende pathogenese worden beschreven, alsmede bestaande diermodellen 
om dit te onderzoeken. 
Hoofdstuk 2 gaat uitgebreid in op verscheidene neurodegeneratieve ziekten, die allen 
veroorzaakt worden door een verlengde trinucleotideherhaling. Zowel de overeenkomsten als de 
verschillen tussen deze ziekten worden belicht. Verschillende mechanismen die ten grondslag liggen 
aan deze aandoeningen worden besproken, evenals het moment en de wijze waarop de verlenging 
van de trinucleotideherhalingen zou kunnen plaatsvinden. Diverse factoren die van invloed blijken te 
zijn op instabiliteit van trinucleotideherhalingen worden beschreven. 
Hoofdstuk 3 laat zien dat, hoewel de (CGG)n in ons muismodel inmiddels is verlengd tot 
meer dan 200 trinucleotiden, er geen methylatie en dus inactivatie van het Fmr1 gen optreedt, wat 
in mensen bij deze lengte gewoonlijk wel gebeurt. De muis produceert nog steeds Fmrp, hoewel 
deze eiwitniveaus wel aanzienlijk lager zijn dan bij muizen met een kortere (CGG)n. Het patroon van 
overerving van de (CGG)n blijkt niet verschillend te zijn voor de overdracht door de vader of de moeder, 
hoewel bij mensen expansie naar een volledige mutatie alleen wordt gezien wanneer een moeder haar 
X-chromosoom doorgeeft.
Hoofdstuk 4 gaat in op de veranderingen die in de cel plaatsvinden, als gevolg van 
expressie van verlengde (CGG)n FMR1 mRNA. Een verstoring van de lamine-architectuur en een stress-
geïnduceerde activatie van ‘heat shock’ eiwitten worden gezien in zowel post mortem hersenmateriaal 
en huidfibroblasten-cellijnen van FXTAS patiënten, als ook in fibroblasten-cellijnen van verlengde 
(CGG)n muizen. Dit impliceert dat cellijnen in de toekomst mogelijk ook nuttige informatie kunnen geven 
over de verstoring van de celfunctie, aangezien zij bepaalde veranderingen in het brein nabootsen, 
maar relatief eenvoudig te verkrijgen zijn terwijl de patiënt nog in leven is.
Hoofdstuk 5 beschrijft veranderingen in het functioneren van de hypothalamus-hypofyse-
bijnier as (de ‘stress-as’) die werden gezien in de (CGG)n muizen. Er zijn aanwijzingen dat PM dragers 
meer psychiatrische problemen als depressie, angst en agressie vertonen, welke veroorzaakt zouden 
kunnen worden door verhoogde stresshormoonniveaus. (CGG)n muizen bleken inderdaad significant 
verhoogde stresshormoonniveaus te hebben in vergelijking tot normale muizen. Organen betrokken 
bij de stress-as laten ook inclusies zien, hetgeen ook als indicatie kan worden opgevat dat de regulatie 
van de stress-as anders is dan in normale muizen. Het is echter nog onduidelijk hoe verhoogde mRNA 
niveaus, die de verlengde (CGG)n, bevatten zouden kunnen leiden tot de beschreven effecten. 
Hoofdstuk 6 beschrijft de onderlinge verbanden tussen (CGG)n lengte, Fmr1 mRNA niveaus, 
Fmrp niveaus en de hoeveelheid inclusies in bepaalde hersengebieden in muizen met verschillende 
(CGG)n lengtes. Als inclusies direct gerelateerd zijn aan de klinische gevolgen, suggereren de beschreven 
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resultaten mogelijk dat niet zozeer de precieze hoeveelheid Fmr1 mRNA belangrijk is voor de vorming 
van inclusies en daarmee cellulaire problemen en uiteindelijk klinische symptomen, maar dat de 
aanwezigheid van het verlengde (CGG)n mRNA op zich reeds voldoende is. De resultaten laten ook zien 
dat er zowel een onder- als een bovengrens van (CGG)n lengte bestaat voor de vorming van inclusies. 
Hoofdstuk 7 vormt een algemene discussie waarin de resultaten van dit promotieonderzoek 
en de huidige stand van zaken in dit onderzoeksveld worden besproken. Ondanks dat de (CGG)n lengte 
de humane drempel van FMR1 gen inactivatie heeft overschreden, is het Fmr1 gen in de muis nog actief. 
Dus is de verlengde (CGG)n muis momenteel nog geen goed model om de gebeurtenissen rondom deze 
inactivatie te bestuderen. Het is echter wel een geschikt model om het ontstaan en het verloop van de 
neuropathologische, biochemische en gedragsmatige kenmerken van FXTAS te bestuderen. Het is nog 
onduidelijk waarom sommige PM dragers FXTAS ontwikkelen en anderen niet. Ook is het onbekend 
hoe en waarom inclusies ontwikkelen en wat zij betekenen in de pathogenese; zijn ze de bron of 
slechts een bijproduct van de cellulaire dysfunctie? Toekomstig onderzoek zal zich ook moeten richten 
op mogelijke eiwitten die een interactie aangaan met (CGG)n mRNA, welke volgens het hypothetisch 
model weggevangen worden van hun normale functie en zodoende mogelijk verantwoordelijk zijn 
voor een verstoorde celfunctie. Aangezien bij patiënten de FMR1 mRNA niveaus gemeten zijn in bloed, 
is het niet bekend of deze ook verhoogd zijn in brein. Alleen als verhoogde mRNA niveaus cruciaal zijn 
voor ontwikkeling van neurotoxiciteit, is het relevant om de mogelijkheden tot verlaging van de FMR1 
mRNA niveaus te onderzoeken, om zo mogelijkheden voor therapeutische interventie te vinden.
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The FMR1 gene, located on the X chromosome, harbours a CGG-trinucleotide repeat in a DNA region 
that is transcribed into RNA, but is not translated into protein. In 1991 it was discovered that this CGG 
repeat ((CGG)n) can vary in length, since it is unstable upon transmission to the next generation. A 
length exceeding 200 CGGs turned out to be responsible for fragile X syndrome, which presents itself 
as mental retardation. This (CGG)n is one of the first trinucleotide repeats identified to be the genetic 
cause of a neurological disorder. In humans, the (CGG)n in the FMR1 gene is between 5 and 55 CGGs 
long in the normal population. Both the FMR1 promoter region and the (CGG)n become methylated 
when the (CGG)n exceeds 200 trinucleotides (full mutation: FM),. This results in inactivation of the gene, 
thus preventing the protein product FMRP from being synthesised. FMRP regulates transport and 
translation of certain mRNA molecules in neural processes. By affecting the plasticity of synapses (the 
space between two neurons where signal transduction takes place) in these dendrites, FMRP plays an 
important role in learning and memory processes. The absence of FMRP in fragile X patients therefore 
results in mental retardation.
It was long thought that people with a (CGG)n length of between 55 and 200 (premutation: 
PM were not at risk of clinical consequences, except for the possibility of expansion of the (CGG)n length 
to an FM, upon transmission to the next generation, which would cause the child to have fragile X 
syndrome. In 2001 however, some aged PM carriers were described to have developed a neurological 
syndrome. This progressive, neurodegenerative disorder was called fragile X-associated tremor/ataxia 
syndrome (FXTAS), after the two most prominent clinical symptoms with which FXTAS patients usually 
present. In the meantime, many more patients have been described and it is now known that this 
syndrome shows major interindividual variability with regard to the severity and the range of clinical 
involvement. FXTAS patients likely develop Parkinsonism, executive defects and in a later stage also 
cognitive decline, among many other possible symptoms.
All PM carriers have elevated FMR1 mRNA levels. Because their FMRP levels are close to 
normal, and since no signs of FXTAS have been observed in elderly FM carriers, it is unlikely that an 
FMRP deficiency is the cause of developing FXTAS. Thus, the working hypothesis is that the presence 
of elevated FMR1 mRNA, containing an expanded (CGG)n, can cause problems in brain cells, ultimately 
leading to clinical symptoms. An indication that this might be the case, comes from the observation 
that FMR1 mRNA has been detected in the intranuclear protein inclusions seen in many regions of post 
mortem brains of FXTAS patients .
The origin of the clinical symptoms in FXTAS remains to be elucidated. In addition, it is 
unknown why some PM carriers develop FXTAS, while others do not. Research into the underlying 
mechanism of this syndrome in humans is limited to post mortem brain material, thus, the end stage 
of the disease. To investigate the onset and development of the disorder, a mouse model could be a 
valuable tool. A genetically modified mouse has been generated in our lab, which serves as a model for 
FXTAS. The endogenous mouse Fmr1 (CGG)8 was exchanged with a human (CGG)98. This mouse model 
was originally developed to study (CGG)n instability and possibly silencing of the Fmr1 when the (CGG)n 
would reach sufficient length. However, when FXTAS was first described, the expanded (CGG)n mice 
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turned out to be a good model for this syndrome as well. Not only (CGG)n instability, but also elevated 
Fmr1 mRNA levels and inclusion formation mimic the human situation.
The aim of this research was to use the expanded (CGG)n mouse model to unravel aspects of 
the mechanisms underlying FXTAS.
Chapter 1 of this thesis gives a general introduction about the characteristics of the FMR1 
gene and the syndromes associated with it. Observations and hypotheses on the underlying pathogenic 
mechanisms are discussed, as well as existing animal models used to study this.
Chapter 2 extensively describes various neurodegenerative disorders, which are all caused 
by expanded trinucleotide repeats. Similarities, as well as differences between these diseases are 
discussed. The different mechanisms underlying the disorders, as well as the timing and the molecular 
mechanism of the trinucleotide repeat expansions are considered. Several factors that have been 
shown to influence trinucleotide repeat instability are touched on.
Chapter 3 shows that in our mice no methylation, thus no Fmr1 gene silencing has taken place, 
although the (CGG)n expanded to over 200 trinucleotides. This length would generally induce gene 
inactivation in humans. (CGG)>200 mice still produce Fmrp, albeit at lower levels than in mice with shorter 
(CGG)n. The (CGG)n transmission pattern is the same for transmission through the father or the mother, 
although in humans more instability is seen upon transmission of the maternal X chromosome. 
Chapter 4 looks into the cellular changes, as a result of expression of an expanded (CGG)n. 
Disturbed lamin-architecture and stress-induced activation of heat shock proteins is seen in post mortem 
brain material and skin fibroblast cell lines of FXTAS patients, as well as fibroblast lines obtained from 
expanded (CGG)n mice. This suggests that cell lines may provide useful information about the cellular 
dysfunction, since they mimic certain changes seen in brain. Naturally, they are more easily accessible 
and available while the patient is still alive.
 Chapter 5 describes altered functioning of the hypothalamo-pituitary-adrenal axis (‘stress 
axis’) in (CGG)n mice. Evidence exists that PM carriers develop more psychiatric problems such as 
anxiety, aggression and depression, which could be caused by elevated stress hormone levels. (CGG)n 
mice indeed showed higher stress hormone levels as compared with normal mice. Organs involved in 
the stress axis also bear inclusions, which might be interpreted that stress axis regulation is aberrant in 
(CGG)n mice. It remains to be elucidated how elevated expanded (CGG)n mRNA levels could lead to the 
effects described. 
Chapter 6 describes correlations between (CGG)n length, Fmr1 mRNA levels, Fmrp levels and 
the proportion of inclusion-bearing cells in (CGG)n mice with different (CGG)n lengths. If inclusions can 
directly be linked to clinical outcome, the results possibly suggest that not so much the precise amount 
of Fmr1 mRNA is important for inclusion formation, but instead the mere presence of the expanded 
(CGG)n mRNA . The results furthermore suggest that a lower as well as an upper threshold (CGG)n length 
exists for inclusions formation.
Chapter 7 is an overall discussion of the results presented in this thesis and the current 
status of this research field. Since Fmr1 gene silencing has not taken place yet, despite having reached 
the human threshold (CGG)n length for this event, the expanded (CGG)n mouse is currently not an 
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appropriate model to study the events associated with Fmr1 inactivation. It is, however, a suitable model 
to study the onset and the course of the biochemical, neuropathological and behavioural parameters. 
It is unclear why some PM carriers develop FXTAS, while others do not. Furthermore, it is unknown how 
and why inclusions are formed and what they mean in the pathogenesis of FXTAS: are they a by-product 
or the source of cellular dysfunction, or do they even exert a protective effect? Future research should 
focus on proteins that might interact with expanded (CGG)n mRNA. According to the hypothetical 
pathogenesis model, such proteins are sequestered away from their normal function, thereby causing 
disturbed cellular function. In addition, the possibilities of decreasing FMR1 mRNA levels should be 
explored, since this may prove promising in light of therapeutic intervention strategies.
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Figure 1.1  |  (CGG)n length and FMR1 expression and clinical outcome. This figure shows the consequences of the different repeat length categories on 
transcription, translation and clinical phenotype. (Adapted from 76 with permission of the authors.)
Figure 1.2  |  Ubiquitin-positive intranuclear inclusions, the neuropathological hallmark of FXTAS in A: human neurons, B: human astrocytes, C: murine 
neurons. No inclusions have been seen in murine astrocytes. 
A B C
CHAPTER 1 - colour figures 165
Figure 1.3  |  A schematic representation of the RNA gain-of-function mechanism proposed for the pathogenesis of FXTAS. The FMR1 gene is 
transcribed in the nucleus and transported to the ribosomes. The expanded (CGG)n present in the 5’UTR of the FMR1 gene hampers translation, leading to 
lower FMRP levels. Through an as yet unknown mechanism, transcription is upregulated, leading to increased FMR1 mRNA levels. In an attempt to get rid 
of the excess of FMR1 mRNA, the cell might attract chaperones or elements of the ubiquitin/proteasome system. Also (CGG)n-binding proteins might be 
recruited. These processes could lead to formation of intranuclear inclusions. Sequestration of proteins into the inclusions might prevent them from exerting 
their normal function, thereby disturbing cellular function, which in the end might cause neurodegeneration. Also, it cannot be excluded that neuroprotection 
takes place, such that cells that are capable of capturing the toxic transcripts in the inclusions are the cells that survive. 
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Figure 2.1  |  Location of repeats within genes in relation to pathogenic mechanism. This schematic gene shows all microsatellite repeats described 
in this chapter, with their location within the gene. The colours indicate which pathogenic mechanism is thought to underlie the associated diseases. All 
repeats depicted above the gene are located in a coding sequence of the gene, while all repeats below are in non-coding regions. Please refer to the text and 
table 2.1 for further information regarding these repeats, genes and associated disorders.
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Figure 2.2  |  The prezygotic model of expansion of 
the fragile X mutation. This model assumes that an 
expansion of a maternal PM to an FM takes place during 
meiosis. The fertilised oocyte carries an FM allele. After 
separation from the embryo proper, the primordial germ 
cells (PGCs) have an FM. Some alleles will contract to PMs. 
To explain why FMs are only transmitted through females, 
some selection must exist agains FMs in the male germ line 
during spermatogenesis. In the mature testes, PM alleles 
predominate. In somatic cells and the female germ line, 
this selection did not take place. Cells with a PM are shown 
ingreen and cells with an FM are depicted in orange 
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Figure 2.3  |  Replication fork  progression and repeat instability. During normal replication, helicases break the hydrogen bonds that keep the 
two DNA strands together, which yields the replication fork. DNA polymerase can only synthesise a new strand in a 5’ to 3’ direction. Hence, on one strand 
(leading strand) DNA polymerase reads the DNA and adds nucleotides to the nascent strand in a continuous matter. On the other strand (lagging strand) the 
complementary strand is synthesised in short segments (Okazaki fragments) at a time, that are later joined together by DNA ligase. Formation of secondary 
structures, such as hairpins can form in one of the strands. This can impair normal replication fork processing. The sequence of the strands, together with the 
position of the origin of replication with respect to the repeat sequence, determine which strand is more prone to form hairpins. Whether a hairpin is present 
in the template or nascent strand, in turn determines whether contraction or expansion results in the next round of replication.
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Figure 3.5  |  Mouse brains from wt (A and B), Fmr1 KO (C and D) and the mouse with >230 CGGs (E and F) were stained with antibodies against Fmrp. Photos 
A,C and E show hippocampus and B,D, and F show cortex tissue. DG: dentate gyrus
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Figure 4.3 |  Post mortem skin biopsy in a case (468-05) with FXTAS 
displays frequently distorted nuclear ring-like distribution of 
lamin A/C (lower panel) compared to an age-matched control (upper 
panel). Green, lamin A/C; blue, DAPI staining of nuclei.
Figure 4.6 |  Immunocytochemical localisation of lamin C and αB-crystallin in mouse embryonic fibroblasts. Lower panel: mouse fibroblasts 
harbouring the expanded-CGG-repeat display irregular nuclear morphology (nuclei counterstained with DAPI, blue), marked lamin C disruption and 
aggregation with loss of the normal ring-like architecture (green), and an increased number of perinuclear aggregates containing αB-crystallin (red).
Figure 4.5 |  Increased nuclear area in human fibroblasts from a patient with FXTAS.  Morphometric values of individual human skin fibroblasts 
contoured on the basis of DAPI fluorescence. (A) Distribution of the nuclear areas of 2013 fibroblasts derived from an 87-year old normal control (C3). (B) The 
nuclear areas of 2009 fibroblasts derived from an 80-year old patient with severe FXTAS (P6) exhibit a broader distribution of nuclear areas, with an average 
1.3-fold increase, compared to the age-matched control (overlay tracing of the distribution in part A).
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Figure 5.3  |  Immunohistochemistry with antibodies against ubiquitin and Fmrp in pituitary gland of 100-week old CGG mice. A: Many intranuclear 
ubiquitin-positive inclusions (arrows) are seen in the pars intermedia, while hardly any were observed in the pars posterior. B: Ubiquitin-positive inclusions 
in the pars intermedia. C: Highest levels of Fmrp are observed in the pars intermedia. D: Fmrp expression in the pars intermedia. PA: pars anterior, PI: pars 
intermedia, PP: pars posterior.
Figure 5.4  |  Immunohistochemistry with an antibody against ubiquitin show ubiquitin-positive inclusions in adrenal gland of 100-week old CGG mice. A: 
Ubiquitin-positive intranuclear inclusions (arrows) in chromaffin cells of the adrenal gland. B+C: Elongated, irregularly shaped ubiquitin-positive intranuclear 
inclusions in the zona fasciculata of the adrenal gland. D: Cytoplasmic inclusions (arrow heads) in the zona fasciculata of the adrenal gland. 
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Figure 5.5 | Ubiquitin-positive intranuclear inclusions in the 
amygdala of a 100-week old CGG mouse. A en B show the 
posteromedial amygdalohippocampal nucleus, where B is a 
higher magnification of what is seen in A.
Figure 6.1 | No ubiquitin-positive inclusions are seen in the 
colliculus inferior of 72-week old mice with (CGG)70 (A), while 
mice with (CGG)106 do show ubiquitin-positive inclusions (B) brown, 
round intranuclear staining). Immunohistochemistry for Fmrp in 
cortex of (CGG)70 (C) and wt (D) animals gives a similar staining 
pattern.
A B
C D
Figure 6.3 | B: Dentate gyrus of an animal with (CGG)106 that does 
not show intranuclear inclusions, while a mouse with (CGG)130 
(C) does.
B C
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Figure 6.4 | Ubiquitin-positive 
inclusions are present in colliculus 
inferior (A-C) and dentate 
gyrus (D-F) of mice with (CGG)130 
and (CGG)180, but not  in mice with 
(CGG)>200.
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Figure 6.6  |  Summary of the molecular correlates. Fold change Fmr1 mRNA (left y-axis), % Fmrp and % of inclusion-bearing neurons in colliculus 
inferior and dentate gyrus  (right y-axis) are given. Please refer to the individual graphs for an indication of the variability of the observed data.
Figure 6.5 | Fmrp levels in mouse brain of the different (CGG)n 
length categories. A shows an example of a Western Blot, visualised 
with the 2F5 antibody against Fmrp, Gapdh was used as a loading control. 
Approximate (CGG)n lengths are indicated. 
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en dat ik besefte hoe leuk dat was en zou gaan worden. En ik had gelijk. Hoe verschillend we ook zijn, 
ik denk dat we elkaar goed aanvoelen en zeker ook aanvullen, of het nou gaat om labkennis (jij vult 
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van ervaring en hulp bij alles wat met muizen te maken heeft. Herma, jouw analytische blik was erg 
handig bij gecompliceerde bisulfiet-zaken en andere problematische PCRs. Asma, wat leuk dat je nu 
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project werkt. Karin, je was zo enthousiast, maar toch lag je hart ergens anders (nog meer). Hoe dan 
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goede aanvulling van de groep. Leontine omdat we elkaars bisulfiet-problemen herkennen en André 
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en muzieksuggesties. And Maria: the only good thing about you leaving is that I have a friend to visit 
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Klinische genetica is een gezellige club mensen. Iedereen leeft met elkaar mee, in leuke en minder 
leuke tijden. Erg belangrijk. De vele uurtjes die ik heb doorgebracht op de traditionele ‘last (or first) 
Friday of the month (or week)’-borrels en andere feestjes, spreken boekdelen over hoe goed ik me heb 
vermaakt. Tussen alle gezelligheid door, is iedereen ook erg attent en behulpzaam in het lab. Fijn ook 
dat mijn milieufundamentalisme werd getole reerd/geac cep teerd/gecontinueerd (ajb?)!
E*, jij bent een vraagbaak voor alles wat een mens bezighoudt, binnen of buiten het lab. Met jou als 
mijn mental coach had ik niets te klagen! Elisabeth, jij bedankt voor alle nuttige, leerzame, maar soms 
verwarrende discussies over statistiek, of eigenlijk alles wat maar ter sprake kwam. Bianca, Christan 
en Erik: bedankt voor het meedenken en hulp bij het runnen van de CGG-repeat op de ABI en andere 
sequentie gerelateerde zaken. Voor dergelijke vragen is Guido ook onmisbaar. Aida, Vincenzo, Alessio, 
Francesca, Tianna and previously Doro and Ania: very nice and interesting to have some international 
influences around! 
En dan het eiwit lab (en omstreken): jullie zie ik vooral op de gang lopen, maar ook dat draagt bij aan 
de goede sfeer: Annelies, Bert, Elly, Mark (bedankt voor lekkere etentjes, mooie skateroutes en culturele 
suggesties), Arnold, Marian, Rachel en Laura. 
Jeannette, bedankt voor al je kleine regeldingetjes. Vooral aan het einde, in het kader van het officiële en 
officieuze promotiereglement, was het erg handig dat jij wél wist wat wanneer en hoe moest gebeuren! 
En Benno, als Jeannette er niet was, hielp jij graag waar je helpen kon. 
Buiten de afdeling zijn ook veel mensen die mijn werk mogelijk of interessanter hebben gemaakt. 
Cluster 15 is een leuke plek om AIO te zijn: dank aan de andere AIO’s die menig cursus en AIO-workshop 
hebben opgeleukt, en ook de feestcommissie van ‘04/’05 verdient een eervolle vermelding! 
Ruud en Tom: de mannen van de plaatjes. Alles heeft altijd ‘best wel’ haast: prettig dat jullie daar mee 
om kunnen gaan! Tom, geweldig wat je van dit proefschrift hebt gemaakt! Fijn dat je mijn ideeën over 
streepjes en kleuren respecteerde: ik vind dat het erg mooi is geworden! 
In de afgelopen jaren is gebleken dat ik een aanleg heb voor heel bijzondere computer problemen. 
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om mijn computer weer werkend te krijgen. Met name Pim en Leo wil ik bedanken voor hun snelle en 
goede hulp, maar ook Sjozef, Mario en Ton hebben menig interessant computerprobleem opgelost!
De dierverzorgers in het EDC wil ik bedanken voor hun goede zorgen voor onze muizen en het 
meedenken en -werken om het onderzoek soepel te laten verlopen. 
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De samenwerking met Axel Themmen, Jenny Visser en Piet Kramer van de afdeling Inwendige 
Geneeskunde was erg prettig en leerzaam. Hoewel het niet echt mijn project was, vond ik het interessant 
om in jullie kennis over POF te mogen delen.
Erwin, Renske, Gregory (DNA diagnostiek): het is alweer lang geleden dat ik jullie regelmatig nodig had 
voor de repeatlengte bepaling. Fijn dat ik van jullie ervaring kon profiteren. 
Aram: wat een doorzettingsvermogen om De Onmogelijke Fmr1 in situ werkend te krijgen! Bedankt 
voor al je pogingen en inzichten; jammer dat het niet mocht baten. 
Alexander, leuk dat je zoveel tijd naar onze rennende en struikelende muisjes wilde kijken. 
Aaron: thanks for your time to help me find a way to convince the (in the end non-existing) reader that 
the results may be statistically, but not meaningfully significant. 
Paul, what a great opportunity it was to be able to work in your lab for a while. I have learnt so much. 
Although it was a hectic period, I was lucky to be there right around the time of all the stimulating 
discussions about the research plans for the Consortium grant. Dolores, I very much enjoyed working 
with you, (despite the clear differences in our ways of working!), not the least because we also got 
along very well. I learnt a lot from your experience and our discussions. It is a pity that there is no paper 
souvenir of this great time in the Window lab. 
Lisa, you were of amazing help in planning my visit to Davis. It was such a comfort to be able to count on 
your efforts to push the visa procedure and all other practical matters involved, including finding a very 
nice place to live, with Megan. Also Ellen O’Shea was of great help to get the visa taken care of in time.
Rob B, also many thanks to you for a pleasant and stimulating collaboration. I am confident that you will 
get interesting data when studying the mice. Chris I, you are a great lab manager. Very enthusiastic and 
efficient, active, helpful not only work-related and fun to talk to. Flora, thanks for nice and educational 
discussions on work and life. Thanks to David and Randi for your valuable input on the HPA paper. 
Claudia, your enthusiastic approach to pathology and life is great. 
It was easy to have a good time with the Hagerman lab people. In busy and hard times they proved 
to be a close group of caring people. It was special to experience that even during a very difficult time 
everybody actively made me feel welcome. Discussions over lunch (those damn delicious fries!) about 
cultural differences, politics, the environment (and more about the environment) were very entertaining 
and insightful (I will admit that I became more critical towards The Netherlands). I appreciate that you 
respected (or got used to listening?!) to my (Dutch) direct, curious and critical remarks. Thanks to Chris 
R for explaining the political system (money!) to me over and over again. I still cannot fully grasp it, but 
that is not your fault. 
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Gisele, how nice that we were in Davis at the same time! I very much enjoyed becoming friends. Chris 
R, Anna, Gisele and Dolores: thanks for fun nights out! Anna and Gisele: special thanks to you for having 
me stay at your places at the homeless end of my stay in Davis! Linda, thank you for welcoming me and 
Gisele into your home and family to celebrate Christmas (and our (in)capacity to whistle in concert!). 
And the others who certainly also ensured that I had a good time: Greg, Tanya, JJ, Ruiqin. Thank you all 
for a very nice, stimulating and inspiring period!
In het kader van ‘work hard, play hard’, verdienen mijn vrienden een groot compliment. Wat een 
gezelligheid. 
Teun: zodra ik aan mijn promotieonderzoek begon, wist ik al dat jij mijn paranimf moest zijn. Omdat wij 
elkaar goed begrijpen in hoe we in de wetenschap staan, en alles (veel) daarbuiten. Ten overvloede: wat 
mooi dat we zoveel contact hebben gehouden, ondanks grote afstanden (ook dank aan Pieter Post). 
Parijs-Londen zal een druk bereisd traject worden!
Alma, jou ga ik ook graag in Londen zien, voor nog meer leuke gesprekken over Dromen, Drinken, 
De Toekomst en wat ons maar bezighoudt. Emile, nog altijd een Grote Vriend. Mooi hoor. Natasha, 
zonder al onze culinaire en culturele uitjes zou ’t leven maar saai zijn! Is er een kunstvorm die we niet 
hebben verkend? Fijn dat je zo dichtbij zit en dat je (en later vaak als Sebasha) graag voor gezellige 
afleiding garant stond! Dasha, how great that such a nice friendship came out of that one-month visit 
to the FCDC! I hope that Floris stays in Paris for another while: I am looking forward to more Parisian 
weekends!
Ideaal dat een aantal Nijmegenaren ook naar het westen kwam, voor wat vertrouwde gezelligheid in de 
Grote Stad: buuv, Yvonne, Remco, Roel, Jaap. Mensen op afstand voor wie ik nog graag eens in de trein 
stap: Liselot & Tom, Anneke, Bart Joris, Nynke, Lucas, Gerjon. Natuurlijk zijn er nog meer mensen die 
bijdragen aan allerlei gezellige momenten, maar het is al zo’n lang verhaal... Kort en bondig schrijven 
heb ik duidelijk níet geleerd de afgelopen jaren.
Ik hoop dat jullie beseffen dat ik erg blij ben dat ik door zulke mooie mensen word omringd. Veel van de 
energie die ik van jullie krijg, is in de totstandkoming van dit proefschrift verwerkt!
Masja en Wouter, hoewel het soms lastig is om je een voorstelling te maken van waar ik me al die tijd 
mee bezig heb gehouden, waardeer ik het dat jullie er wel naar blijven vragen. 
Papa en mama, jullie vroegen je vroeger al af wanneer ik nou eens klaar was met mijn huiswerk en dat 
is niet minder geworden. Gelukkig begrijpen jullie goed dat het de moeite waard is geweest. Vooral 
voor praktische zaken zijn jullie van grote waarde, maar ook andere adviezen worden, soms na enige 
discussie, toch opgevolgd! Bedankt dat jullie altijd mijn keuzes in studie en werk hebben gesteund.
En nu: Paris, j’arrive! 
Ik zie jullie daar!

